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Abstract 
Irritable bowel syndrome (IBS) remains a heterogeneous condition and is a common 
condition. The causes of IBS remain poorly understood and there is a lack in 
biomarkers to distinguish this condition.  
Recently, there have been reports on the release of immune mediators leading to 
symptoms of irritable bowel syndrome. Mast cells, which can be activated by allergy 
or stress, are thought to be important cause of symptoms in some IBS patients 
because they can release chemicals, which cause pain and diarrhoea.  Currently, 
there are few effective treatments available to alleviate these symptoms. Recent 
small studies have shown that Mesalazine, an ͚aŶti-iŶflaŵŵatoƌǇ͛ dƌug, ŵaǇ ďe aďle 
to modify and reverse the symptoms of IBS with diarrhoea.  One small study 
suggested Mesalazine reduced mast cell numbers. This current study is one of the 
largest studies looking at the use of Mesalazine as a form of treatment for IBS with 
diarrhoea. Unfortunately, this study did not show any beneficial effect of 
Mesalazine treatment in unselected patients with IBS and diarrhoea. Potentially, 
there is a subgroup of IBS patients who developed their symptoms following a bout 
of gastroenteritis who appeared to benefit from Mesalazine treatment but a larger 
study is needed to confirm this. In this study, the mast cell mediators released from 
mucosal biopsies was not a useful marker of disease since it failed to correlate with 
any symptoms. 
Magnetic resonance imaging (MRI) is a potentially useful tool to assess the 
physiology of the gastrointestinal tract in patients with functional gut disorders as it 
does not involve radiation and is not invasive. So far, there is a lack of biomarkers to 
ii 
assist in diagnosis and treatment of irritable bowel syndrome. The MRI marker pill 
used in the multiple studies in Chapter 3 to assess whole gut transit time is very 
promising as it is now applied, in the research setting, to patients with chronic 
constipation such as slow transit constipation and irritable bowel syndrome with 
constipation. Further use of the MRI and adding a stimulus such as laxative in 
patients with chronic constipation is helpful to distinguish between functional 
constipation and irritable bowel syndrome with constipation; thus helping with its 
medical management. The use of MRI as a biomarker for diagnosis of irritable bowel 
syndrome remains promising although it was not demonstrated in this thesis.   
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Introduction  
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1.1. Definition of Irritable Bowel Syndrome 
Irritable bowel syndrome (IBS) is a chronic condition. The key features are 
abdominal pain /discomfort together with erratic bowel habit. The absence of 
biomarkers or gold standards for diagnosis of IBS has inhibited many physicians and 
general practitioners from labelling a patient with the diagnosis of IBS. This has led 
to many unnecessary investigations as a means of achieving a diagnosis of 
exclusion, thus leading to a substantial burden to the National Health Service (NHS).  
Throughout the years, there have been multiple attempts to define IBS using a set 
of criteria. Later, an international consensus group has developed the Rome criteria 
based on positive symptoms to standardise recruitment of patients with IBS in 
research. Table 1 shows the development of IBS diagnostic criteria throughout the 
years.  
Table 1: Development of IBS diagnostic criteria 
Criteria Diagnostic criteria Year  Sensitivity Specificity 
Manning1 
At least 2 of these symptoms with 
abdominal pain:  Abdominal pain relief by defecation  Loose stool associated with onset of 
pain  Pain relief by passage of stool  Abdominal bloating  Passing of mucus  Incomplete evacuation 
1978 0.782 0.722 
Kruis3 
Combination of symptoms such as: 
(for more than 2 years)  Abdominal pain  Flatulence  Irregular bowel habit alternating 
between diarrhoea and constipation  Excluding symptoms suggesting other 
organic disease including per rectum 
bleeding 
1984 0.772 0.892 
3 
 Normal physical examination   Normal laboratory tests  Normal haemoglobin  Normal leukocyte count  Erythrocyte sedimentation rate 
Rome I 2 
At least 3 months of continuous 
abdominal pain or discomfort relieved by 
defecation or associated with changes in 
stool frequency or consistency and at 
least 2 of the following (on at least шϮϱ% 
of occasions):  Altered stool frequency  Altered stool consistency  Alteration in stool passage  Passing of mucus per rectum  Bloating or distension 
1990 0.712 0.852 
Rome II 4 
Abdominal pain or discomfort of at least 
12 weeks with preceding symptoms for 
ϭϮ ŵoŶths aloŶg ǁith шϮ of these 
features:  Relief with defecation  Onset associated with a change in 
frequency of stool  Onset associated with a change in 
consistency of stool 
1999 0.695 0.665 
Vanner 6 
Combination of Rome criteria AND red 
flag syndrome such as  Weight loss  Nocturnal symptoms  Blood mixed with stool  Recent antibiotics use  Abnormal physical examination  Family history of colon cancer 
1999 
0.786 
PPV = 
98%6 
0.356 
Rome III7 
Recurrent abdominal pain or discomfort 
at least 3 days/month in the last 3 
months with symptom onset 6 months 
prior to diagnosis 
At least 2 or more of the following  Improved with defecation  Onset associated with change in 
frequency of stool  Onset associate with change in 
consistency of stool 
2006 0.758 0.809 
4 
 
IBS is further sub typed using the Bristol Stool Form Scale (BSFS)7 (Figure 1):  
Diarrhoea predominant IBS (IBS-D): 25% stools having consistency of 6 or 7 and 
<25% stools with consistency 1 or 2 
Constipation predominant IBS (IBS-C): 25% or more of stools have consistency of 1 
or 2 and <25% stools with a consistency 6 or 7 
Mixed IBS (IBS-M): 25% or more of stools have consistency of 6 or 7 and   25% 
stools have a consistency 1 or 2 
 
Figure 1:  Subtyping IBS according to stool consistency 
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1.2. Epidemiology 
IBS is a common chronic condition and accounts for up to 20% of gastroenterology 
referrals from the primary care to the secondary care in the United Kingdom (UK)10. 
In a large population survey by the Royal College of General Practitioners, 1 in 12 
general practice consultations are due to digestive problems and up to 30% of all 
digestive problems are due to irritable bowel syndrome 11. Most IBS patients are 
young to middle aged females.  A recent study using the UK General Practice 
Research Database (GPRD) gave an overall female to male ratio of 3 to 1 in newly 
diagnosed IBS in primary care 12. This suggested that females are more likely to 
report symptoms during consultations compared to males. The incidence of new IBS 
peaks in the ϯϬ͛s aŶd ϰϬ͛s with only a few new diagnoses of IBS in the older age 
groups (Figure 2)13. Overall, the incidence of IBS in the United Kingdom (UK) appears 
somewhat similar to other European countries and the United States of America 
(USA) 14, 15. Overall incidence of IBS may be under represented as many patients do 
not seek medical attention and one plausible reason may be the disillusionment 
with current treatment options.  
IB“ is a ĐhƌoŶiĐ ĐoŶditioŶ that ĐaŶ iŵpaiƌ patieŶts͛ ƋualitǇ of life aŶd theiƌ 
performance both at work and at home 15, 16. Specific factors that impinged on their 
lifestyle were diet, concentration, long journeys, physical appearance, the ability to 
eat out aŶd the aďilitǇ to lead a ͚Ŷoƌŵal life͛15. Work productivity would be affected 
with more sickness days off work and more consultations with medical professions. 
Studies by Amouretti et al. 17 and Creed et al. 18 demonstrated that quality of life in 
IBS is significantly worse than the general population. Cost incurred by this disease 
for each patient could be approximately £1500 per patient/year 16, 18 
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Figure 2: Incidence of newly diagnosed patients with IBS in primary care in the UK 
which peaked in the 3rd to 4th decade of life. Redrawn from Jones et al 12 
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1.3. Pathophysiology 
1.3.1. Genetic 
 
A study on monozygotic and dizygotic twins in Australia suggested that there is a 
genetic link predisposing to IBS, with a heritability of 57%19. Later, Levy et al.20 
showed concordance for IBS is greater in monozygotic twins than dizygotic twins, 
which supports a hereditary component in IBS. On the contrary, IBS in twins  could 
be due to social conditioning since having an IBS parent is an independent predictor 
of IBS and a stronger predictor than having a twin with IBS. These studies have their 
limitations since the diagnosis of functional bowel disease was not based on a set 
criterion such as the Rome I or II criteria. A study in 200421 showed the concordance 
rate of IBS in monozygotic and dizygotic twins are similar which may conclude that 
genetic factor has little influence on IBS development. So far, the only strong 
geŶetiĐ liŶk to IB“ is the TNF“Fϭϱ geŶe, ǁhiĐh is assoĐiated ǁith CƌohŶ͛s disease 22, 
23. A large cohort study in America and Sweden22 showed that the TNFSF15 gene is 
strongly associated with an increased risk of developing IBS (OR=1.37). This was 
again confirmed with a British cohort of IBS-D associated with TNFSF15 and TNF 
genetic polymorphism23. 
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1.3.2. Stress/ life events 
 
Childhood learning and conditioning played a role in determining whether one 
develops IBS. If a mother has IBS, the child independently reports more medical 
problems and school absences24. This correlated with having the diagnosis of IBS as 
an adult in later life25. High stress and anxiety levels in subjects are more prone to 
developing IBS after gastroenteritis26. A review article by Spiller and Garsed 27 
succinctly summarised the psychological stressors that could influence one to 
develop IBS following a bout of gastroenteritis. These stressors are hypochondriasis 
(relative risk = 2.0), adverse life events in the preceding 3 months (relative risk = 
2.0) and depression (relative risk 3.2).  
Mechanistic study on stress: 
It is now recognised that there is interaction between stress and the gut. The 
corticotrophin releasing factor (CRF) activation is the key to initiation of stress 
response via the hypothalamic-pituitary-adrenal axis in IBS 28, 29.  Recent evidence 
has shown that the CRF1 receptor interacts with CRF ligands and is involved in 
colonic motor response to various stressors 30, 31. A study by Gue et al. 32 
demonstrated the interaction between CRF and stress via the central CRF pathway, 
caused worsening of abdominal pain and activation of mast cells in rats. A human 
study by Santos et al.33 showed activation of mast cells in the gut by releasing of 
mast cell mediators such as histamine and tryptase following immersion of a hand 
into cold water. This confirmed that stress could activate intestinal mast cells 
providing a possible mechanism for stress as a cause for accelerating small bowel 
transit. 
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1.3.3. Somatisation/psychological 
 
One of the most difficult aspects of managing IBS are patients often have multiple 
co-morbidities. These include psychological disorders such somatisation disorder 
and panic attacks, urinary symptoms such as dysuria, nocturia, frequency and 
urgency of micturition, gynaecological symptoms such as dyspareunia and chronic 
pelvic pain and musculoskeletal problems such as chronic fatigue syndrome. Some 
may have undergone unnecessary invasive tests and treatment leading up to 
laparotomy, hysterectomy or cholecystectomy 12, 34, 35. The rates of 
abdominal/pelvic surgery in IBS patients were reported twice as high as those of the 
normal population and there was as high as a 3-fold increase in gall bladder surgery 
in this group of patients 36. 30-60% of patients with IBS symptoms have fibromyalgia 
and vice versa 37, 38. Patients who have both of these conditions have worse quality 
of life and displayed significant hypersensitivity to pain compared to those with only 
either IBS or fibromyalgia alone38.  
Somatization disorder (SD) is a psychiatric disorder defined as multiple medically 
unexplained symptoms. These symptoms include psychiatric and neurological 
complaints. Although SD is rare with an incidence of around 1 per 1000, there is a 
Ŷeaƌ siŵilaƌ pƌoďleŵ ǁhiĐh is the ͞phǇsiĐal sǇŵptoŵ disoƌdeƌ͟ fouŶd iŶ as ŵaŶǇ as 
1 in 10 of primary care consultations 39 . It may go unrecognized by physicians and 
general practitioners because training is focused on the identification and 
treatment of specific organic diseases40. DoĐuŵeŶtiŶg the patieŶt͛s ĐoŵplaiŶts, Đo-
morbidities and previous attendances to hospitals provide a helpful pointer towards 
the existence of SD. Patients with irritable bowel syndrome who manifest a degree 
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of somatisation often meet diagnostic criteria for other functional disorders41. It is 
important to recognize and identify these patients since they are more difficult to 
manage as they often report worse global IBS symptomatology with a poorer 
response to conventional IBS treatments 40. 
The Patient Health Questionnaire 15 (PHQ-15) is a useful questionnaire, which 
documents somatic symptoms from different parts of the body. The PHQ15 
contains 3 gastrointestinal symptoms which if deleted leave the PHQ12 Somatic 
Symptoms scale (PHQ12SS) as a useful measurement of non-gastrointestinal (GI) 
symptoms 42.  A PHQ12SS score >6 identify patients with IBS with a sensitivity of 
66.4% and specificity of 94.7% and a positive likelihood ratio of 13.2. A low score is 
useful and should prompt a search for other diagnoses. Another tool that is useful is 
the 14-item Hospital Anxiety and Depression scale (HAD). This is a reliable tool to 
detect anxiety and depression 43 which is important since it contributes to the 
severity of the disease and if severe (score >15), it will warrant specific treatment 
such as antidepressants/anxiolytics.  
 
1.3.4. Visceral hypersensitivity 
 
Visceral hypersensitivity plays a pivotal role in the motor function of the gut and 
abdominal discomfort in IBS patients. Visceral pain is defined as reduction in 
threshold for pain and discomfort. The causes of visceral hypersensitivity are varied 
and may reflect the heterogeneity of IBS.  
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Over the past decade, visceral hypersensitivity can be measured using the rectal 
barostat to induce abdominal pain. Previous studies showed IBS patients have 
hypersensitivity to rectal distension 44-46. One of the large studies by Mertz in 1995 
44 showed 94% of IBS patients have lower threshold of rectal distension, increased 
intensity of sensation or altered viscerosomatic referral. A more recent study by the 
Mayo clinic reported only 7.6% having thresholds for pain sensation below the 10th 
percentile and 13% having thresholds above the 90th percentile. The discrepancies 
between these 2 studies were probably due to the strict protocol adherence for 
studies performed in the Mayo clinic and differences in the definition of the word 
͚thƌeshold͛. IŶ the UŶited KiŶgdoŵ, Agƌaǁal aŶd Đolleagues 47 showed IBS patients 
with bloating without distension have lower pain threshold and a bigger desire to 
defecate compared to IBS patients who have symptoms of bloating with abdominal 
distension.  
Immune activation leading to activation of mast cells and its release of their 
mediators e.g. histamine and tryptase may play a part in altered sensation in IBS 
patients 46, 48. (The role of inflammation in IBS will be discussed later.)  
Review articles by Aspiroz et al.49 and Larauche 50 have summed up visceral 
hypersensitivity in IBS clearly (see Figure 3). The central mechanism, which is the 
brain, plays a role in how one modulates the perception of afferent information/ 
visceral pain. The development of functional magnetic resonance imaging (fMRI) 
has helped us achieve a better understanding in brain activities during stimulation 
of pain/sensation. In IBS subjects, pain by rectal distension led to greater activation 
of anterior cingulate cortex, which is the main area in the central nervous system 
where the emotional aspect of pain is registered51.  This postulated that IBS patients 
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might have abnormal brain pathways, which led to a low threshold of pain. Another 
study by Piche showed IBS patients have thermal cutaneous and visceral 
hypersensitivity, which may indicate abnormalities in the descending anti-
nociceptive pathways 52.   
 
Figure 3: Putative role of central and peripheral CRF signaling pathways to 
influence immune processes and potential implications in stress-related IBD and 
IBS symptoms 
 
1.3.5. Inflammation 
 
Approximately 25% of patients who had acute bacterial gastroenteritis such as 
Campylobacter, Salmonella and Shigella;, develop IBS, which is often a continuation 
of the initial diarrhoeal illness and hence frequently meet the Rome criteria for IBS 
53, 54. Patients who developed post-infectious IBS (PI-IBS) have similar features as a 
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subgroup of IBS patients with diarrhoea. The relative risk of one developing IBS 
following a bacterial gastroenteritis in a year was 11.9 compared to the general 
population in the United Kingdom (UK) 55. Risk factors that predispose this group of 
patients to IBS were prolonged illness during the acute gastroenteritis episode, 
female sex, the use of antibiotics and previous psychological disturbance 27, 54, 56, 57. 
Therefore, PI-IBS has been used in many studies to further understand the 
pathophysiology of IBS in general. (Further discussion on PI-IBS and the role of 
inflammation will be continued in Section 2) 
 
1.3.6. Intestinal permeability 
 
Following the outbreak of gastroenteritis in Walkerton, Canada due to 
contamination of the municipal water supply, a significant number of patients 
developed PI-IBS after 2 years following the event 58. In this group of subjects, there 
was increased intestinal permeability. This provided further evidence in the organic 
nature patient with functional bowel disorder. These finding were consistent with 
previous findings by Spiller and colleagues 59 where the gut permeability was 
increased in patients infected with Campylobacter jejuni gastroenteritis and in PI-
IBS. Another study by Park et al. 60 showed increased intestinal permeability in 
unselected IBS patients. Further study by Dunlop and colleagues61 showed 
increased intestinal permeability in both PI-IBS and IBS-C patients. IBS-D patients 
who have increased intestinal permeability seemed to correlate with abdominal 
pain severity and worsening IBS symptoms62.  
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A study looking for genetic risk factors for PI-IBS had identified 3 genetic regions of 
interest i.e. Cadherin 1 (CDH1), Interleukin 6 (IL-6) and Toll-like receptor 9 (TLR9) 
which played a part in the intestinal barrier 63. CDH 1 is a transmembrane 
glycoprotein that acts as a tight junction and is responsible for the intestinal barrier. 
IL-6, an inflammatory cytokine, was elevated in IBS patients more so in patients 
with diarrhoea and this raised the possibility that this pro-inflammatory cytokine 
may be involved in the integrity of intestinal barrier64.  
Numerous animal studies have showed stress increased gut permeability via mast 
cell activation. Piche et al. 65 showed all IBS subtypes have increased intestinal 
permeability to fluorescein isothyocyanate (FITC)-sulfonic acid. Biopsies from IBS 
patients had reduced zonulin-1 mRNA (Zonulin-1 is a modulator of intestinal barrier 
function). Supernatant from incubated IBS biopsies increased the permeability of 
Caco-2 monolayers to FITC-dextran, an effect not blocked by histamine receptor 
antagonists. A likely candidate for mediating this effect would be mast cell tryptase 
which other groups have showed increased in IBS biopsy supernatant 66. In this 
study by Buhner et al., resected colon specimens were used and loaded with a 
voltage sensitive dye to image the response of human myenteric plexus neurons to 
supernatant from IBS colonic biopsies. It evoked action potential discharges in 
submucosal plexus neurons when supernatants from the IBS specimen were applied 
but not on control supernatant samples. Furthermore, serotonin, histamine and 
tryptase antagonists were able to reduce these neurone responses.   
Increased tryptase has recently been reported in IBS-D which suggested tryptase 
may mediate increased permeability in IBS67. Interestingly, tryptase levels were 
enhanced in IBS compared to controls. When tryptase inhibitor was added into the 
15 
rectal biopsy of the IBS patients, the permeability normalised68. This study found no 
increase in expression of protease-activated receptor 2; suggesting tryptase activity 
itself played a role in the increase of intestinal permeability of IBS patients.  
Modulation of the intestinal barrier 
Probiotics are living organisms that provide health benefits to the host. The mode of 
action of probiotics consist of (a) binding of intestinal epithelial cells and inhibiting 
adhesions of pathogen, (b) enhance intestinal barrier function, (c) acidification of 
colon fermentation, (d) immune-modulatory actions, (e) secretion of bacteriocins, 
(f) alteration in mucosal response to stress and (g) inhibition of visceral 
hypersensitivity 69. A randomised clinical trial in China had demonstrated that the 
use of probiotics is beneficial in surgical patients undergoing colectomy70. This study 
demonstrated the use of probiotics would stabilise the integrity of tight junction 
proteins in colonic mucosa epithelium and the balance of gut microbiota thereby 
reducing postoperative infection. A mechanistic study by Zeng and colleagues 71 
showed the use of probiotics, such as active lactic acid bacteria, decreased 
intestinal permeability in IBS-D patients along with improvement in their global well 
being and abdominal pain. This may be a promising treatment in IBS72 but  there is 
still a need to establish types of species, strains and the dose of probiotics which 
may be beneficial. 
 
 
 
16 
1.3.7. Transit 
 
Assessing transit is an important part of characterising the subtypes of IBS as most 
studies showed faster transit in IBS-D. However transit through the bowel is 
intrinsically quite variable depending as it does on many factors including diet, 
emotion and menstrual cycle. Metcalf et al.73 refined the method for whole gut 
transit that involved taking 20 radio-opaque pellets for 3 days and an abdominal x-
ray (AXR) on the 4th day. This became a conventional method to assess whole gut 
transit and is currently used across all healthcare providers.  In the past, we 
believed that different gut transit plays a predominant role in different subtype of 
IBS patients. The differences in gut motility between IBS patients and healthy 
controls are variable and may not be a good parameter to be used as a diagnostic 
tool for IBS 74-76. An earlier study by Cann and colleagues 77 showed a relationship 
between gut dysmotility in IBS subtypes both affecting the small bowel transit and 
colonic transit. Later in 1999, Horikawa and colleagues 78 studied gut transit in IBS 
and found it to have accelerated whole gut and colonic transit in IBS-D but remain 
normal in IBS-C. When bowel transit was assessed along with symptoms, a study in 
the USA 79 demonstrated that patients with IBS-D have faster colonic transit and 
there was a correlation of abdominal symptoms with powerful contractions of the 
colon. In the IBS-C subtype, Agrawal et al. 80 demonstrated that the IBS-C patients 
have delayed colonic and orocaecal transit time. In that study, it showed significant 
correlation between colonic/ orocaecal transit with clinical symptoms such as 
abdominal distension, a symptom that most IBS patients suffer from. Also, this 
study demonstrated that abdominal bloating was inversely correlated with stool 
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ĐoŶsisteŶĐǇ. The IB“ ͚ďloateƌs͛ ǁith alteƌŶatiŶg ďoǁel haďits deŵoŶstƌated ƌapid 
small bowel transit without any difference in colonic transit when compared with 
healthy volunteers 81. This finding was very different from one studied by Cann et al. 
77 where the small transit was delayed in IBS patients who have predominantly pain 
and bloating. Overall, small and large bowel transit in IBS is variable and studies 
have confirmed that there is great heterogeneity in the healthy population and IBS 
patients.  
 
1.3.8. Diet 
 
PƌoŵotiŶg a healthǇ diet, ͚ϱ a daǇ͛, ǁhiĐh iŶĐludes dietaƌǇ iŶtake of ϱ ǆ ͚ϴϬg͛ 
portions of fruit and vegetables daily makes good sense from a public health 
perspective as it may well reduce the risk of cardiovascular disease, type-2 diabetes 
aŶd oďesitǇ iŶ the UK populatioŶ. Hoǁeǀeƌ the ͚ϱ a daǇ͛ diet ŵaǇ Ŷot ďe ďeŶefiĐial 
to patients with an irritable and hypersensitive bowel since these foods typically 
have high content of fibre, fructose, fructans, and polyhydric alcohols.  
A dietaƌǇ histoƌǇ should distiŶguish soluďle fƌoŵ iŶsoluďle ͞fiďƌe͟ ǁhiĐh is a 
ŵisŶoŵeƌ siŶĐe ŵost ͞fiďƌe͟ is Ŷot fiďƌous. Hoǁeǀeƌ the teƌŵ is ǁidelǇ used to 
describe non-starch polysaccharides often found in plants characteristically 
resistant to human digestive enzymes.  Soluble fibres consist of pectins, gums and 
mucilages, best known as guar gum and psyllium. These soluble fibres 
characteristically form viscous solutions with water and can be prescribed in pure 
form. Insoluble fibre consists of harder structural components of plants including 
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celluloses, hemicelluloses and lignins. They are typically particulate and insoluble in 
water for example corn fibre and wheat bran. While soluble fibre can help IBS 
patients with constipation 82  insoluble fibre like bran can adversely affect 
symptoms and it is important that levels of dietary fibre intake are assessed. It is 
also important for symptom assessments during a reduced dietary fibre trial period. 
Effect of bran 
Patients who are symptomatic may modify their diet or increase their fibre intake 
prior to consulting their general practitioner. Some studies show that increasing 
fibre intake such as bran may be beneficial in constipation but not diarrhoea and in 
some IBS patients aggravates abdominal distension, flatulence and diarrhoea 81, 83, 
84. About half (55%) of IBS patients believe it worsens their symptoms while only 
small proportion (10%) report any symptom improvement 85. 
FODMAPs  
Recent work in Australia showed that a diet high in FODMAPs (Fermentable Oligo-Di 
and Mono-saccharides and Polyl hydric alcohols) could trigger abdominal symptoms 
such as flatulence, bloating, abdominal discomfort and changes in bowel habit in 
some IBS patients86, 87. FODMAPs consist of fructose, lactose, fructo-and galacto-
oligosaccharides (fructans and galactans) and polyols (sorbitol, mannitol, xylitol and 
maltitol) (see Figure 4 for examples of foods with high FODMAPS content).  
Fructose is a 6-carbon monosaccharide found in many foods and comes in 3 forms 
e.g. monosaccharide (free fructose), dissacharide (sucrose) or fructans (polymer of 
fructose). Free fructose is found in fruit and honey.  Fructose may also be present in 
the diet as a constituent of the disaccharide sucrose or as fructans, which are 
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polymers of fructose with small amounts of glucose. Fructose is usually absorbed 
via two transporters in the small intestine epithelium: the GLUT5 fructose-specific 
transporter in the apical membrane and the GLUT2 transporter which carries 
glucose, fructose and galactose across the basolateral membrane 88. GLUT2 
transporters have also been seen on the apical membrane when glucose is 
present and being transported by a SGLT1 (sodium/glucose-galactose co-
transporter) which increases the uptake of fructose 89 – in part explaining why 
malabsorption of fructose can be seen when there are lower levels of glucose 
present 90.  Absorption of fructose in the gut is less efficient than glucose therefore 
it is possible to exceed the absorptive capacity of the small bowel, leading to 
excessive fructose delivered to the colon. In the colon, it would be rapidly 
fermented by bacteria producing short-chain fatty acids, carbon dioxide, hydrogen 
and methane 86, 91. The hydrogen and methane that are produced are expired 
through the breath or passed as flatus. When these osmotic changes and rapid gas 
productions occur, it induces bowel symptoms such as flatus, bloating, abdominal 
discomfort and erratic bowel habit 92, 93. IBS patients do not appear to malabsorb 
more than normal controls but they seem to be more sensitive to the effects of 
these carbohydrates 94. An MRI study recently showed that fructose increased small 
bowel water content and its effect was dampened with addition of glucose together 
with fructose95.  
Over recent years there has been a marked increase in consumption of fructose and 
fructans; particularly in the United States where high-fructose corn syrup is widely 
used as a sweetener in soft drinks, sugared fruit drinks, jams and baked goods 96, 97.  
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It is important to assess intake of such substances since two randomized controlled 
trials 87 demonstrated that fructose and fructans worsened IBS symptoms 98. 
Lactose malabsorption affects up to 70% of adults worldwide and in some, it can 
cause IBS-like symptoms99, although only about 1 in 3 would be aware of their 
intolerance. Severity of symptoms is very much dose dependent and the effect of 
this would be lessened if lactose is mixed with other foods ensuring slower delivery 
of chyme to the small intestine100. A mutation which arose in North Western Europe 
and Northern Nigeria prevented the normal post weaning reduction in lactase levels 
and thus led to high lactase levels throughout adult life (lactase persistence)101. The 
prevalence of this mutation is highest in Scotland and declines as one moves south 
and west102.   
Assessing dietary intolerance to FODMAPS by history is difficult since the effect of 
each FODMAPS component depends on what is consumed simultaneously 92, 103. If 
fructose and sorbitol were given in a mixture, it seemed to cause more symptoms 
than when each of these components were given separately 92. If each of these 
components were given along with glucose, the malabsorption process would be 
reduced104. This may explain why some sources of fructose with low glucose 
content; such as pears are less well tolerated than sources with high glucose 
content such as grapes105 . 
It is likely that some IBS patients may respond to a low FODMAPS diet, though with 
such a complex diet requiring intensive dietician input, placebo effects may cause 
similar positive responses. So far, the results of a low FODMAPS diet for IBS patients 
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remain promising86, 87, 106 since most patients would rather modify their diet than to 
take medication(s) that may cause unnecessary adverse events. 
 
Figure 4: Food sources containing high FODMAPS content90 
 
1.4. Conclusion 
IBS consists of a large heterogeneous group of patients where its pathophysiology 
remains to be elucidated. Immune activation is believed to play an essential role in 
developing IBS. IBS may possibly be sitting at the other end of a spectrum similar to 
inflammatory bowel disease; since it shares certain common pathways in its 
pathogenesis; for example genetic defects, increased gut permeability and 
exacerbation of symptoms following stress.  
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1.5. Aim of this thesis: 
The main aim of this thesis was to assess the role of inflammation in a subgroup of 
patients who have IBS with diarrhoea. This thesis will describe the effect of 
Mesalazine, an anti-inflammatory drug, in the treatment of IBS-D with the aim of 
looking for relevant mediators or biomarkers. The second aim was to explore the 
use of magnetic resonance imaging (MRI) to look for potential biomarkers in IBS. 
  
23 
Role of inflammation in Irritable Bowel Syndrome 
 
24 
1.6. Post-infectious IBS 
1.6.1. Epidemiology 
Post-infectious irritable bowel syndrome (PI-IBS), a chronic condition, is defined by 
newly developed of IBS symptoms following an episode of acute infectious 
gastroenteritis. This subgroup of IBS patients has a normal bowel habit prior to this 
acute episode. The acute episode of infectious gastroenteritis is defined by having 
at least 2 or more clinical features such as fever, vomiting, diarrhoea and a positive 
stool culture 107.  
A recent large community survey in the United Kingdom (UK) which involved over 
6800 participants has revealed that the overall incidence of infective diarrhoea was 
274 cases/ 1000 persons/ year with a maximum incidence in young children 108. 
Viral gastroenteritis was the commonest cause with norovirus being the most 
frequent organism isolate. The most common bacterium was Campylobacter spp. 
with incidence rate of 11 cases/ 1000 persons/ year in 2009. Other common 
bacterial intestinal infections were Salmonella spp. and Escherichia coli. However, it 
is worth noting that less than 1 % of episodes of gastrointestinal infections in the 
community are reported to the national surveillance systems, therefore its true 
incidence would be grossly underestimated. Due to the under reporting of 
infectious   gastroenteritis, the true incidence of PI-IBS may be greater than what is 
currently believed. 
Epidemiological studies have suggested that enteric infection is one of the most 
important risk factors for developing IBS. These findings generally equate to those 
found for psychological risk factors, such as anxiety and increased levels of 
depression and sleeping disorders. Smoking, body mass index and alcohol excess 
25 
also show similar effects 109. The proportion of patients developing IBS following 
gastrointestinal infections varies in different series of studies. This can be from 3.7% 
110 to 36% with the highest incidence being seen in those with  the most severe 
infection as judged by bleeding, fever and weight loss111. The most common causes 
of bacteria causing PI-IBS in the UK are C. jejuni, Salmonella enteritidis and Shigella 
flexneri. Most often, PI-IBS patients describe a persistence of their initial illness 
leading to multiple visits to the general practitioners or hospitals. Most of these 
patients meet the Rome criteria diagnosis for IBS with diarrhoea (IBS-D) 53. 
Therefore, the similarities between PI-IBS and other subtypes of IBS may provide a 
better insight into the pathophysiology of all IBS especially when the onset and 
cause of symptoms in PI-IBS is clearly defined  
 
1.7. Risk factors 
In a meta-analysis, the overall effect of developing IBS following an infectious 
gastroenteritis gave a pooled odds ratio of 7.3 (CI 4.8-11.1)112. A review by Spiller 
and Garsed summarised succinctly risk factors and the relative risks with each 
component. See figure 5. 
26 
 
Figure 5: Summary of risk factors of developing PI-IBS 
 
1.7.1. Genetics 
 
Previous studies have demonstrated that there may be a familial tendency when 
studying monozygotic and dizygotic twins but social learning also is an important 
factor in a child developing IBS 19-21. Recent studies on single nucleotide 
polymorphism (SNP) supports the idea of genetic influence contributing to IBS. A 
greater proportion of IBS patients are heterozygous for the -308 (G/A) SNP, which is 
a high producer of TNF-α 113.  A high producer TNF- α aŶd loǁ pƌoduĐeƌ of IL-10-10-
1082 A allele was more prevalent in IBS patients (9%) versus control (3%). Recently, 
a geŶe that is assoĐiated ǁith CƌohŶ͛s disease was identified and has demonstrated 
an increased risk of IBS (OR 1.37) in a cohort of IBS patient 22. The gene that was 
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identified was the G allele of SNP rs4263839 in the TNFSF15 gene. Another study by 
Swan and colleagues 114 had identified a closely related SNP in the TNFSF15 gene, 
which increased the risk of developing IBS-D, and there was an increased 
prevalence of the TNF-α “NP ƌsϭϴϬϬϲϮϵ geŶotǇpe GA iŶ PI-IBS. Other reports such 
as the Walkerton outbreak in 2007 have shown association between SNPs with PI-
IBS. They identified 3 gene regions such as the Cadherin 1, IL-6 and Toll-like receptor 
9 63. The limitation of this study was its small sampling size that did not withstand 
corrections for multiple testing. These associations would need to be reproduced 
again in another separate cohort. 
 
1.7.2. Physical and Psychosocial 
 
Studies have confirmed that high stress and anxiety levels, hypochondriasis, adverse 
life events occurring in the preceding 3 months and depression increase the risk of 
developing PI-IBS 26, 27, 57, 107. Smoking increases the risk of developing PI-IBS to 
about 5 fold but its mechanism is yet unclear at present whilst age (>60 years) 
protects one from developing PI-IBS (RR 0.36) 27, either due to declining immune 
response as one becomes older or alternatively prior immunity reducing the 
severity of the initial illness. 
Psychological stress can exacerbate pain syndromes such as IBS but how it increases 
the risk of developing PI-IBS is still unclear; although stress is known to alter 
immune function. In the animal models, corticotrophin-releasing hormone (CRH) 
seems to be a key mediator of stress acting via the hypothalamic-pituitary-adrenal 
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axis as well as locally in the gut. CRH acts via the CRF1 receptors that cause 
stimulation of colonic motility and watery diarrhoea in rats and mice 28, 30. When 
CRH1 receptor antagonist was used, it prevented diarrhoea in rats, indicating that 
the brain CRF1 signalling pathway is important in colonic motor responses115. In 
another animal model, rats that were previously infected with Citrobacter 
rodentium showed raised level of corticosterone and epinephrine levels following 
chronic water avoidance stress. They also found increased peripheral nociceptive 
signalling from rectal distension and tissue proteases. These proteases are likely 
released from activated mast cells that can induce hyperexcitability in colonic dorsal 
root ganglia cells 116. In humans, inducing stress such as immersion of the hand into 
cold water can cause pain and sympathetic activation. This could lead to activation 
of mast cells releasing mediators such as histamine and tryptase in the small bowel 
33. Santos and group have also demonstrated in their study that with stress, this 
could lead to an increase in human small bowel secretion 33. The same group have 
shown evidence of increased numbers of mast cells and tryptase in jejunal biopsies 
of anxious IBS-D patients 117, which is replicated by the Nottingham group 118. 
Therefore, there is a possible explanation that stress could increase human small 
bowel secretion and motility that leads to accelerated transit which is a 
characteristic of IBS-D.  
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1.8. Pathophysiology  
 
The pathophysiological causes of PI-IBS are multiple. However there is evidence to 
shoǁ loǁ gƌade ͚iŵŵuŶe aĐtiǀatioŶ͛ iŶ PI-IBS and IBS patients. Changes in enteric 
nerves and altered microbiome may also be implicated in the pathophysiology of PI-
IBS.  
 
1.8.1. Immune activation 
 
Enterochromaffin cells (EC cells) & lymphocytes 
The EC cell is a subtype of neuroendocrine cells in the gut and contains a 90% 
proportion of its body store of serotonin (5-HT) 119. EC cells act as a sensory 
transducer and play an important role in response to luminal pressure and contents 
such as nutrients and bacterial products by secreting peptides and amines that 
activate the enteric nerves and transmit information to the central nervous system. 
5-HT strongly influences the gut͛s ŵotilitǇ aŶd seĐƌetioŶ espeĐiallǇ ǁheŶ eǆposed to 
toxins such as cholera. The 5-HT activates enteric reflexes via the 5-HT1p, 5-HT3, 5-
HT4 and 5-HT7  receptors to stimulate secretion and propulsion of the gut 120. In 
animal studies, mice infected with Trichinella species or Trichuris muris develop T-
cell mediated immune response in the gut causing an increase in EC cells and 5-HT 
content 121-123. Although acute inflammation resolves, following acute infection, 
there is persistent T lymphocyte-dependent EC cell hyperplasia. Other studies in IBS 
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patients have shown similar evidence. Serial rectal biopsies on patients following 
Campylobacter jejuni gastroenteritis who developed PI-IBS has shown raised 5HT 
containing EC cells, intra-epithelial lymphocytes(IELs) and T lymphocytes which 
could persist for many years 59, 107.  
Cytokines 
The cytokines are products of monocytes or macrophages. The monocytes and 
macrophages are parts of innate immunity and play an important part in mounting 
an acute inflammatory phase when there is invasion of infectious agent. Recent 
studies increasingly have shown B cell and T cell expressions are increased in IBS 
patients. A group from Sweden demonstrated isolated B cells in blood, showed 
increased expression of IgG and co-stimulatory molecules CD80 and CD86 124. 
Moƌeoǀeƌ, the gut hoŵiŶg iŶtegƌiŶ βϳ+ B cells in IBS patients were higher than in 
the controls which may implicate that the source of B cell activation may be from 
antigens in the gut.  Another study from the group has demonstrated increased T 
cell activation, CD4 and CD8, in IBS patients. Pro-inflammatory cytokine IL-ϭβ is 
raised compared to the control and showed a weak correlation with dissatisfaction 
of bowel habit in IBS patients 125. Neither of the two studies stated whether the IBS 
cohorts were PI-IBS patients. 
Other studies have demonstrated similar results showing raised pro-inflammatory 
cytokines such as IL-1, TNF-α, IL6 and reduction in IL-10, which is an anti-
inflammatory cytokine, in colonic biopsies or peripheral blood mononuclear cells in 
PI-IBS patients 54, 126, 127. Other studies have showed imbalance in cytokines of 
different subtypes of IBS patients 23, 128. Overall there is lack consistency with 
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findings on the cytokines and their methodologies and patient selection is varied 
which may explain the variability in the results. 
Mast cells 
Recently, there is evidence to show that mast cells may be implicated as one part of 
the pathogenesis of IBS. Recent studies have shown that mast cells are increased in 
the small and large bowel of all subtypes of IBS patients but especially  in IBS-D 
patients 54, 117, 118, 129-131.  Mast cell products can activate enteric nerves within the 
lamina propria which may be relevant to IBS symptoms. The number of mast cells 
which lie in close proximity to the enteric nerves, <5 μm from the nerve, correlate 
with the severity and frequency of visceral pain in IBS 48, 132. When mast cells are 
activated, mediators such as histamine, prostaglandin and proteases such as 
tryptase 133 are released, which can activate enteric nerves. Tryptase signals to the 
cells through proteinase-activated receptor 2 (PAR2 receptor) which can cause 
neuronal excitability 134, 135 leading to visceral hypersensitivity and increased gut 
motility. Recently, a study demonstrated that the down regulation of proteinase-
activated receptors 4 (PAR4 receptor) may be implicated in the pathogenesis of IBS 
136 although previous studies were mostly in animal models and in studies of 
inflammatory bowel disease. Histamine also activates the enteric nerves by 
interaction via H1 and H2 receptors 48. These mast cell mediators such as histamine 
and tryptase are increased in the biopsy supernatants of IBS patients compared to 
healthy controls 48, 66, 137 and this release of mediators activate human enteric 
afferent nerves which likely play a role in visceral sensitivity but so far, there are no 
correlations between this and clinical symptoms. 
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1.9. Prognosis  
Over time (years), there is a slow decline in the prevalence of PI-IBS once the initial 
diagnosis has been established. In a 5 year review following Salmonella spp 
infection, a study by McKendrick et al 138 showed 7 out of 11 patients had abnormal 
bowel habit but only 5 had diarrhoea more than once a week. Another study 
reported 43% of PI-IBS patients had recovered after a 6 year follow up 139 while a 
meta-analysis of PI-IBS reported steady reduction in PI-IBS symptoms. The odd 
ratios for those infected compared to healthy controls at 3 months was 7.6 and at 3 
years it was 3.8 140. The long term follow up of the outbreak of gastroenteritis in the 
Walkerton outbreak showed a decline in the prevalence of PI-IBS from 28% to 
15.4% after 8 years. These data are reassuring as the prognosis of PI-IBS is good. 
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1.10. Mesalazine  
1.10.1. Background 
 
Mesalazine is an anti-inflammatory drug commonly used to treat mild to moderate 
iŶflaŵŵatoƌǇ ďoǁel diseases suĐh as ulĐeƌatiǀe Đolitis aŶd CƌohŶ͛s disease. It was 
first introduced in 1975 and it is a derivative of salicylate acid. Mesalazine is 
delivered as enteric-coated 5-amino-salicylate acid and exerts its effect mainly in 
the gastrointestinal tract. It is metabolised into N-acetyl-mesalazine by the 
intestinal mucosa and systemically in the liver. Some acetylation occurs through the 
action of colonic bacteria. It does not cross through the blood-brain barrier since 
the majority of the compound is protein bound.  Mesalazine is excreted in urine and 
faeces. In general, the medication is safe. 
 
1.10.2. Mode of action of Mesalazine/ Sulphasalazine in 
  IBS: 
 
Many studies in the past have showed Mesalazine can interfere with the activation 
of the inflammatory pathway. There is substantial evidence of low-grade immune 
activation in IBS particularly in those with diarrhoea following acute bacterial 
gastroenteritis141. The mucosal changes observed in the PI-IBS group were very 
similar to those in the IBS-D group64, 139, 142. Therefore, with these similar changes 
observed in both of these groups, it was worth using mesalazine as a treatment for 
the unselected group of patients with IBS-D.  
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Prior studies using mesalazine 
The first anecdotal open label trial of 12 patients with resistant IBS-D, who 
responded to mesalazine 143, showed a benefit that took about 2-3 months to 
become apparent.  There have since been three further reports of open label 
treatment 144, 145 and two small randomised control trials 146, 147.  All but the 
Corinaldesi trial 146 used patients with IBS-D.  The Bafutto trial used mesalazine 800 
mgs tds for 30 days in 61 IBS-D patients and showed benefit with a reduction in 
stool frequency, stool consistency and abdominal pain but was uncontrolled 145.  
The Andrews study involved just 6 patients but this showed mesalazine decreased 
biopsy proteolytic activity.  Both of the randomised control trials are rather too 
small to be sure of their significance with n=20 and 17 respectively.  One study 
showed a significant reduction of mast cell numbers and an overall reduction in 
inflammatory cells 146. 
 
1.10.3. Risk and benefits 
 
Mesalazine has been widely used for more than 45 years and there is extensive data 
on side effects.  In general, the drug is well tolerated.  Nephrotoxicity is seen at a 
rate of about 1 per 100,000 prescriptions 148, more common but less serious side 
effects include diarrhoea, nausea, vomiting and abdominal pain together with 
headaches and rarely pancreatitis and blood disorders.  Balancing this, irritable 
bowel syndrome patients suffer marked decrease in quality of life, similar to that of 
other chronic diseases like diabetes and heart failure.  They also lose significant 
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amounts of time off work, and when they are at work; work less efficiently.  A 
simple safe and effective treatment would be of undoubted benefit to what is a 
substantial subgroup of the population given that IBS with diarrhoea affects around 
3% of the general population. 
 
1.10.4. Rationale for the current study 
 
Studies in Nottingham over the last decade have identified the importance of 
inflammation in various subgroups of IBS.  We have focused on the group of IBS 
patients who develop symptoms following acute bacterial gastroenteritis, the so 
called post infectious IBS.  In this group, we have been able to show that the acute 
inflammatory insult associated with acute Campylobacter jejuni enteritis is followed 
by a more prolonged indolent phase with increased chronic inflammatory cells long 
after the infecting organism has left the body.  In this subgroup of IBS we have 
demonstrated activated circulating peripheral blood mononuclear cells with 
increased cytokine production and an associated increase in inflammatory gene 
expression 141.  We also demonstrated the importance of anxiety and depression 
107, which along with  adverse life events that increase the risk of post infective IBS 
(PI-IBS) 57.  The changes observed in PI-IBS are very similar to those in IBS-D, the 
predominant bowel disturbance being diarrhoea with a similar prognosis 139.  This 
work has been supported by others who have shown inflammatory changes in IBS-D 
patients who did not have a background of previous infection 64, 142.  Such studies 
have also shown increased inflammatory cells and increased expression of 
inflammatory cytokines including IL-ϭβ 127. Increased gut permeability has also been 
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shown  in IBS-D 61, making a trial of an anti-inflammatory treatment a logical choice.  
Safety is of pre-eminent importance in IBS drugs as can be seen by the recent 
withdrawal of Tegaserod 149 and the previous withdrawal of Alosetron 150. Both 
drugs, which were therapeutically effective, had to be withdrawn owing to rare side 
effects (incidence < 1 per 700 patient treated).  This leaves such patients bereft of 
effective treatments, a gap which mesalazine might well have filled.  Our hypothesis 
was that mesalazine by virtue of its anti-inflammatory actions will alter the 
inflammatory mediators; leading over a number of weeks, to a reduction in the 
number of mast cells and a reduction in the release of inflammatory mediators.  
Previous studies have shown that 5-Aminosalicylic acid (5-ASA) inhibits the release 
of inflammatory mediators including histamine and prostaglandin D2151.  It also 
iŶhiďits aĐtiǀatioŶ of the tƌaŶsĐƌiptioŶ faĐtoƌ NFκB ǁhiĐh is a ŵajoƌ liŶk iŶ the 
inflammatory cascade 152.  More recently, it has been recognised that 5-ASA exerts 
an anti-inflammatory effect mediated via peroxisome proliferator-activated 
receptor- (PPAR-receptors)153.  Whether directly or indirectly, 5-ASA has also been 
reported to inhibit inducible nitric oxide synthetase production and also 
prostaglandin production via its COX-2 inhibitory effects 154. Mesalazine therefore 
both by virtue of inhibiting other inflammatory pathways and by directly inhibiting 
mast cell pathways may reduce mucosal immune activation.   
We planned to investigate the effect of long term mesalazine on mast cell numbers, 
the chronic inflammatory cells and the mucosal production of inflammatory 
cytokines, IL-ϭβ, TNF- as well as mast cell specific tryptase. 
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1.10.5. Mesalazine product used for this study 
 
The product that was used for this study (described below) was called Pentasa, 
manufactured by Ferring Pharmaceuticals Ltd. The followings are the pharmacology 
properties based on the summary of product characteristics provided by the 
company:  
Pentasa sachet prolonged release granules consist of ethylcellulose coated 
microgranules of mesalazine. Recommended dose for adults is up to 4g / day in 
divided doses. Following administration, mesalazine is released continuously 
throughout the gastrointestinal tract in any enteral pH conditions. The 
microgranules enter the duodenum within an hour of administration, independent 
of food co-administration. The average small intestinal transit time is approximately 
3 – 4 h in healthy volunteers. 30-50% of Pentasa is absorbed predominantly in the 
small intestine155. It reaches a steady state after 5 days following oral 
administration. 
Manufacturer of Pentasa (including packaging): Ferring Pharmaceuticals Ltd. 
The manufacturing, packaging and labelling of the placebo was identical to the 
active drug except for the active ingredient.  
Manufacturer of placebo: QPharma AB (Sweden) and Ferring Pharmaceuticals Ltd. 
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1.11. Clinical trial to assess efficacy of Mesalazine in IBS-D 
Title of trial: Efficacy and mode of action of Mesalazine in the treatment of 
diarrhoea predominant irritable bowel syndrome  
 
This was a multi-centre, two-arm, parallel group, double blind, randomised placebo- 
controlled trial comparing mesalazine with placebo in patients with diarrhoea-
predominant irritable bowel syndrome.  
 
1.11.1. Aim of study 
 
a) The purpose of this trial was to define the clinical benefit and possible 
mediators of the benefit of mesalazine in IBS-D.  
b) Symptoms (primarily bowel frequency) and markers reflecting mast cell 
activation and small bowel tone were evaluated in this study.  
 
1) The primary objective  
Effect of mesalazine on stool frequency at end of study (weeks 11 and 12) 
2) The secondary objectives 
Effect of mesalazine on: 
a) Overall IBS symptoms 
b) Mast cell numbers, mucosal lymphocytes and faecal tryptases 
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c) Small bowel tone by measurement of fasting small bowel water content 
through MRI (discussed in the next chapter) 
d) To assess ability of biomarkers (mucosal/ MRI parameters) to predict 
treatment response 
 
1.11.2. Trial / study design 
 
This was a multi-centre, two-arm, parallel group, double blind, randomised placebo- 
controlled trial comparing Mesalazine with placebo in patients with diarrhoea-
predominant irritable bowel syndrome.  Design of the study was modified after 
consultation with a selection of interested patients from the Nottingham Digestive 
Diseases Biomedical Research Unit patient advisory group who provided a lay 
member for the Trial Steering Committee. 
1) Randomisation and blinding 
This was a double-blind parallel group study. Neither participant nor supervising 
doctor nor study nurse, were aware of the treatment allocation.  
The randomisation was based on a computer generated pseudo-random code using 
random permuted blocks of randomly varying size, created by the Nottingham 
Clinical Trials Unit (CTU) in accordance with their standard operating procedure 
(SOP) and held on a secure server. The randomisation was stratified by the 
recruiting centre.  The supervising doctor or study nurse obtained a randomisation 
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reference number for each participant by means of a remote, internet-based 
randomisation system developed and maintained by the Nottingham CTU.  
The sequence and decode of treatment allocations were concealed until all 
interventions were assigned and recruitment, data collection, and all other trial-
related assessments were complete.     
2) Participants 
a) Recruitment 
Participants were recruited between April 2011 and May 2013 with the last patient 
completed in August 2013. Participants were recruited from IBS clinics at the 
iŶǀestigatoƌ͛s hospital, oƌ fƌoŵ lists of patieŶts ǁho had pƌeǀiouslǇ takeŶ paƌt iŶ 
research studies and had indicated that they would like to be contacted about 
future relevant research projects. In addition, we had, in conjunction with the local 
Primary Care Research Network, approached GPs to ask them to search their 
databases for eligible participants and send out letters of invitation along with 
participant information sheet (PIS). This ensured that the initial approach to 
patients ǁas fƌoŵ a ŵeŵďeƌ of the patieŶt͛s usual Đaƌe teaŵ oƌ fƌoŵ appƌopƌiatelǇ 
authorised research nurses. We also advertised in the local newspaper due to slow 
recruitment and information about the study was on display in the relevant clinical 
areas. Ethical approval was sought for any adverts or posters displayed. Patients 
were seen in the research centres in participating hospitals and enrolled by 
research nurses or doctors.   
Initial recruitment into this trial was slow and it was felt that the eligibility criteria 
for IBS-D, was too demanding. We therefore modified the eligible criteria for IBS-D 
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following registration with the clinicaltrials.gov to reflect the fact that, as others 
have found, the bowel habit of IBS-D patieŶts is less aďŶoƌŵal thaŶ patieŶt͛s ƌeĐall 
suggests156. 
The patients were required to meet the modified Rome III criteria for IBS-D7, 
defiŶed as a stool fƌeƋueŶĐǇ of шϯ peƌ daǇ foƌ ŵoƌe thaŶ Ϯ daǇs peƌ ǁeek aŶd шϮϱ% 
of stools to be of type 5-ϳ aŶd чϮϱ% tǇpe ϭ-2 according to the Bristol Stool Form 
Scale (BSFS)157. To exclude other causes of diarrhoea, we required normal 
colonoscopy and colonic biopsies, normal full blood count, serum calcium and 
albumin, C-reactive protein and negative serological test for coeliac disease. Lactose 
intolerance was tested by asking patients to consume 568 ml of milk/day and 
performing a lactose breath hydrogen test to see whether they developed 
diarrhoeal symptoms within 3 hours.  If the stools were watery and frequent, the 
patient then underwent a 7-day retention of selenium75-labelled homocholic acid 
taurine test or a trial of cholestyramine to exclude bile acid malabsorption. If any of 
these tests were positive patients were excluded from the study.  
All patients gave written consent.  
During the screening period of 2 weeks, patients were only allowed a maximum 2 
doses of 4mg Loperamide per week and discontinued any IBS medication. Once 
randomised, patients were allowed to take Loperamide (as required) to control 
their symptoms, as we hypothesised that Mesalazine would take at least 6 weeks to 
exert its effect on the gut. At the last 2 weeks of the trial, patients were not allowed 
Loperamide or any antibiotics.  
Other inclusion and exclusion criteria were as stated below: 
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b) Inclusion criteria 
i. Male or Female patients aged 18-75 years able to give informed consent. 
ii. Patients should all have had a colonoscopy or sigmoidoscopy within the last 
12 months to exclude microscopic or any inflammatory colitis. (If not, but they 
have had a negative colonoscopy within 5 years and symptoms are 
unchanged, then a sigmoidoscopy and mucosal biopsy of the left colon would 
be sufficient to exclude microscopic or any inflammatory colitis). 
iii. IBS-D Patients meeting Rome III criteria prior to screening phase. 
iv. PatieŶts ǁith шϮϱ% soft ;sĐoƌe >ϰͿ aŶd <Ϯϱ% haƌd ;sĐoƌe ϭ oƌ ϮͿ stools duƌiŶg 
the screening phase, as scored by the daily symptom and stool diary*. 
v. Patients with a stool frequency of 3 or more per day for 2 or more days per 
week during the screening phase*. 
vi. Satisfactory completion of the daily stool and symptom diary during the 
screening phase at the discretion of the investigator. 
vii. Women of childbearing potential willing and able to use at least one highly 
effective contraceptive method throughout the study. In the context of this 
study, an effective method is defined as those which result in low failure rate 
(i.e. less than 1% per year) when used consistently and correctly such as: 
implants, injectables, combined oral contraceptives, sexual abstinence or 
vasectomised partner.  
*If inclusion criterion 4 and/or 5 were not met but the results were considered 
atypical (as observed from medical history and patient recall) then the patient was 
allowed to re-screen on 1 occasion only. There had to be sufficient data completed 
during the screening phase to allow adequate classification. 
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Definition of IBS-D meeting Rome III criteria 7. 
Abdominal pain or discomfort at least 2- 3 days/month in the last 3 months 
(criterion fulfilled for the last 3 months with symptom onset at least 6 months prior 
to screening) associated with two or more of the following: 
 Improvement with defecation;  
 Onset associated with a change of stool frequency;  
 Onset associated with a change in form (appearance) of stool. 
 
c) Exclusion criteria 
i. Women who are pregnant or breast-feeding. 
ii. Prior abdominal surgery which may cause bowel symptoms similar to IBS 
(note appendectomy and cholecystectomy will not be an exclusion). 
iii. Patients unable to stop anti-muscarinics, anti-spasmodics, high dose tricyclic 
antidepressants (i.e. above 50 mg/day), opiates / anti-diarrhoeal drugs*, 
NSAIDs (occasional over the counter use and topical formulations are 
allowed), long-term antibiotics, other anti-inflammatory drugs or 5-ASA 
containing drugs.  
iv. Patients on selective serotonin re-uptake inhibitors and low dose tricyclic 
antidepressants (i.e. up to 50 mg/day) for at least 3 months previous unwilling 
to remain on a stable dose for the duration of the trial 
v. Patients with other gastro-intestinal diseases including Đolitis aŶd CƌohŶ͛s 
disease. 
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vi. Patients with the following conditions: Renal impairment, severe hepatic 
impairment or salicylate hypersensitivity. 
vii. Patients currently participating in another trial or have been in a trial within 
the previous 3 months. 
viii. Patients who in the opinion of the investigator are considered unsuitable due 
to inability to comply with instructions. 
ix. Patients with serious concomitant diseases e.g. cardiovascular, respiratory, 
neurological etc. 
x. Positive test for bile acid malabsorption 
*(A full list of excluded or dose controlled medications can be found in Appendix 1) 
*Loperamide was allowed as rescue medication throughout the trial, however if >2 
doses / week were taken during the screening phase then they were not eligible, 
though they could be re-screened on 1 occasion only. 
 
d) Expected duration of participant participation 
Study participants participated in the study for 14 weeks.  
 
e) Removal of participants from therapy or assessments 
The following subject withdrawal criteria applied: 
i. Non-compliance - if less than 75% of IMP doses* are taken between visits, at 
the iŶǀestigatoƌ͛s disĐƌetioŶ. 
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*as advised by the study doctor, taking into account that not all participants will be 
advised to take the full study dose due to intolerance. 
ii. If the participant has remained on the initial lower dose of 2g once a day for 3 
ǁeeks aŶd the ŵediĐatioŶ is still Ŷot toleƌated, at the iŶǀestigatoƌ͛s disĐƌetioŶ. 
iii. Adverse reaction (serious and non-serious) with clear contraindications. 
iv. Participant withdraws consent. 
v. Safety reasons e.g. pregnancy** 
vi. Lost to follow up. 
vii. Participant develops an excluded/contraindicated condition. 
viii. Investigator discretion. (e.g. Protocol violations) 
ix. Un-blinding, at the discretion of the PI in conjunction with the CI. 
Participants withdrawn from the study were replaced. The participants were told 
that withdrawal would not affect their future care. Participants were also made 
aware (via the information sheet and consent form) that should they withdraw the 
data collected up to their withdrawal cannot be erased and may still be used in the 
final analysis. 
** In the event of a pregnancy occurring in a trial participant or the partner of a trial 
participant, monitoring shall occur during the pregnancy and after delivery to 
ascertain any trial related adverse events in the mother or the offspring. Where it is 
the partner of a trial participant, consent will be obtained for this observation from 
both the partner and her medical practitioner. 
3) Summary of overall trial design: 
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Participants were identified from both primary and secondary care. They were 
required to meet the modified Rome III criteria and then underwent a 2-week 
screening with stool diary (see inclusion and exclusion criteria). If eligible, they were 
randomised (week 0) into taking either a 2g Mesalazine or placebo for the first 
week and an increment of 4g if they tolerated the medication after 7 days. A weekly 
stool diary had to be completed for 12 weeks. Participants had telephone call visits 
at week 1, 3 and 9 to assess for tolerance and compliance. They then returned, in 
the middle of the trial (week 6) to replenish their medication. They were required to 
fill in study questionnaires at the beginning and end of the study. Samples of stool, 
blood and serum were taken at the beginning and end of the study.  
For participants in Nottingham (following consent), participants had a fasting 
baseline and end of study magnetic resonance imaging of their abdomen and 
sigmoid biopsy (Figure 6 and Table 2). 
Figure 6: Schematic drawing of the study design 
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Table 2: Patient visits and contacts 
Procedure 
(Time (T) in wk) 
Visit 1 
Screening 
(T = -2) 
Visit 2 
Randomisation 
(T = 0, from 1st dose) 
 
 
(T = 1) 
e 
 
(T = 3) 
Visit 3 
 
(T = 6) 
e 
 
(T = 9) 
Visit 4 
Final visit 
(T = 12) 
Check eligibility   ● ● 
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Informed consent ●    
Demographics and bowel symptoms ●    
Physical examination and history  ●    
Daily symptom and stool diarya ● ● ● ● 
Sigmoidoscopy with biopsy to exclude microscopic colitisb ●    
Pregnancy test  ●   
Randomisation  ●   
Questionnairesc  ●  ● 
Blood and stool sample   ● ● ● 
Flexible sigmoidoscopy and biopsiesd  ● ;NottiŶghaŵ oŶlǇͿ  ● ;NottiŶghaŵ oŶlǇͿ 
MRI scansd  ● ;NottiŶghaŵ oŶlǇͿ  ● ;NottiŶghaŵ oŶlǇͿ 
IMP Dispense  ● ●  
Return   ● ● 
Adverse reaction recording   ● ● 
a Daily symptom and stool diary ǁas Đoŵpleted thƌoughout the paƌtiĐipaŶt͛s iŶǀolǀeŵeŶt iŶ the tƌial. These ǁeƌe ƌeǀieǁed at eaĐh ǀisit 
b Unless the participant had had a colonoscopy within the last 12 months that excluded microscopic or any inflammatory colitis. 
c CDC HRQOL4, EQ-5D, HADS and PHQ-15.  
d Only participants recruited at the Nottingham site underwent MRI scans and flexible Sigmoidoscopy with biopsies. 
e Telephone contact was either by telephone or e-mail or if convenient at the hospital 
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1.11.3. Main outcome measure: 
 
1) Clinical outcome: 
a) Primary endpoint:  
Daily mean stool frequency during weeks 11-12 of the treatment period 
b) Secondary endpoint  
(all assessed during weeks 11-12 of the treatment period) 
i. Average daily severity of abdominal pain on a 0-10 scale.  
ii. Days with urgency during weeks 11-12 post-randomisation. 
iii. Mean stool consistency using Bristol Stool Form Score. 
iv. Global satisfaction with control of IBS symptoms as assessed from the answer 
to the ƋuestioŶ ͞Haǀe Ǉou had satisfaĐtoƌǇ ƌelief of Ǉouƌ IB“ sǇŵptoms this 
ǁeek? Yes/No.͟ 
c) Ancillary secondary endpoints 
i. EQ-5D  
ii. CDC HRQOL4 
iii. HADS  
iv. PHQ-15 
 
d) Safety endpoints 
i. Adverse events related to the trial treatment  
ii. Withdrawal from the trial treatment due to adverse events. 
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2) Mechanistic outcome:  
a) Primary endpoint: 
Mast cell numbers (mean % area stained per m2) at week 12 
b) Secondary endpoints: 
i. Mast cell tryptase release during 6-hour biopsy incubation  
ii. IL-ϭβ, TNF-, histamine and serotonin secretion during same incubation  
iii. Small bowel tone assessed by volume of fasting small bowel water (Section 3) 
iv. Faecal Tryptases and calprotectin 
 
1.11.4. Sample size 
 
Our previous study on diarrhoea predominant IBS patients gives a mean stool 
frequency of 3.1 (standard deviation 2.0). Tuteja and colleagues reported 
Mesalazine decreasing stool frequency by 1.4 bowel movements per day147. Our 
study had 80% power to detect such an effect at the 1% two-sided alpha level. We 
aimed to randomise at least 125 patients to allow for a 20% drop out rate but owing 
to recruitment ongoing at multiple sites and patient requests we actually recruited 
136.  
Much smaller numbers are needed to assess the effect of Mesalazine on mast cell 
numbers and tryptase release. Corinaldesi et al reported a 36% decrease in mast 
cell numbers from mean 9.2, (standard deviation 2.5) 146 that required just 12 
50 
patients to show such a decrease with a power of 90% at the 1% alpha level.   
 
1.11.5. Data Analysis 
 
(An independent statistician at the University of Nottingham performed all clinical 
primary and secondary analyses. The remaining analyses such as the mechanistic 
and post hoc analyses were carried out by myself.) 
Analysis and presentation of data was in accordance with CONSORT guidance. The 
primary data set included stool diary filled out for at least 10 days out of 14. Balance 
between the trial arms at baseline was examined using appropriate descriptive 
statistics. For continuous variables, data was summarised in terms of the mean, 
standard deviation, median, lower & upper quartiles, minimum, maximum and 
number of observations.  Categorical variables were summarised in terms of 
frequency counts and percentages.   
The general approach for between-group comparisons was intention-to-treat (ITT).  
Appropriate regression modelling was used to evaluate the primary and secondary 
outcomes, and safety data, with due emphasis placed on clinical importance of 95% 
confidence intervals for between-group estimates. 
No formal adjustment for multiple significance testing was applied. 
Full details were given in a separate Statistical Analysis Plan and approved before 
data lock. 
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The safety monitoring functions of the trial were undertaken by the Data 
Monitoring Ethics Committee (DMEC). The DMEC meetings were held bi-annually 
and the committee members were happy with the progress of the trial. 
Clinical  
1) Assessment of efficacy 
We used descriptive statistics to compare the randomised groups at baseline. The 
primary outcome was assessed using intention to treat without imputation. We 
used a generalised linear mixed model to compare Mesalazine group and placebo 
group for the primary outcome, with adjustment for the baseline value of the 
outcome, and study centre as a random effect. Additionally, we adjusted for any 
variables showing imbalance at baseline in secondary models. We compared the 
characteristics of participants who did and did not adhere with the study 
medication before estimating the treatment effect and if the medication was 
actually taken using Complier Average Causal Effect (CACE) analysis. We 
investigated the effect of missing primary outcome data using multiple imputations. 
The secondary outcomes were assessed using similar models as for primary 
outcome, or logistic or Poisson regression as appropriate dependent on outcome 
type.  
We undertook subgroup analyses by including appropriate interaction terms in the 
linear mixed model for primary outcome according to baseline daily mean stool 
frequency, baseline mean abdominal pain score and baseline mean HADS anxiety 
score.  
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Secondary outcomes were treated similarly, after transformation if appropriate, 
while binary and count outcomes were handled by multiple logistic or Poisson 
regression as appropriate. All analyses were performed using the current version of 
Stata adopting the intention to treat principle without imputation for missing data 
(with a sensitivity analysis using multiple imputation for the primary outcome). . 
We planned to conduct a number of pre-specified subgroup analyses.  
For each of the following three outcomes: 
a) Stool frequency during week 11-12  
b) Number of days with any stool consistency scoring 6 or 7 during week 11-12 
c) Average of worst pain for each day during week 11-12 
We investigated whether there were any differences in between-group effects 
according to the following baseline variables: (1) anxiety; (2) stool frequency; (3) 
abdominal pain; (4) mast cell activation* 
These sub-group analyses were conducted by including appropriate interaction 
terms in the regression models, and as the study has not been powered to detect 
any such sub-group effects, were considered as exploratory and would require 
confirmation in future research 
*Mast cell activation will be defined as elevation of any of the inflammatory 
mediator components such as mast cell tryptase, IL-ϭβ, TNF-α, histaŵiŶe aŶd 
serotonin in biopsy supernatant. 
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The primary mechanism hypothesis to be investigated was that treatment with 
Mesalazine reduces inflammation, which in turn reduces clinical symptoms. The aim 
of this type of analysis is to estimate how much of any observed treatment effect 
can be attributed to a variable that is thought to be an intermediate on the causal 
pathway, or mediator. 
After summarising inflammatory markers at baseline and 11-ϭϮ ǁeeks͛ folloǁ up ďǇ 
trial arm using appropriate descriptive statistics, we will examine change in these 
markers (stool calprotectin, mast cell tryptase and mast cell  % area stained) and 
change in stool frequency using a scatterplot.  
2) Procedures for missing data 
The effect of missing data will be investigated in sensitivity analyses by multiple 
imputations using the method of chained equations.  Incomplete data is defined as 
stool diary completed for <10 out of 14 days during weeks 11-12. 
3) Definition of populations analysed 
Safety set: All randomised participants who received at least one dose of the study 
drug. 
ITT set: All randomised participants for whom at least one post-baseline assessment 
of the primary endpoint is available 
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Mechanistic 
The primary mechanistic hypothesis to be investigated was that treatment with 
Mesalazine reduces inflammation, which in turn reduces clinical symptoms. The aim 
of this type of analysis is to estimate how much of any observed treatment effect 
can be attributed to a variable that is thought to be an intermediate on the causal 
pathway, or mediator. After summarising inflammatory markers at baseline and 11-
ϭϮ ǁeeks͛ folloǁ up ďǇ tƌial aƌŵ usiŶg appƌopƌiate desĐƌiptiǀe statistiĐs, the change 
in these markers (stool calprotectin, mast cell tryptase, mast cell  % area stained) 
and change in stool frequency using scatterplots were examined.  
The statistical analysis was carried out with the use of Prism 6 (GraphPad Software 
Inc, San Diego, CA). Normality of the data was tested by using the D'Agostino & 
Pearson omnibus normality test. Comparisons between 2 different groups were 
done using the two-tailed Mann Whitney test or unpaired t-test depending on 
normality. Comparisons within similar group were done using Wilcoxon matched-
pairs sign rank test or paired t-test depending on normality. The sample size for 
further subgroup analyses were small, therefore no assumptions were made about 
the distribution of data, and non-parametric testing was used. The data are 
expressed as mean (± SD) when normally distributed and as median (interquartile 
range) when not normally distributed. 
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1) Sigmoid biopsy 
Patients who consented to this had a sigmoid biopsy taken before and after 
treatment. This was performed in the unprepared bowel.  8 tissue biopsy samples 
were obtained from the sigŵoid ĐoloŶ ;ϯϬĐŵ fƌoŵ the aŶusͿ usiŶg a ͚Ϯ.ϰ ŵŵ 
Captuƌa ďiopsǇ foƌĐeps ǁithout spike͛ ďǇ Cook@ Medical. They were taken for: 
Immunohistochemistry (H+E, CD3, CD68, 5-HT and mast cell tryptase) 
Supernatants for tryptase, carboxypeptidase A3, chymase, histamine and serotonin 
Results of the immunohistochemistry and supernatants for tryptase, 
carboxypeptidase A3, chymase, histamine and serotonin were compared against a 
group of healthy controls from a previous study. The preparation of the sigmoid 
biopsy samples was similar for the healthy control. Biopsy samples obtained from 
the healthy controls were processed in the same period of time as the IBS-D 
patients.  
 
a. Immunohistochemistry 
2 biopsy samples obtained were soaked in formalin until they are ready to be cut, 
fixed and embedded in paraffin wax. Samples were sent to the histopathology 
laboratory at QueeŶ͛s MediĐal CeŶtƌe, Nottingham University Hospitals Trust, for 
dissection, embedding and staining. Immunohistochemistry staining were for CD3, 
CD68, enterochromaffin cells containing serotonin (5-HT) and mast cell tryptase 
(MCT). Table 3 (below) shows a simplified protocol for these stains. 
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Table 3: Protocol for immunohistochemistry staining (courtesy from 
Immunohistochemistry laboratory in Nottingham University Hospitals Trust) 
Antibody Supplier (order code) Dilution Pretreatment 
MCT Dako (M7052) 1/500 Protease 1 for 4 min 
Primary antibody for 32 min 
Roche Ultraview detection kit 
plus Amplification 
CD3 Leica (NCL-L-CD3-565) 1/50 SCC1 (EDTA based buffer) for 64 
min 
Primary antibody for 32 min 
Ultraview detection kit plus 
Amplification 
CD68 Dako (M0814) 1/2000 SCC1 for 64 min 
Primary antibody for 32 min 
Ultraview detection 
5HT Dako (M0758) 1/400 Protease1 for 4 min 
Primary antibody for 32 min 
Ultraview detection 
 
The slides prepared were scanned into the computer using the nanozoomer and 
were magnified x40 for ease of portability. Cell counting was performed by a single 
person (LTX; fellow from the FRAME lab, University of Nottingham) who was 
blinded to the study. Detection of each stained cell type was checked for 
reproducibility (>95%) before cell counting began. At least 5-10 areas around lamina 
propria were drawn and CD68 cells were counted giving an average cell number per 
mm2. CD3, which is a marker of lymphocytes, was assessed by counting the number 
of stained cells at the superficial epithelium per area drawn (mm2) and an average 
obtained. The 5-HT cells were counted at the deep lamina propria and an average of 
number of cells/mm2 obtained. Mast cell tryptase expression was detected in the 
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lamina propria using automatic software (i-Tem by Olympus) as some mast cells 
may be in a de-granulated state, thus making cell counting difficult. Results were 
presented as the percentage area stained for mast cell tryptase.  
b. Tissue biopsy for supernatants: 
Preparation:  
2 biopsies were obtained and immediately processed to obtain biopsy 
supernatants. Initial biopsies were weighed before each was placed into a Falcon 
3037. 1 ml sterile water was placed around the edge of each biopsy before adding 2 
ml of Hanks balanced salt solution (LH-SIG2025E) into the centre of the Falcon 3037. 
This was then placed into the incubator for 30 minutes at 37oC, 5% CO2. After 30 
minutes, the central solution (supernatant) was collected and placed into a cryovial 
for storage at -80oC. A further 2 ml Hanks solution was added to the centre of the 
Falcon 037 and incubated for a further 30 minutes at the same temperature and 
CO2 setting. Following 30 minutes, the supernatant was collected and placed into a 
2nd cryovial for storage at -80oC. This process is repeated again for a third time. At 
the end of the 3rd incubation, the biopsy was weighed and stored at -80oC.  
The supernatants from the 1st incubation (0-30 min) were used to measure these 
contents: 
i. Serotonin (5HT)  
ii. Tryptase 
iii. Chymase 
iv. Carboxypeptidate 3 (CPA3) and  
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v. Histamine 
Serotonin (5HT) supernatant assay protocol 
The samples were processed and analysed by Dr Gulzar Singh (School of Medicine, 
University of Nottingham). 
Preparation of samples for analysis 
5HT release supernatant samples were freeze-dried initially.  
The residue was dissolved in 400ul of methanol: water (50:50).  
The samples were then vortexed for 30 seconds, and centrifuged at 25,000g for 
10min.  
The 5HT-containing supernatant was filtered through cellulose acetate membrane 
with pore size 0.2um and analysed using liquid-chromatography mass-spectrometry 
system (LC-MS). 
5HT assay using LC-MS 
Reversed-phase HPLC was used, a Luna column C18 (3um, 2.1 x 75mm) 
chromatographed at 0.4mL.min-1 on a Jasco PU-2085 Plus semi-micro HPLC pump 
system using an isocratic  system of 5% acetonitrile and 0.01% formic acid in water.  
A Triple Quadrupole mass-spectrometer (Waters Quattro Ultima) was employed 
using positive-ion Electrospray ionisation with time-resolved MRM transitions for 
precursor and product ion analysis and using MassLynx 4.0 software to control all 
systems and data processing.  
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Analysers was mass-calibrated using a range of standard 5HT concentrations and 
alpha-methyl 5HT was be used as an internal standard. 
 
Waters Quattro Ultima LC-MS/MS. 
This is a triple quadrupole instrument with excellent performance for quantitative 
analysis.  It is used for targeted metabolite profiling and readily capable of 
monitoring multiple analysates simultaneously. The Liquid Chromatography mass-
spectrometry (LC-MS-MS) system consists briefly of:- 
Waters 2700 Sample Manager autosampler. 
Alltech degassing system. 
Perkin –Elmer column oven. 
Jasco PU-2085 Plus semi-micro HPLC pumps. 
Waters MS-MS triple quadrupole Quattro Ultima 
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Mast cell mediators 
Mast cell proteases (tryptase, chymase and CPA3) were measured by sandwich 
ELISA assays provided by the Immunopharmacology Research Group, the University 
of Southampton, as described previously 158-160. Briefly, coating antibodies against 
tryptase (EAR), chymase (CC2) and CPA3 (CA2) were coated on 96 well ELISA plates 
(COSTAR) for overnight at +40C. Blocking with 2% BSA after three washes for one 
hour at room temperature; followed by adding samples or protein standards of 
tryptase, chymase or CPA3 which were extracted and purified by the same research 
group. The plates were incubated for 90 min; then detecting antibodies specifically 
against tryptase (AA1), chymase (CC5) or CPA3 (CA5) were used.  Finally, the avidin-
HRP and colorimetric subtract TMB system was used, and the absorbance was read 
at 450nm of the microplate reader, Thermo max (Molecular Devices). Prior to all 
assays, the validation to the specific body fluids and protein spiking were carried 
out. The assays were blinded. 
Histamine was measured using a commercial kit called Histamine (Life science 
format) Elisa kit by Neogen® Cooperation. This was processed by the 
Immunopharmacology Research Group, the University of Southampton. See 
Appendix 4 for instructions.  
c) Serotonin and 5HIAA content 
Sigmoid biopsies obtained, were immediately snap frozen in liquid nitrogen before 
being stored in a -80oC freezer prior to processing. 
Preparation of samples for analysis 
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Preparation and analysis for Serotonin and 5HIAA content was performed by Dr 
Gulzar Singh (School of Medicine, University of Nottingham).  
i. 5HT release supernatant samples were freeze-dried initially.  
ii. The residue was dissolved in 400ul of methanol: water (50:50).  
iii. The biopsies were homogenised for 10 s using MSE sonicator (Soniprep 150, 
MSE (UK) LTD., Worsley Bridge Rd. Lower Sydenham, London). 
iv. The samples were then vortexed for 30 seconds, and centrifuged at 25,000g 
for 10min.  
v. The 5HT-containing supernatant was filtered through cellulose acetate 
membrane with pore size 0.2um and analysed using liquid-chromatography 
mass-spectrometry system (LC-MS). 
vi. The rest of the processing was similar as above for Serotonin supernatant 
assay analysis. 
 
d) Inflammatory mediators 
Levels of IL-1 and TNF- was analysed by using a commercial kit V-Plex 
immunoassay by Meso Scale Discovery, Rockville, United States of America. This 
was processed by a clinical fellow from the Centre of Biomolecular Science, 
University of Nottingham. He was blinded to the study. 
e) Stool: 
i. Stool tryptase methodology 
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Stool samples were collected no more than 2 hours before it was handed over to 
the research staff for storage in the -80 0C freezer. All processing has been 
performed by BRU technicians (Melanie Lingaya and Yirga Falcone) and results 
obtained thereafter. Samples were analysed for faecal tryptase based on methods 
published recently by our group161.  See Appendix 6 for methodology. Faecal 
protease activity is expressed in trypsin units per milligram of protein 
ii. Stool calprotectin  
Note: freezing stool samples may result in slight increased in calprotectin 
concentrations due to lysis of neutrophils in the sample. 
The Buhlmann calprotectin ELISA kit was used for extraction and quantification of 
stool calprotectin (MRP8/14; S100A8/S100A9). Below (Figure 7) is the short 
protocol for calprotectin extraction 
Full instruction in Appendix 5 
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Figure 7: Short protocol on calprotectin extraction  
 
BÜ
APPENDIX IV 
SHORT PROTOCOL 
CALPROTECTIN EXTRACTION 
 
Standard Extraction Procedure  
 
 
 
 
CALPROTECTIN ELISA 
 
Precoated Microtiter Plate 
 
 wash 2 x 
 
 
100 µL Calibrators Controls 
or diluted Samples  
 
 incubate 30 (+ 5) minutes 
 at 18-28°C on a plate rotator 
 wash 3 x 
 
add 100 µL Enzyme Label 
 
 incubate 30 +/- 5 minutes 
 at 18-28°C on a plate rotator 
 wash 5 x 
 
add 100 µL TMB Substrate 
 
 incubate 15 +/- 2 minutes 
 at 18-28°C on a plate rotator 
 
add 100 µL Stop Solution 
 
Read absorbance at 450 nm (within 30 minutes) 
 
TIME TO RESULT: 75 MINUTES 
0.0 mg 
Pre-weigh empty tube  
+ Inoculation loop 
75.0 mg 
Weigh 50 to100 mg 
faeces 
Add 49 volumes  
of 1x B-CAL-EX 
Close tube and 
vortex vigorously 
for 30 min 
Centrifuge 5 min 
at 3’000 x g  Transfer supernatant into a fresh tube and continue with the lower 
or extended range ELISA 
procedure (1:50 or 1:150). 
Transfer ~1.0 ml  
into a fresh tube 
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1.11.6. Results 
 
Of 221 initially screened, 185 were eligible and 136 were enrolled and randomised 
into the study (Figure 8). Follow up was completed in August 2013. The most 
frequent reason for exclusion was decline to participate.  The commonest reason 
for not meeting inĐlusioŶ Đƌiteƌia ǁas that the patieŶts͛ diaƌies duƌiŶg the Ϯ ǁeeks 
ƌuŶ iŶ peƌiod iŶdiĐated that theǇ did Ŷot haǀe loose stools шϮϱ% of the tiŵe oƌ stool 
frequency of 3 or more per day for 2 or more days per week. 
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Figure 8: Patient flow diagram (CONSORT diagram) 
  
  
Number of patients 
screened (n=221) 
 
Randomised (n= 136) 
Allocated to IMP (n= 68) 
 
Allocated to placebo (n= 68) 
 
Primary outcome not available 
(n = 11) 
 
Withdrew consent = 2 
Loss to follow up = 1 
Adverse event  (n =8) 
 
Pregnant = 1 
Dizzy = 1 
Discoloured urine = 1 
Exacerbation of IBS = 2 
Chest pain = 1 
Breast cancer = 1 
Flu-like illness  = 1 
 
 
Primary outcome not available 
(n = 10) 
 
Withdrew consent  = 2 
Loss to follow up  = 1 
Incomplete diary wk11-12 =1 
Adverse event (n=6) 
 
Bloating = 2 
Exacerbation IBS = 3 
Rash = 1 
 
 
 
Included in ITT analysis (n =57) 
 
Included in ITT analysis (n =58) 
 
Excluded  (n=85) 
=  Not meeting inclusion criteria 
(n=36) 
=  Declined to participate (n= 49) 
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1) Demographics: 
There were a total of 8 sites that participated in this study. Table 4 and 
Supplementary tables 1 and 2 (Appendix 7) showed a summary of recruitment by 
site and by treatment arm. 
Characteristics of enrolled patients in both groups were similar at baseline (Table 5).  
Table 4: Summary of recruitment by site and by treatment arm 
Site  Placebo Mesalazine 
Nottingham  38 40 
Manchester  16 15 
Derby  2 2 
Mansfield  4 3 
Doncaster  5 5 
Stoke on Trent  1 1 
South tees  1 1 
North tees  1 1 
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Table 5: Summary of baseline data by treatment group 
Characteristic Mesalazine 
(n=68) 
Placebo 
(n=68) 
Total 
(n=136) 
Age at enrolment 
Mean (SD) 
 
42.6 (15.2) 
 
47.1 (13.5) 
 
44.8 (14.4) 
Gender 
Male N (%)  
26 (38.2%) 28 (41.2%) 54(39.7%) 
Ethnicity 
White 
Black 
Asian 
Mixed 
Other 
 
66 (97.1%) 
0 
1 (1.5%) 
1 (1.5%) 
0 
 
66 (97.1%) 
1 (1.5%) 
0 
0 
1 (1.5%) 
 
132(97.1%) 
1(0.7%) 
1(0.7%) 
1(0.7%) 
1(0.7%) 
Daily mean stool frequency   
Mean (SD) 
 
3.6 (1.6) 
 
3.6 (1.8) 
 
3.6 (1.7) 
Daily mean abdominal pain 
score 
 Mean (SD) 
 
4.1 (2.2) 
 
3.6 (2.0) 
 
3.6 (1.7) 
Number of days with urgency  
Median (IQR) 
 
13 (10-14) 
 
12 (9-14) 
 
12.5 (9-14) 
Stool consistency  
Mean (SD) 
 
5.4 (0.7) 
 
5.6 (1.0) 
 
5.5 (4.4) 
HADS score  
Mean (SD) 
 
9.1 (4.5) 
 
8.6 (4.3) 
 
8.8 (4.4) 
PHQ-15 score  
Mean (SD) 
 
12.6 (5.2) 
 
13.1 (5.6) 
 
12.8 (5.4) 
 
Symptoms are based on 14 days screening symptom diaries 
Primary and secondary outcome data were collected for 115 (85%) and 116 (85%) 
participants respectively at 11-12 weeks of follow up.    
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2) Clinical primary outcome: 
The primary intention to treat comparison showed no evidence of any clinically 
significant difference between Mesalazine and placebo for the primary outcome 
(Table 6). Additional adjustments for variables (age, abdominal pain score, number 
of days with urgency and PHQ-15 score) displaying imbalance at baseline did not 
materially change the results, nor did multiple imputation analysis or CACE analysis 
(Tables 7a-c).  
Subgroup analyses (Table 8a) of the primary outcome by baseline daily mean stool 
frequency suggest that Mesalazine may be more effective among patients with 
greater baseline stool frequency which is associated with larger treatment effect 
but this could be a chance finding and would require confirmation in further 
studies. There was no evidence that treatment effect differed according to baseline 
pain or hospital anxiety and depression score (HADS) (Tables 8b and 8c).   
Our sensitivity analysis using multiple imputation of missing data for the primary 
outcome showed no effect on primary outcome (Table 7b).  
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Table 6: Clinical primary outcome of daily mean stool frequency at week 11-12 
Daily mean stool frequency   [mean (SD)] 
 11-12 weeks Between group difference at 
11-12 weeks (95% CI)* 
P value 
Placebo (N=58) 2.7 (1.9)  -- -- 
Mesalazine 
(N=57) 
2.8 (1.2)  -- -- 
Mesalazine vs. 
Placebo 
-- 0.10 (-0.33,0.53) 0.66 
 
Table 7a: Primary analysis with further adjustment of baseline covariates 
Average Stool 
Frequency 
Adjusted* Diff. in 
mean frequency 
P-value 95% C.I. 
Mesalazine (N=57) 
vs.  Placebo (N=58) 
 
0.13 
 
0.56 
 
(-0.31, 0.57) 
*Adjusted by age, study centre and baseline daily mean stool frequency  
Table 7b: Primary analysis with multiple imputation 
Average Stool  
Frequency 
Adjusted* Diff. in 
mean frequency 
P-value 95% C.I. 
 
Mesalazine (N=57) 
vs. Placebo (N=58) 
 
0.06 
 
0.17 
 
(-0.18, 0.99) 
*Adjusted by baseline daily mean stool frequency and study centre  
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Table 7c: Primary analysis (CACE) 
Average Stool 
Frequency 
Adjusted* Diff. in 
mean frequency 
P-value 95% C.I. 
 
Mesalazine (N=57) 
vs. Placebo (N=58) 
 
0.16 
 
0.67 
 
(-0.58, 0.91) 
*Adjusted by baseline daily mean stool frequency and study centre 
Table 8a: Primary outcome subgroup analysis by baseline stool frequency 
 Placebo (N=58) Mesalazine (N=57) 
Daily mean stool frequency at 11-12 weeks by baseline frequency    [mean (SD)] 
Baseline frequency 2.4 1.6(0.5) 1.7(0.4) 
Baseline frequency >2.4 and 3.4 2.2(1.1) 2.2(0.5) 
Baseline frequency  >3.4 and 4.6 2.7(0.9) 3.1(1.3) 
Baseline frequency  >4.6 4.7(2.9) 4.1(1.1) 
Estimates* for interaction in primary analysis model with 95% CI and P value 
Primary outcome by baseline 
stool frequency 
-0.26 (-0.51, -0.01); p=0.04 
*adjusted by baseline daily mean stool frequency and study centre  
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Table 8b: Primary outcome subgroup analysis by baseline abdominal pain score 
 Placebo (N=58) Mesalazine (N=57) 
Daily mean stool frequency at 11-12 weeks by baseline abdominal pain score    
[mean (SD)] 
Baseline pain score 2.2 
2.9(2.8) 2.7(0.9) 
Baseline pain score  >2.2 and 4.1 2.6(1.4) 2.4(0.7) 
Baseline pain score  >4.1 and 5.3 2.4(1.4) 3.0(1.6) 
Baseline pain score  >5.3 
3.2(1.7) 2.9(1.3) 
Estimates* for interaction in primary analysis model  with 95% CI and P 
Primary outcome by baseline 
pain score 
-0.03 (-0.10, 0.04); p=0.36 
*adjusted by baseline daily mean stool frequency and study centre 
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Table 8c: Primary outcome subgroup analysis by baseline HADS score 
 Placebo (N=58) Mesalazine (N=57) 
Daily mean stool frequency at 11-12 weeks by baseline HADS score [mean (SD)] 
Baseline HADS score 5.0 
3.1(3.2) 3.0(1.4) 
Baseline HADS score  >5.0 
and 9.0 2.3(1.3) 2.8(1.2) 
Baseline HADS score  >9.0 
and 11.5 3.0(1.5) 2.9(1.3) 
Baseline HADS score  >11.5 
2.0(0.9) 2.6(1.3) 
Estimates* for interaction in primary analysis model with 95% CI and P 
Primary outcome by baseline 
HADS score 
-0.01 (-0.04, 0.03); p=0.79 
*Adjusted by baseline daily mean stool frequency and study centre 
 
3) Clinical secondary outcomes: 
No differences were apparent for any of the secondary outcomes, with the 
exception of number of days with urgency (Table 9), which were increased by about 
20% on Mesalazine treatment compared to placebo.  
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Table 9: Secondary outcome results 
 Baseline 11-12 weeks Between group 
comparison at 11-
12 weeks (95% 
CI)1 
P value 
Daily mean abdominal pain score [mean (SD)] 
Placebo  3.6(2.0) 2.2(2.1) 
(N=59) 
-- -- 
Mesalazine 4.1(2.2) 2.8(2.1) 
(N=57) 
-- -- 
Mesalazine vs. 
Placebo 
-- -- 0.07 (-0.54, 0.68)2 0.83 
 
Number of days with urgency [median (IQR)] 
Placebo 12[9-14] 8(1-13) (N=59) -- -- 
Mesalazine 13[10-14] 11(5-14) 
(N=57) 
-- -- 
Mesalazine vs. 
Placebo 
-- -- 1.22 (1.07, 1.39)3 <0.01 
 
Weekly mean stool consistency [mean (SD)] 
Placebo  5.6[1.0] 4.7(1.1) 
(N=59) 
-- -- 
Mesalazine  5.4[0.7] 4.7(1.0) 
(N=57) 
-- -- 
Mesalazine vs. 
Placebo 
-- -- 0.13(-0.21, 0.48)2 0.45 
 
Number of days with consistency score 6 or 7 [median (IQR)]  
Placebo  11(8-13) 6(2-9) 
(N=59) 
-- -- 
Mesalazine 11(8-13) 7(2-11] (N=57) -- -- 
Mesalazine vs. 
Placebo 
-- -- 1.09(0.95, 1.27)3 0.21 
 
Mean HADS score (SD) 
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Placebo 8.6(4.3) 6.9(3.6) 
(N=59) 
-- -- 
Mesalazine 9.0(4.5) 7.5(5.0) 
(N=57) 
-- -- 
Mesalazine vs. 
Placebo 
-- -- 0.67(-0.38, 1.72)2 0.21 
 
Mean PHQ15 score [mean (SD)] 
Placebo  13.1(5.6) 9.4(5.0) 
(N=59) 
-- -- 
Mesalazine  12.6(5.2) 10.0(5.2) 
(N=57) 
-- -- 
Mesalazine vs. 
Placebo 
-- -- 0.63(-0.93, 2.20)2 0.43 
 
Number of people with satisfactory relief of IBS symptoms [N (%)] 
Placebo 0 24(40.7%) 
(N=59) 
-- -- 
Mesalazine 0 25(43.9%) 
(N=57) 
-- -- 
Mesalazine vs. 
Placebo 
-- -- 1.13(0.51, 2.47)4 0.76 
 
EQ5D: 5 division components [N(%)] who have no problems 
 Baseline After treatment 
 Placebo Mesalazine Placebo Mesalazine 
Mobility 46(67.6%) 53 (77.9%) 47(79.3%) 44(77.2%) 
Self-care                     66(97.1%) 63(92.6%) 57(96.6%) 52(91.2%) 
Usual activity 39(57.4%) 44(64.7%) 44(74.6%) 45(78.9%) 
Pain/ 
Discomfort 
7(10.3%) 8(11.8%) 15(25.4%) 15(26.3%) 
Anxiety/ 
Depression 
39(57.4%) 39(57.4%) 37(62.7%) 35(61.4%) 
 
EQ VAS score [mean(SD)] 
 Baseline After Between 
group 
P value 
75 
treatment comparison 
Placebo 64.3(20.2) 69.7(18.3) 
(N=59) 
-- -- 
Mesalazine  64.2(20.6) 72.6(19.2) 
(N=57) 
-- -- 
Mesalazine vs. 
Placebo 
-- -- 2.39 (-3.24, 
8.02)2 
0.41 
1 estimate depends on type of outcome variable and is adjusted by baseline value of 
the outcomes if appropriate 
2 difference in means  
3 incidence rate ratio  
4 odds ratio  
 
 
4) Compliance: 
Compliance was defined, a priori, as takiŶg шϳϱ% of the ŵediĐatioŶ thƌoughout the 
12 weeks. Each patient was given 2 boxes of medication during the 12-week study, 
each box containing 100 sachets. The amount of medication taken was calculated 
by 200 minus the number of medication sachets returned at EOT. Compliance with 
medication (Table 10) and baseline characteristics of compliers (defined as taking 
шϳϱ% of the ŵediĐatioŶ thƌoughout the ϭϮ ǁeeksͿ (Table 11) were similar in both 
groups. Analysis of the primary outcome using CACE approach showed no 
difference between the two treatment arms [Mean difference (95% Confidence 
Interval)]: 0.2(-0.6,0.9).  
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Table 10: Summary of compliance with trial medication (Participants who 
completed 12 weeks of treatment) 
 Placebo (n=59) Mesalazine (n=57) 
Compliance1  
Mean (SD) 
 
72%[17%] 
 
71%[19%] 
Complier2  
N (%) 
 
35(59%) 
 
33(58%) 
1 Calculated as 100 minus proportion of trial medication returned 
2 Coŵplier is defiŶed as coŵpliaŶce ≥75% 
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Table 11: Summary of baseline data by complier and treatment group 
 Non-complier (n=48) Complier (n=68) 
Placebo 
(N=24) 
Mesalazine 
(N=24) 
Placebo 
(N=35) 
Mesalazine 
(N=33) 
Age   
Mean (SD) 
 
48.9(13.6) 
 
41.4(14.1) 
 
45.2(14.2) 
 
40.6(14.7) 
Gender  
Male N (%) 
 
12(50.0%) 
 
10(41.7%) 
 
11(31.4%) 
 
12(36.4%) 
Ethnicity  
White N (%) 
Asian N (%) 
Other N (%) 
 
24(100%) 
0 
0 
 
24(100%) 
0 
0 
 
34(97.1%) 
0 
1(2.9%) 
 
32(97.0%) 
1(3.0%) 
0 
Daily mean stool 
frequency, Mean [SD]  3.7(1.8) 4.2(1.7) 3.7(2.0) 3.3[1.5) 
Abdominal pain score 
Mean [SD]  3.6(2.1) 4.3(1.6) 3.5(2.0) 4.5(2.4) 
Number of days with 
urgency, Median [IQR]  13(10-14) 13(11-14) 12(7-14) 13(10-14) 
HADS score, Mean (SD) 9.2(4.1) 7.9(3.8]) 8.1(4.2) 9.9(4.9) 
Stool consistency, 
Mean (SD)  5.4(0.7) 5.5(0.7) 5.7(1.2) 5.3(0.6) 
PHQ-15 score, Mean 
(SD) 12.3(4.7) 12.0(3.9) 13.2(6.2) 13.8(5.4) 
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5) Adverse events 
The most frequent occurring side effect was exacerbation of IBS symptoms, which 
could be worsening abdominal pain or diarrhoea. 2 patients (3%) from the 
Mesalazine and 3 patients (5%) from the placebo group complained of this and 
were withdrawn from the study. 1 patient was pregnant in the middle of the trial 
period although she had a negative  pregnancy test at the start of the trial. She was 
withdrawn from study with no adverse consequence to herself or her newborn162. 1 
patient from the Mesalazine group was found to have breast cancer and she was 
withdrawn from the study as her IBS symptoms and stool diary would be very 
difficult to interpret. All participants who developed these adverse events were 
withdrawn from the study and their symptoms settled on follow up (Table 12). 
Table 12: Adverse events following randomisation 
Adverse event Mesalazine Placebo 
Exacerbation of IBS 
(worsening abdominal pain 
and/ or diarrhoea) 
2 3 
Bloating 0 2 
Dizziness 1 0 
Chest pain  1 0 
Rash 0 1 
Discoloured urine 1 0 
Pregnant 1 0 
Flu-like illness 1 0 
Breast cancer 1 0 
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6) Mechanistic primary outcome: 
(All tissue samples obtained from the IBS-D patients and healthy volunteers [from 
another study] were processed in the same period of time.) 
 
The mast cell percentage area stained was elevated in IBS-D patients when 
compared to our normal range previously established in our laboratory. Median 
(IQR) for IBS-D were 4569 (3500-5884) while the normal range is 1936 (1453-3145) 
per m2; (Figure 9). There was no reduction in mast cell % area stained following 
treatment with Mesalazine (Figure 10 and Table 13). 
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Figure 9: Mast cell count assessed from % area stained comparing healthy controls 
and patients with IBS-D 
 
 
Table 13: Effect of Mesalazine vs. placebo on mast cell % area stained in patients 
with IBS-D 
Mast cell percentage 
area stained/m2 
Mesalazine 
baseline 
Mesalazine 
after 
treatment 
Placebo 
baseline 
Placebo 
after 
treatment 
Mean (SD) 5167 (2729) 5303 (2014) 4765 (1238) 3978 (1802) 
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Figure 10: Effect of Mesalazine vs. placebo on mast cell % area stained in patients 
with IBS-D, (Mean,SD)  
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7) Mechanistic secondary outcome: 
a) Mast cell tryptase and other mediator release during biopsy incubation 
Baseline supernatant levels were compared between IBS-D and healthy volunteers. 
There was no significant increase in the baseline mediator levels except 
carboxypeptidase A3 (CPA3). See Figure 11 and Table 14.  
 
Figure 11: Baseline Carboxypeptidase A3 levels in IBS-D patients. Shaded area 
indicates normal range in healthy volunteers(HV), (Median,IQR). 
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Table 14: Baseline supernatant levels between HV and IBS-D patients 
 
Following treatment of either Mesalazine or placebo in the IBS-D patients, there 
was no change in the mediators. See Table 15 and Figures 12-16. 
  
Baseline supernatant 
levels (ng/ml), Median 
(IQR) 
Healthy volunteer 
(HV) 
N=21 
IBS-D patient, 
N=45 
P value 
Tryptase 6.7 (3.8-11.4) 4.3 (1.8-8.9) 0.07 
Chymase 0 0 (0-0.9) 0.14 
CPA3 0.34 (0.28-0.52) 0 (0-0.9) 0.05 
Histamine 1.6 (0.7-3.8) 0.7 (0-1.3) <0.01 
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Table 15: Supernatant mediators following treatment of Mesalazine or placebo 
Supernatant 
mediators (ng/ml), 
Median (IQR) 
Mesalazine 
baseline 
(n=21) 
Placebo 
baseline 
(n=23) 
Mesalazine 
after 
treatment 
Placebo 
after 
treatment 
Tryptase 4.3 (1.5-8.6) 4.6 (2.5-9.1) 4.9 (1.8-8.2) 
5.8 (2.1-
10.3) 
Chymase 0 (0-0.3) 0 (0-0.8) 0 (0-1.7) 0 (0-0.4) 
CPA3 0 (0-0.3) 0 (0-1.0) 0 (0-0.8) 0 (0-0.5) 
Histamine 0.9 (0.3-1.4) 0.7 (0-1.4) 0.8 (0-1.2) 0.7 (0.2-1.0) 
5-HT (pmol/mg) 
9.4 (6.1-
15.1) 
6.3 (2.7-
13.7) 
10.7 (5.4-
14.0) 
9.3 (3.4-
14.7) 
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Figure 12: Tryptase levels before and following treatment with Mesalazine or 
placebo, (Median,IQR) 
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Figure 13: Chymase levels before and after treatment with Mesalazine or placebo, 
(Median,IQR). 
-5
0
5
10
15
ng
/m
l
p=0.38
p=0.52p=0.52
Mesalazine group
baseline
Placebo group
baseline
Mesalazine group
after treatment 
Placebo group
after treatment 
87 
 
Figure 14: Carboxypeptidase A3 (CPA3) levels before and after  treatment with 
Mesalazine or placebo, (Median,IQR). 
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Figure 15: Histamine levels before and after treatment with Mesalazine or 
placebo, (Median,IQR). 
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Figure 16: Serotonin (5HT) levels before and after treatment of Mesalazine or 
placebo (Median,IQR).  
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b) Serotonin and 5HIAA release (sigmoid biopsy) 
The baseline 5HIAA and 5-HT ratios is significantly higher in the patient group 
compared to the healthy control with median (IQR) of 0.11 (0.06-0.27) and 0.02 
(0.01-0.05) respectively with p<0.01. See Figure 17.  
Following treatment of mesalazine/placebo, there were no significant changes in 
either group. See Figure 18. Mean differences (SD) following treatment for 
mesalazine was -0.06 (0.37) and placebo group was 0.02 (0.42); p=0.43. 
There was no correlation between baseline 5HIAA: 5-HT ratio with baseline 
serotonin supernatant or serotonin cell count (Table 16).  
There was no correlation between baseline 5HIAA: 5-HT ratio with clinical 
symptoms (Table 16). 
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Table 16: Correlation between 5HIAA:5-HT ratio with 5-HT supernatant/cell count 
and clinical symptoms 
Correlation between baseline 
5HIAA: 5-HT ratio  
Correlation Spearman, r P value 
Mechanistic: 
Serotonin supernatant (pmol/mg) -0.11 0.49 
Serotonin cell count (per mm2) -0.22 0.15 
Clinical symptoms: 
Abdominal pain severity -0.04 0.80 
Urgency  0.07 0.64 
Bloating -0.23 0.14 
Average daily bowel frequency 0.18 0.25 
Average stool consistency 0.18 0.24 
Anxiety -0.06 0.69 
Depression 0.03 0.86 
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Figure 17: Baseline 5HIAA and 5HT ratio in healthy volunteer and IBS-D 
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Figure 18: 5HIAA and 5HT ratio following treatment of either mesalazine or 
placebo, Median (IQR). 
 
c) IL-ϭβ, TNF- 
Levels of IL-ϭβ aŶd TNF- in supernatant were below the level of detection.   
d) Small bowel tone assessed by volume of fasting small bowel water  
Further details/results (see Section 3.4) 
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e) Faecal Tryptases  
27 and 30 pairs of stool samples were collected in the Mesalazine and placebo 
groups respectively.  The baseline faecal tryptase level was in the range between 
6.8 and 577.8 trypsin units/mg of protein, which was variable. There was a 
significant increase in faecal tryptase following treatment of Mesalazine (Figure 19 
and Table 17). There was no correlation between baseline faecal tryptase and 
baseline supernatant tryptase level, Spearman r=0.13, p=0.41. There was no 
significant correlation between baseline faecal tryptase with anxiety, depression 
and bowel symptoms (Table 18). 
Table 17: Faecal tryptase levels following treatment with Mesalazine or placebo 
Faecal tryptase 
(trypsin units/ 
mg of protein), 
Median (IQR) 
Mesalazine 
baseline 
(n=30) 
Placebo 
baseline 
(n=27) 
Mesalazine 
after 
treatment 
Placebo after 
treatment 
 
61.2 
(37.6-101.4) 
66.5 
(44.8-126.5) 
82.7 
(40.5-194.8) 
70.9 
(36.0-191) 
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Table 18: Correlation between faecal tryptase and anxiety, depression and 
abdominal symptoms 
Correlation between 
baseline faecal 
tryptase (trypsin 
units/mg of protein) 
Spearman r correlation P value 
Baseline abdominal pain 
severity 
-0.19 0.14 
Baseline urgency  -0.15 0.23 
Baseline bloating -0.13 0.31 
Baseline average daily 
stool frequency 
-0.08 0.54 
Baseline average stool 
consistency 
-0.15 0.23 
Baseline anxiety score -0.02 0.88 
Baseline depression score -0.02 0.85 
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Figure 19: Change in faecal tryptase following treatment of Mesalazine compared 
with placebo, (Median,IQR). 
 
f) Difference in primary outcome measure between those with different 
TNFSF15 polymorphism  
Genotyping has yet to be done but given the predicted small numbers with the risk 
allele and the lack of evidence of immuŶe aĐtiǀatioŶ ǁe doŶ͛t thiŶk theƌe ǁill ďe 
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8) Post-hoc analysis 
a) Mast cell % area stained 
There was weak correlation for mast cell count with urgency score and stool 
consistency (Table 19) but no correlation with abdominal pain severity or bloating. 
Table 19: Correlation between mast cell count with clinical symptoms 
Clinical Symptoms 
No correlation of mast cell % area stained with abdominal pain severity, average 
stool frequency and bloating  
Correlation between 
mast cell count (n=44) 
Spearman r 95% CI P value 
Urgency score (0-10) 0.27 -0.005 to 0.51 0.05 
Stool consistency 
(Bristol Stool Form 
Scale) 
0.30 0.01 to 0.5 0.04 
 
There was no significant correlation of mast cell percentage area stained with 
objective measures of tryptase, chymase, CPA3 and histamine in biopsy 
supernatants. 
Definition of ͚Ŷoƌŵal͛ ŵast Đell peƌĐeŶtage aƌea staiŶed was 0-4936/m2 (cut off at 
90th centile from healthy control). This study showed 9 out of 23 in the Mesalazine 
group have high mast cell percentage area stained. In the Mesalazine group who 
had high mast cell percentage area stained, there were no significant changes in 
clinical symptoms such as abdominal pain severity, bloating, urgency, average daily 
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bowel frequency and stool consistency following treatment compared to the 
͚Ŷoƌŵal͛ ŵast Đell peƌĐeŶtage aƌea staiŶed group. See Table 20 and Figures 20-24. 
Table 20: MeaŶ differeŶĐe iŶ sǇŵptoŵs ďetǁeeŶ the ͚Ŷorŵal͛ aŶd ͚high͛ ŵast Đell 
percentage area stained IBS-D patients who were on Mesalazine 
Mean difference in 
symptoms scores 
following 
treatment with 
Mesalazine (after-
before), (SD) 
͚Norŵal͛ ŵast Đell 
percentage area 
stained in IBS-D 
patients treated with 
Mesalazine 
(N=14) 
͚High͛ ŵast Đell 
percentage area 
stained in IBS-D 
patients treated with 
Mesalazine 
(N= 9) 
P value 
Abdominal pain 
severity 
-1.66 (1.44) -1.88 (2.14) P=0.77 
Urgency symptoms -2.26 (2.16) -1.96 (1.52) P=0.73 
Bloating symptoms -1.70 (1.58) -0.41 (1.63) P=0.07 
Average daily 
bowel frequency 
-0.91 (1.83) -1.21 (0.73) P=0.65 
Average stool 
consistency 
-0.94 (1.37) -0.16 (0.48) 0.08 
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Figure 20: Differences in abdominal pain severity score following treatment of 
Mesalazine in the groups with ͚high͛ aŶd ͚Ŷorŵal͛ ŵast Đell perĐeŶtage area 
stained 
 
Figure 21: Differences in urgency score following treatment of Mesalazine in the 
groups with ͚high͛ aŶd ͚Ŷorŵal͛ ŵast Đell perĐeŶtage area staiŶed 
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Figure 22: Differences in bloating score following treatment of Mesalazine in the 
groups ǁith ͚high͛ aŶd ͚Ŷorŵal͛ ŵast Đell perĐeŶtage area staiŶed 
 
Figure 23: Differences in average daily stool frequency following treatment of 
Mesalazine in the groups with ͚high͛ aŶd ͚Ŷorŵal͛ ŵast Đell percentage area 
stained 
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Figure 24: Differences in average daily stool consistency following treatment of 
Mesalazine in the groups with ͚high͛ and ͚normal͛ mast cell percentage area 
stained 
 
b) Other immune cells e.g. CD3, CD68 and serotonin (5-HT) containing 
enterochromaffin cells 
i. CD68 
The CD68 is a marker of macrophage. Baseline CD68 is significantly lower in the IBS-
D compared to healthy control. Median (IQR) were 1037 (836.8-1204) and 1326 
(1257-1549); p<0.01. Figure 25. 
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Figure 25: Baseline CD68 cell count comparing HV and IBS-D patients 
 
Following treatment with mesalazine/placebo, there was no significant change in 
CD68. See Figure 26. 
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Figure 26: CD68 count following treatment with either Mesalazine or placebo 
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iii. Serotonin (5-HT) containing enterochromaffin cells 
The 5-HT cell count in deep lamina propria is significantly lower in IBS-D patients 
compared to healthy control. Median (IQR) were 304.9 (189.2-480.9) for healthy 
control and 159.4 (109.1-221.0); p<0.01 (Figure 27).  There was no change in 5HT 
cells numbers following treatment with mesalazine or placebo (Figure 28).  
 
 
Figure 27: Baseline Serotonin (5-HT) cell count comparing HV with IBS-D patients 
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Figure 28: 5HT cell count following treatment of with Mesalazine or placebo 
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v. CD3  
The baseline CD3 count is significantly lower in the IBS-D group compared to the 
healthy control. Median values were 51.2 (IQR 0-154.6) vs. 716.3 (IQR 460.1-1163) 
cell/mm2; p<0.01 (Figure 29). 
 
Figure 29: CD3 count between healthy control and IBS-D patients 
 
There was a paradoxical increase in CD3 count following treatment with Mesalazine 
for reasons which are unclear. Given Mesalazine is an anti-inflammatory agent; it 
was surprising that there was an increase in CD3 count. See Figure 30. 
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Figure 30: CD3 count before and after treatment of Mesalazine or placebo 
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c) Stool calprotectin 
Samples were obtained in 53 patients (30 placebo, 23 Mesalazine). Baseline stool 
calprotectin levels varied widely ranging from undetectable to as high as 420µg/g. 
There was a negative correlation between calprotectin levels and baseline total 
hospital anxiety and depression scores (HADS) but this did not reach significance 
(r=0.25; p=0.07). See Figure 31. 
 
Figure 31: Correlation between baseline calprotectin levels (ug/g) and baseline 
total hospital anxiety and depression score (HADS) 
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baseline clinical characteristics such as abdominal pain severity, average daily stool 
frequency and stool consistency. Group A with higher calprotectin levels ;шϭϬϬ 
ug/g) at baseline showed a significantly lower total HADS score (median = 7.0, IQR= 
3.75-13.5) than Group B (Median= 13.0, IQR = 7.0-18.0); p=0.03. See Figure 32.  
 
Figure 32: Baseline stool calprotectin levels when divided into 2 groups, 
(Median,IQR). 
 
Overall Mesalazine did not alter calprotectin levels. Median (IQR) differences in the 
mesalazine and placebo group were 0.01 (-14.9-15.4) and -0.14 (-43.7 -17.2), p=0.99 
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(Figure 33). If the participants who have abŶoƌŵal ĐalpƌoteĐtiŶ leǀels ;шϭϬϭ ug/g) 
were excluded in the analysis, there was no significant improvement in stool 
calprotectin levels following treatment with Mesalazine or placebo (Figure 34). 
There was no significant improvement of clinical symptoms following treatment 
with Mesalazine when compared with placebo. See Figures 35-40 below.  
 
 
Figure 33: Stool calprotectin levels following treatment with Mesalazine or 
placebo, Median (IQR). 
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Figure 34: Stool calprotectin levels following treatment with Mesalazine or 
plaĐeďo ;FolloǁiŶg eǆĐlusioŶ of stool ĐalproteĐtiŶ leǀel ;≥ϭϬϭ ug/gͿ, Median (IQR). 
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Figure 35: Abdominal severity score following treatment with either mesalazine or 
placebo ;FolloǁiŶg eǆĐlusioŶ of stool ĐalproteĐtiŶ leǀel ;≥ϭϬϭ ug/gͿ, MeaŶ ;SDͿ. 
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Figure 36: Urgency score following treatment with either mesalazine or placebo 
;FolloǁiŶg eǆĐlusioŶ of stool ĐalproteĐtiŶ leǀel ;≥ϭϬϭ ug/gͿ, MeaŶ ;SDͿ. 
 
0
2
4
6
8
10
Mesalazine group
baseline
Placebo group
baseline
Mesalazine group
after treatment
Placebo group
after treatment
p=0.48
p<0.01 p<0.01
114 
 
Figure 37: Bloating score following treatment with either mesalazine or placebo 
;FolloǁiŶg eǆĐlusioŶ of stool ĐalproteĐtiŶ leǀel ;≥ϭϬϭ ug/gͿ, MediaŶ ;IQ‘Ϳ. 
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Figure 38: Average daily stool frequency following treatment with either 
mesalazine or placebo ;FolloǁiŶg eǆĐlusioŶ of stool ĐalproteĐtiŶ leǀel ;≥ϭϬϭ ug/gͿ, 
Median (IQR). 
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Figure 39: Average daily stool consistency following treatment with either 
mesalazine or placebo (FolloǁiŶg eǆĐlusioŶ of stool ĐalproteĐtiŶ leǀel ;≥ϭϬϭ ug/gͿ, 
Mean (SD). 
0
1
2
3
4
5
6
7
Mesalazine group
baseline
Placebo group
baseline
Mesalazine group
after treatment
Placebo group
after treatment
p=0.07
p=0.61
p=0.03
117 
 
Figure 40: Total HAD score following treatment with either mesalazine or placebo 
;FolloǁiŶg eǆĐlusioŶ of stool ĐalproteĐtiŶ leǀel ;≥ϭϬϭ ug/gͿ, MediaŶ ;IQ‘Ϳ. 
 
Group with stool calprotectin levels> 100 ug/g 
There were in total 12 IBS-D patients who have stool calprotectin levels of more 
than 100 ug/g. 5 patients were in the Mesalazine group and 7 in the placebo group.  
There was no significant change in stool calprotectin levels following treatment. 
Mean difference (SD) in the Mesalazine group was -98.13 (141.6) ug/g and 30.26 
(158.3), p = 0.60 (Figure 41). There was no significant changes in the total HAD and 
clinical symptoms e.g. average abdominal pain, urgency, bloating, bowel frequency 
or stool consistency following treatment with either Mesalazine or placebo.  
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Figure 41: A subgroup of IBS-D patients who have high stool calprotectin levels 
(>100 ug/g) following treatment with Mesalazine or placebo. 
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d) Post infectious irritable bowel syndrome (PI-IBS) 
Rome III criteria for irritable bowel syndrome following an episode of infectious 
gastroenteritis are ĐhaƌaĐteƌised ďǇ шϮ of the folloǁiŶg sǇŵptoŵs: feǀeƌ, ǀoŵitiŶg, 
diarrhoea and positive stool culture 131.  13 participants in the study met the criteria 
for PI-IBS. 8 participants were randomised into the Mesalazine group and 5 were 
allocated to the placebo.  There was significant improvement in the clinical 
symptoms such as abdominal pain, urgency and stool consistency following 
treatment of Mesalazine. See figures 42-44.  
 
Figure 42: Abdominal pain severity before and after treatment of either 
Mesalazine or placebo 
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Figure 43: Urgency symptom before and after treatment of either Mesalazine or 
placebo 
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Figure 44: Urgency symptom before and after treatment of either Mesalazine or 
placebo 
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1.11.7. Discussion 
 
Over the past decade, there have been several promising studies using 5-
aminosalicylate acid for treatment of both IBS predominantly diarrhoea143, 146, 163 
and PI-IBS164, 165 but sample sizes were small and their significance uncertain. These 
studies ǁeƌe ŵotiǀated ďǇ ƌeĐeŶt fiŶdiŶgs of ͚iŵŵuŶe aĐtiǀatioŶ͛ iŶ the gut mucosa 
of IBS patients, dominated by mast cells and T lymphocytes rather than the 
polymorphonuclear leukocytes characteristic of colitis. These studies were 
supported by several studies suggesting impaired mucosal barrier in IBS166, which by 
allowing access of luminal bacterial products to the mucosal immunocytes might 
cause this activation167. These data suggested that Mesalazine, being an anti-
inflammatory agent, might benefit this condition. Animal studies suggest 
Mesalazine improves barrier function in colitis but whether this is true in IBS is 
uncertain168. This study is one of the largest trials so far looking at the treatment of 
Mesalazine in IBS-D patients following best practice to ensure that both 
investigators and patients were blinded to the study and that data analysis was 
carried out by independent statisticians. The effect of Mesalazine was analysed only 
after 12 week treatment as it was felt that Mesalazine was a disease modifying 
rather than symptomatic treatment and early reports suggested benefit was most 
obvious after 2-3 months143. This study showed that Mesalazine did not improve 
bowel frequency after 12 weeks treatment when compared to placebo in 
unselected patients.   As with other studies in IBS, this study showed a strong 
placebo effect on bowel symptoms and also on the total hospital anxiety and 
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depression and somatic scores suggesting that patients felt better in general after 
taking part in the trial. 
Despite lack of benefit in unselected patients, a sub-analysis of the primary 
outcome of stool frequency in patients divided according to severity was 
determined a priori. This suggested that a group of patients who had the greatest 
bowel frequency did benefit from Mesalazine (mean difference -0.26,p=0.04). Our 
clinical findings seem consistent with another recent report169.  There was no 
significant improvement in other IBS symptoms such as abdominal pain, bloating 
and stool consistency. There is strong evidence from this study that Mesalazine 
treatment increases the number of days with urgency by about 20%.  There have 
been previous case studies reported of Mesalazine worsening diarrhoea in colitis170, 
171. This may represent an allergic response to the drug, as there was an increase in 
T lymphocytes.  
Raised mast cells numbers in the gut mucosa have been implicated in all subtypes 
of IBS172 but mainly in IBS-D. Mast cells contain many mediators including 
histamine, serotonin and proteases such as tryptase66. Recently, there has been an 
interest in tryptase release as it has been shown to activate proteinase-activated 
receptor 2 which is found on afferent nerves and can lead to increased sensitivity of 
bowel distension48. In this study, the average mast cell count in IBS-D patients was 
elevated compared to those in healthy subjects previously studied in our 
laboratory. While most IBS-D patients have normal mast cell count (below 90th 
centile of healthy control) there was a subgroup with elevated counts. However 
comparing their baseline IBS symptoms, there was no difference between the 2 
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groups.  There were no gender differences in mast cell count of IBS-D patients as 
previously described by others173, nor any gender effect on other immune cells such 
as CD3, CD68 and 5-HT containing enterochromaffin cells.  
Although mast cell count was elevated in IBS-D patients compared to the healthy 
controls, the supernatant levels of tryptase in IBS-D patients were not significantly 
elevated. Median (IQR) tryptase levels for IBS-D vs. healthy control were 4.3 (1.8-
8.9) and 6.7 (3.8-11.4) ng/ml; p=0.07. Surprisingly supernatant histamine levels in 
our study were lower in IBS-D patients compared to healthy control, being [Mean 
(SD)] 0.7 (0.6) and 1.1 (0.8) ng/ml, respectively, p=0.02. Supernatant levels of 
tryptase and histamine were not altered following treatment of Mesalazine. 
Disappointingly we found no apparent association correlation between mast cell 
count and supernatant levels of release of the mast cell mediators examined, 
whether those released by all mast cells (tryptase and histamine) or restricted to a 
subpopulation (chymase and carboxypeptidase A3).  This suggests that the overall 
degree of mediator release from colonic mast cells is independent of mast cell 
numbers, tryptase and histamine suggesting factors other than mere numbers 
determine mediator release. When designing the study, we followed previous 
published methods by other authors for obtaining biopsy samples48. However, in 
retrospect, the process of taking a biopsy involves considerable trauma and this is 
unstandardized which may possibly account for the lack of correlation with release 
of mediators during normal bowel function. 
This study also looked further into patients who were on active Mesalazine 
treatment. Those who had a high baseline mast cell count did not show greater 
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improvement in abdominal pain, urgency, bloating, bowel frequency and stool 
ĐoŶsisteŶĐǇ ǁheŶ this ǁas Đoŵpaƌed to the gƌoup ǁho had ͚Ŷoƌŵal͛ ŵast Đell 
count.  Although mast cell count was weakly correlated with urgency symptom, it 
did not predict response to Mesalazine. Again, this provides no support for the 
previous suggestion that Mesalazine can reduce mast cell numbers146.  
Stool collected in Nottingham was used to obtain calprotectin level at baseline and 
EOT. Although a small proportion of patients have raised calprotectin levels 
;шϭϬ1ug/g), organic diseases such as inflammatory bowel disease were excluded in 
gastroenterology clinics using standard tests prior to patients entering the study.  
Others have also reported up to a quarter of IBS patients have marginally elevated 
calprotectin though the origin of this is unclear174, 175. Interestingly, the subgroup of 
patieŶts ;Gƌoup AͿ ǁho had ƌaised ĐalpƌoteĐtiŶ leǀel ;шϭϬϬug/gͿ, haǀe sigŶifiĐaŶtlǇ 
less psǇĐhologiĐal distƌess thaŶ the gƌoup ǁith stool ĐalpƌoteĐtiŶ leǀel чϭϬϬ ug/g 
(Group B).  This is felt that subgroup A͛s symptoms are secondary to local gut 
iŶflaŵŵatioŶ ǁhile suďgƌoup B͛s sǇŵptoŵs aƌe dƌiǀeŶ pƌiŵaƌilǇ ďǇ distƌess ǁhiĐh 
causes gut symptoms secondarily.  Unfortunately numbers were too small to 
answer the question of whether subgroup A responded better to Mesalazine. Stool 
calprotectin could therefore be used as a screening tool to allow more detailed 
studies of the mucosa in IBS-D in the future. 
One uncontrolled study has suggested that Mesalazine might be effective in 
treating PI-IBS patients164 but the only randomised controlled trial of Mesalazine in 
this condition was negative though possibly underpowered165. In our post-hoc 
analysis, a small subgroup fulfilling criteria for PI-IBS appeared to benefit from 
126 
Mesalazine but our study was also underpowered. Confirming this would require a 
larger and more adequately powered study.  
Although Mesalazine has been available to use for many decades with good safety 
profile, this adequately powered study have showed it did not help the majority of 
IBS-D patients. The fact that certain subgroups might benefit emphasises that there 
is still a need for better phenotyping of this heterogeneous group of patients when 
evaluating new treatments. 
 
1.11.8. Limitations 
 
Despite strict entry criteria the population in this study was still heterogeneous. In 
retrospect this could have been better stratified by postinfectious onset. This was  
considered during the initial set up of the study  but felt that this would make the 
trial very difficult to recruit. This could be overcome in future studies by having a 
great many more recruitment sites and around 5 times as many participants given 
that PI-IBS accounts for only around 20% of all cases of IBS-D but this would require 
more resources than we had available for this study. It is worth noting that there 
was an appreciable loss to follow up (15.5%) but not out of line with other similar 
studies. Dropouts are mostly likely due to failure of treatment and so unlikely to 
account for the negative result. 
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1.11.9. Research recommendations 
 
This data suggests that it is unlikely that future trials of Mesalazine in unselected IBS 
would be fruitful. 
If, there is a subgroup of IBS-D patients that may benefit from mesalazine, it is likely 
to be those with post-infective IBS and patients who have severe diarrhoea.  
The link between mast cells and urgency is weak and again future work on the role 
of mast cells needs to better characterise the patients since the majority of 
unselected IBS do not have elevated mast cell numbers. It may be that as others 
have reported it is the number of activated mast cells that are important48 and 
better markers of activation would be useful rather than the current gold standard 
of electron microscopy which is expensive and time consuming.  
Finally the release of mediators from biopsies does not link well to symptoms or 
mast cell numbers. The dominant factor for release is likely to be crushing and 
tissue injury by the biopsy process, which is not well standardised and may 
overwhelm other factors which would be of further interest. There is a need for a 
better way of assessing in vivo activity of the mucosal cells.  
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1.11.10. Conclusion 
 
This randomised placebo controlled trial in 115 unselected IBS-D showed that 
Mesalazine 4g per day was no better than placebo in relieving the symptoms of 
abdominal pain or disturbed bowel habit. A subgroup of IBS-D patients had elevated 
mast cell percentage area stained which correlates weakly with urgency and stool 
consistency. However, contrary to the previous report in just 10 patients, 
Mesalazine did not reduce mast cell percentage area stained. Further post hoc 
analysis showed raised calprotectin was associated with less psychological distress 
implying a more gut centred abnormality. A small subgroup with PI-IBS appeared to 
benefit but this requires a larger adequately powered study to confirm this findings. 
Further phenotyping of the heterogeneous group of patients with IBS and diarrhoea 
is needed to allow better evaluation of new treatment.  
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Role of Magnetic Resonance Imaging in the 
Gastrointestinal Tract 
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1.12. Introduction 
 
Magnetic resonance imaging (MRI) is very widely used worldwide because of its 
ability to non-invasively assess internal structures of the human body without 
exposing one to ionising radiation. MRI was previously termed,  nuclear magnetic 
resonance (NMR) in the 20th century and was initially used by chemists to study 
chemical, physical and biological matters before it was used to investigate blood 
products, blood flow, skeletal muscle and living subjects using a 1 dimensional view. 
It was in the 1970s where MRI was developed by Paul Lauterbur and Peter 
Mansfield to allow 2 dimensional imaging.  In 1975, Richard Ernst perfected the 
reconstruction of 2D images, which now became the basis of MRI worldwide176. The 
first scan using MRI to obtain images of a live subject was by Sir Peter Mansfield and 
colleagues in Nottingham in 1977. The scan comprised of a cross section of a human 
finger showing for the first time a detailed image of the soft tissue of the finger177. 
Following from this, the use of MRI in obtaining images of internal organs of the 
human body had expanded and has been widely used in clinical practice 
complimenting other radiological modalities176. 
MRI uses electromagnetic fields to produce internal images of a subject scanned by 
manipulating the hydrogen protons within the body. A spinning proton produces a 
mild magnetic field as it has the properties of a positive electric charge, spin and 
mass. The biggest source of hydrogen/proton in a human body is water followed by 
body fat. When a subject is placed in the magnetic field in the MRI machine, the 
protons align and spin around their axis when an external magnetic field is applied. 
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This creates a magnetic vector, M0. When radio wave energy (radio frequency) is 
added into the magnetic field, the magnetic vector is deflected. When this radio 
frequency is switched off, the M0 will return to its resting state and during this 
period, it will re-transmit the radio frequency. This signal will produce the MR 
images. In a semi-classical description the return to the resting state can be 
decomposed in a component parallel to the static magnetic field (longitudinal 
magnetisation) and one perpendicular to it (transverse magnetisation). The M0 
return to its resting state has therefore two separate components, one in the 
longitudinal plane (T1 relaxation)* and one in the transverse plane where it reflects 
the process of de-phasing of the excited protons (T2 relaxation)178**.  A short 
review article by Berger 179 summarised the principles of the MRI very succinctly. 
Different body parts / organs/ tissues will exhibit different relaxation times (T1/T2) 
which is what gives the richness of contrast in the MRI images.  
*T1 relaxation, which is also called spin-lattice relaxation time, is when the excited 
magnetisation returns to its resting state in the longitudinal plane. This is when the 
radio frequency energy is released back into its surrounding (lattice). Therefore this 
recovery period follows an exponential curve which will be shown later in this 
chapter. The time course whereby the system returns to its equilibrium state is 
characterised by the time constant T1 which is unique to every tissue178. T1 
relaxation time is influenced by the strength of its magnetic field. 
**T2 relaxation time is called spin-spin relaxation time. This is when the excited 
magnetisation which is initially composed of all protons spinning in phase, begin to 
get ͚out of phase͛. Slowly, the loss of phase results iŶ the sigŶal decay aŶd this is 
how T2 relaxation time is measured. The signal decay is described mathematically 
by an exponential curve. An example of this will be shown later in this chapter. T2 
values are also influenced by magnetic field strength but not as much as T1s are. 
 
Over the past decade, there has been an increase in the use of MRI in imaging the 
gastrointestinal tract especially in the diagnosis of inflammatory bowel disease in 
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the small bowel and staging of lower rectal cancer. The use of MRI in functional 
bowel disease such as IBS is very limited at this present time. The advantages of 
MRI are the ability to visualise soft tissue in detail. No ionising radiation is involved 
which is very advantageous for scanning children and young female patients, 
furthermore it is none invasive, hence an ideal test for repeated examination 
following treatment or in a research environment and lastly, potentially able to test 
the gastrointestinal tract function and motility such as gastric emptying180 and 
anorectal function181. The disadvantages of MRI are the cost of MRI scans, 
prolonged length of time for image acquisition, difficulty in correcting motion 
artefacts such as intestinal motility and breathing, the use of the machine has a 
weight limit (for example, the machine used for this thesis had a weight limit of  
approximate 120 kg) and some patients might find the MRI scanner claustrophobic. 
These current disadvantages may not be relevant in the near future due to the 
continuous development in MRI imaging techniques.  
The Sir Peter Mansfield Magnetic Resonance Centre (SPMMRC) at the University of 
Nottingham is one of the very few centres in the world with a team dedicated to 
study gastrointestinal physiology and its function using MRI. Throughout the years, 
there has been development in the use of MRI parameters to study the 
gastrointestinal tract in a fasted and fed state, gastrointestinal motility and sensory 
function. Therefore, the use of MRI in research has proved to be very advantageous 
as we are able to visualise and observe undisturbed gastrointestinal function 
without the use of contrast or bowel cleansing agents. 
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In this chapter, new techniques to assess small and large bowel transit will be 
discussed, together with the use of a laxative challenge test and MRI to look at 
functional bowel disorders such as constipation and potentially to look for an MRI 
biomarker in patients with irritable bowel syndrome with diarrhoea (IBS-D). 
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1.13. Gut transit  
1.13.1. Introduction 
 
Small and large bowel transit measurements are variable as it depends on the 
methodologies used. The discussion of the gut transit measurements will be divided 
into 2 sections. First the orocaecal transit time (OCTT), which is to assess transit 
time from mouth to terminal ileum/ caecum. Secondly, whole gut transit time 
(WGTT) measurement is to assess transit time of the whole gut from mouth to 
colon.   
1) Orocaecal transit time (OCTT)  
a) Barium studies 
The barium meal is one of the earlier methods used as a transit test. Commonly, it is 
still used to evaluate or rule out mechanical obstruction, small bowel diverticula 
and motility disorders. Small bowel transit is measured by drinking 200-400 ml of 
barium before abdominal x-rays are taken at specific periods of up to 9 hours. OCTT 
is defined as the time of ingestion of barium to the time barium reaches the 
caecum. Previous studies to assess small bowel transit on healthy volunteers were 
not standardized thus the results for each study were variable182, 183. The barium 
meal is not widely used today to assess motility due to the amount of radiation 
involved in this test. 
b) Lactulose hydrogen breath test (LHBT) 
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Lactulose is a synthetic sugar containing fructose and galactose. It is not digestible 
in the small bowel and when it reaches the large bowel, lactulose is fermented by 
colonic bacteria producing hydrogen, methane and short chain fatty acids. 
Hydrogen produced by the gut bacteria is excreted in the breath184, and  this can be 
measured to assess OCTT. Routinely, 10g of lactulose are ingested and breath 
collected every 10-15 min for approximately 10 hours. The definition of the OCTT 
would be a rise in breath hydrogen as sustained release of hydrogen more than 5 
parts per million (ppm) compared to baseline185. Due to its hyperosmolar effect of 
lactulose, it can increase bowel transit as described by Miller et al185, hence 
disturbing the parameter which is being measured. Despite this limitation it is still a 
common test to use for assessment of OCTT due to its availability, ease of use and 
low cost.  
c) 13C-labelled glycosyl ureides (LUBT) 
13C-labelled glycosyl ureides have been accepted and applied for measuring 
intestinal transit time.  Their chemical properties and physiological significance have 
been studied in detailed in the past by Heine and colleagues in 1995186. It has been 
validated187 and is a non-invasive method of measuring OCTT. These 13C-glycosyl 
ureides have properties of low intestinal absorption as it resists cleavage by brush 
border enzymes of the gastrointestinal tract. The 13C-glycosyl ureides is used in 
small amounts unlike lactulose therefore it does not cause osmotic secretion into 
the small bowel and hence does not accelerate small bowel transit188. Importantly 
enzymatic degradation of the sugar-urea bond in the small bowel does not occur 
with mammalian enzymes but in the colon by the bacteria flora (Clostridium 
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Innocuum189). Previous research papers186-188 have established the safety and 
usefulness of the product to test for OCTT. It is tasteless and there is no problem 
integrating it into test meals, subjects tolerated the product well and caused 
minimal discomfort. There have been no reported adverse events following this 
investigation and this test has also been used in paediatrics for similar indication i.e. 
to assess small bowel transit190. This method involved the use of stable isotope 13C 
which is non radioactive. Subjects need to be pre-conditioned with unlabelled 
lactose ureide (LU) e.g. 1g LU 3-5 times/day prior to the test to induce enzymatic 
activity in the colon186-188 before a small dose of 13C lactose ureide is given along 
with the test meal the next day. Breath collections are taken from baseline and 
every 10-15 minutes for the next 9 hours. Breath analysis is performed using a 
spectrometer; on average it takes 2 hours to complete analysis of a set of breath 
bags per participant. Although this might be a simpler test compared to 
scintigraphy, the high expense of purchasing 13C lactose ureide compared to 
lactulose has discouraged its use as a routine clinical test. The cost to purchase 500 
mg of 13C lactose ureide and 3g of unlabelled lactose ureide for a patient would cost 
approximately £80.  
d) Small bowel transit using scintigraphy 
This is not widely used in a clinical setting as it is expensive, labour intensive and 
involves the use of special equipment. Either radiolabelled Indium or Technetium 
labelled material is ingested in either a liquid or solid meal followed by intermittent 
scans using a gamma camera. The small bowel transit time can be calculated as the 
time for 10 or 50% of the activity to arrive at the caecum191-193 and subtracting the 
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time for the equivalent proportion (10 or 50%) to be emptied from the stomach in 
the gastric emptying. The Mayo group assess small bowel transit rate from the 
percentage of delivered radioactivity entering the caecum at 6 h192. Normal values 
for small bowel transit would be between 11-70%184 of radioactivity in caecum at 6 
h. Although scintigraphy may provide a reliable method of measuring small and 
large bowel transit (see below for colonic transit), cautious interpretations need to 
be taken into account of assessment of small bowel transit in patients with delayed 
gastric or colonic transit. 
 
2) Whole gut transit time (WGTT) 
a) Radio-opaque markers (ROM) 
The colon functions include storage of faecal residue, absorption of water, 
propulsion and defaecation. Dysequilibrium of any of these factors would lead to 
diarrhoea or constipation. Colonic transit is defined as the time food transits 
through the colon and accounts for 70-90% of whole gut transit time (WGTT). There 
have been different methods of measuring WGTT. The downside of these tests as 
currently used is the exposure to radiation especially in young women where 
functional bowel is more common. Hinton et al194 described the use of radio-
opaque markers (ROM) in measuring the WGTT. It had a good recovery rate of the 
markers and did not alter transit time theoretically but the task was arduous as it 
was required to either take multiple abdominal imaging to assess progression of 
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ROM or observing the passing of these markers in the stool. Later, Metcalf et al 
simplified this methodology by taking multiple ROM consistently for 3 days before 
an abdominal imaging taken at day 4  +/- day 7 (to localised abnormal colonic 
segment) thus reducing the amount of radiation exposure to the patients73. This 
Metcalf method of assessing WGTT in now widely used worldwide and is currently 
the gold standard to assess colonic transit.  
b) Colonic scintigraphy  
Scintigraphic methods to assess colon transit require the use of radioisotope 
materials, specialised equipment such as gamma cameras and it is expensive even 
though it is non invasive and safe to use. It has the advantage that multiple images 
can be taken without increasing radiation exposure. The radioisotope is either 
mixed in a meal or encapsulated in an acid resistant material such as 
methylmethacrylate and given together with a meal. Once the capsule passes the 
duodenum, the rise in pH causes the capsule to start to dissolve which takes around 
4 hours by which time the capsule is in the terminal ileum or caecum. A gamma 
camera, obtains anterior and posterior images of the bowel, and as for assessing 
gastric emptying, regions of interest are drawn and radioisotope count is measured 
using a dedicated nuclear medicine computer195, 196. The images are taken at 
different times after ingestion e.g. 4 h, 24 h, 48 h and 72 h depending on protocols. 
Dual isotopes are used to allow assessment of both liquid and solid phases, 
Technetium and Indium. The interpretation of colonic transit is based on the 
geometric centre, which is a weighted average of the radioactivity counted over 
specific parts of the large bowel. There are 2 different methods of assessment, one 
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by the Mayo clinic using 5 segmented regions of the large bowel and defecated 
stool, e.g. ascending, transverse, descending, rectosigmoid and defecated stool. The 
2nd method using the Temple method is similar except there are 7-segmented 
regions of the large bowel including ascending colon, hepatic flexure, transverse 
colon, splenic flexure, descending colon, rectosigmoid and excreted stool. The 
geometric centre (GC) is calculated as the sum of the fraction represented by the 
counts in each region divided by the total counts with the sum multiplied by the 
region number (Equation 1)197. A low value of GC indicates the radioisotope 
material is close to the caecum and a higher value indicated the radioisotope 
material is in the rectosigmoid/excreted stool. 
 
Equation 1: Formula to calculate the geometric centre. i= region of interest 
number, ROIi = the number of counts in the region of interest number i.197 
 
The normal values for geometric centre (Temple method) are 2 to 7 for 24h, 4.6 to 7 
for 48 h and 6.2 to 7 for 72 h. 
Colonic transit using scintigraphy has been shown to have positive correlation with 
stool consistency and bowel frequency and it is easily reproducible198 though it is 
worth noting that the coefficient of variation of repeated measures is 28% of GC at 
24 hours and 14 at 48 hours, a figure no method improves on and which in part 
represents the true underlying variability in transit  
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3) Other tests for measuring colonic transit 
a) Wireless motility capsule (WMC or SmartPill Wireless Motility Capsule) 
This capsule which measures 2.68 x1.17cm in size is a wireless recording device that 
provides real-time measurement of its surrounding. It is ingested orally to measure 
the whole gut transit giving information of gastric emptying time, small bowel 
transit time and colonic transit time and overall whole gut transit time. It has the 
ability to measure pH, temperature and pressure thus providing information when 
the pill transits through the gastrointestinal tract before it is expelled out from the 
body199. The patient needs to wear a receiver belt during the test that normally 
takes up to 5 days. The use of this novel wireless pill is very informative as it 
reduces the number of investigations needed to assess pan enteric dysmotility of 
the gut plus it is ǀeƌǇ patieŶt aĐĐeptaďle due to it͛s ŶoŶ-invasive technique. The 
drawback to this although it might be minor would be the risk of pill retention, 
equipment malfunction or inability of patient to swallow the pill. The use of WMC 
has been validated against radio-opaque markers and scintigraphy with both 
showing good correlation with WMC200, 201. In the UK, the use of WMC here is 
limited by its cost and is not widely available in all NHS hospitals and it is not 
approved by the National Institute for Health and Care Excellence (NICE) for use on 
functional bowel disorders.  
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b) Fluorine marker using MRI 
Recently, there have been some developments on the use of a fluorine (19F) 
marker to assess gut transit202. Although this might be at its developmental stage, it 
does not involve radiation and the size of the pill is smaller than the WMC, as it 
measures 1.15 x 0.72 cm. To image and track the position of the 19F pill, a 
transmitter coil is used. Studies so far are promising but at present hardware 
needed to carry out fluorine MRI is only available in a handful of research units 202, 
203. 
c) Magnetic pill 
A magnetic pill to assess colonic transit/bowel transit is also in a developmental 
stage. It is non invasive and as for the WMC, the patient only needs to swallow a 
magnetic pill of 0.6 x 0.7 cm in size and to wear a sensor belt throughout until the 
pill is expelled. The sensor belt will pick up signals which are then digitalised and 
transmitted to a laptop nearby for processing and storage204. Magnetic pill 
movement in the large bowel correlated well with radio-opaque markers205. 
WGTT varies within individuals, genders, dietary habit, age206, 207 and race208. Other 
studies have shown that females have prolonged WGTT compared to their male 
counter-parts73, 76, 209. Upper limit of normal value for WGTT should be less than 72 
hours73, 195 and if this were prolonged, this would be defined as slow transit. 
In conclusion, there are a wide range of different methods for measuring gut transit 
in healthy volunteers and patients. Some involve exposure to radiation, which 
would not be ideal in a cohort of gastrointestinal dysfunction patients, as they 
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would comprise mostly of young women. Therefore, subsequence sub-chapters 
would be a discussion on optimising the measurement of small and large bowel 
transit using MRI and its application in patients with irritable bowel syndrome to 
ascertain biomarkers.  
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1.13.2. Optimising measurement of small and large bowel 
transit using MRI 
 
1.13.2.1. Background 
Secondary care referrals for further management of functional gastrointestinal 
disorders are common and account for nearly 40% of all referrals10. Irritable bowel 
syndrome, functional constipation and functional diarrhoea are very common and 
diagnosis is mainly based on patient reported symptoms that can be unreliable210. 
The gut transit is an objective measurement to assess motor function and it could 
be used to guide treatment and predict efficacy of drugs211. Gut transit tests 
described in the previous sub-chapter, have been developed to measure OCTT and 
colonic transit/ whole gut transit (WGTT). Each test has its advantages and 
limitations as described earlier. We would like to take advantage of our easy 
accessibility of MRI in research to look at gut transit and hopefully we could 
overcome some of the limitations mentioned.  
Therefore, the aims of this study were to validate 2 novel MRI methods to assess 
OCTT and WGTT and to assess their reproducibility. 
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1.13.2.2. Aims of the study 
To optimise measurement of small bowel and large bowel transit using MRI 
scanning in particular to assess the reliability and precision of different 
measurement tools for these parameters in healthy volunteers 
Examine the relation between bowel habit, colonic volumes and transit times in 
healthy volunteers 
 
1) Primary outcome of the study: 
a) Correlation between OCTT measurements using the MRI method and the 
LUBT 
b) Correlation between WGTT measurements using the MRI marker pills and 
ROM method 
 
2) Secondary outcome of the study: 
Reproducibility between each test methods 
 
 
145 
1.13.2.3. Methods 
The participants took part in an open label study that involved 2 separate test-
retest regimes. Study 1 was to compared small bowel transit i.e. orocaecal transit 
using MRI against lactose ureide breath test (LUBT) and Study 2 was to compare 
whole gut transit (WGT) using MRI against the commonly used Metcalf radio-
opaque marker (ROM) method.  
This study was approved by the National Research Ethics Service (REC number 
11/EM/0245) and was registered with the ClinicalTrial.gov identifier: NCT01534507. 
All volunteers gave written informed consent following assessment of eligibility. The 
studies were carried out according to the Good Clinical Practice principles.  
 
1) Subjects 
21 healthy volunteers (12 males, 9 females) aged between 21-70 years were 
enrolled into both the studies. Participants who had a history of gastrointestinal 
disease and taking any medication known to alter bowel motility were excluded 
from the studies. All volunteers completed an MRI safety questionnaire, to exclude 
persons with contraindications to MRI, and a hospital anxiety and depression score 
(HADS) questionnaire. All 21 volunteers completed study 1, which was repeated 
after a 1-week washout period, to assess reproducibility and 20 of 21 completed 
Study 2. See Figure 45. 
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Figure 45: Schematic drawing showing how Study 1 and Study 2 were done 
cohesively 
 
2) Study 1: Orocaecal transit time (OCTT) 
a) MRI OCTT test 
The healthy volunteers attended the 1.5 T Sir Peter Mansfield Magnetic Resonance 
Centre, University of Nottingham, at 8:00am after an overnight fast and underwent 
a baseline MRI scan before they were fed with a mixed meal which was used in a 
previous study 212. This ŵeal ĐoŶsisted of: ϮϮϬ g Đƌeaŵed ƌiĐe puddiŶg ;“aiŶsďuƌǇ͛s, 
UKͿ, ϯϰ g seedless stƌaǁďeƌƌǇ jaŵ ;“aiŶsďuƌǇ͛s, UKͿ, ϭϱ g Đoaƌse ǁheat ďƌaŶ 
(Holland and Barrett, UK) and a glass of 100 ml orange juice from concentrate 
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;“aiŶsďuƌǇ͛s, UKͿ, altogetheƌ pƌoǀidiŶg ϯϲϮ kĐal. The ǀoluŶteeƌs ǁeƌe sĐaŶŶed at ϰϱ 
min intervals for a total of 8.5 hours. The second meal was provided at 6.5 hours. 
This ĐoŶsisted of: ϰϬϬ g ŵiĐƌoǁaǀeaďle ŵaĐaƌoŶi Đheese ;“aiŶsďuƌǇ͛s, UKͿ, ϭϬϬ g 
straǁďeƌƌǇ ĐheeseĐake ;“aiŶsďuƌǇ͛s, UKͿ aŶd ϮϱϬ ŵl still ǁateƌ ;“aiŶsďuƌǇ͛s, UKͿ. IŶ 
between each scan, the volunteers were sat in an upright position in the waiting 
room. 
The MRI scanning was performed using a 1.5 T Philips Achieva scanner with a 16-
channel XL torso coil. The arrival of the head of the meal into the caecum was 
determined from the MRI images using a dual-echo 2D multi-slice FFE sequence 
(Time [TR] = 212 ms, Flip Angle [FA] = 80°). 24 coronal images were acquired to 
cover the abdomen with an acquired voxel size of 2.01 x 2.87 x 7.00 mm3 
(reconstructed voxel size of 1.76 x 1.77 x 7.00 mm3), a field of view [FOV] of 450 9 
360 mm2, and a slice thickness of 7 mm with no gaps (SENSE factor = 1.7). Images 
were acquired during a breath hold of 17 s 213. An additional single shot turbo spin 
echo (TSE) sequence was acquired to measure small bowel water content (SBWC)214 
which meant subjects spent ~10 min inside the magnet for each time point. The 
arrival of the head of the rice pudding meal was assessed visually using the 2D FFE 
images. The OCTT was estimated as the time from the first scan to show entry of 
bolus of material giving a high intensity signal into the ascending colon. Prior to this 
event, most images were of low intensity. Measurement of the colonic volumes 
before (t=360min) and after (t=405min) a high calorie meal was based on the 2D 
FFE MRI images. This was measured as older studies have shown that clearance of 
the proximal colon may correlate with overall transit time215. Colonic volumes were 
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measured using a software called Analyze© 9.0 (Biomedical Imaging Resource, 
Mayo clinic, Rochester, USA).  
b) Lactose Ureide Breath test (LUBT) for OCTT 
LUBT was used to assess OCTT as this will be used to compare it with the MRI 
method for assessing small bowel transit. The LUBT protocol was based on the 
study by Geypens et al as the group had validated using LUBT with scintigraphy187. 
24 hours before the test day, healthy volunteers ingested 1g (6mmol) of unlabeled 
lactose ureide (Euriso-top, Saint-Aubin Cedex, France) three times a day with their 
meals (morning, afternoon and evening). This was to stimulate bacterial enzyme 
activity to cleave the lactose ureide in the colon. On the test day, LUBT was 
performed alongside the MRI OCTT test (see Figure 45). The volunteer provided a 
baseline breath sample before being given the mixed meal (detailed above). The 
test meal was mixed with 500 mg 13C labeled lactose ureide (Euriso-top, Saint-Aubin 
Cedex, France). Breath samples were taken every 10 min for an hour and then every 
15 minutes for the next 9 hours. A second high calorie meal was given 6.5 hours 
later after the mixed meal. Breath samples were collected and analysed using an 
Infrared Isotope (IRIS) analyser machine (Wagner Analysen Technik GmbH, 
Germany). Results were expressed as delta over baseline, which is the difference 
between the ratio of 13CO2/12CO2 in the post dose breath sample and the 
corresponding ratio in the baseline sample. The OCTT was taken at the time in 
which there was a significant increase from the background breath 13C. This was 
defined as 2.5 times the SD of all previous above the running average of all previous 
points187 (Figure 46). The OCTT was automatically determined from the data 
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obtained by using an in-house program written in Matlab (MathWorks, Natik, USA). 
The amount of lactose used in this test was 6 mmol and this would not exert a 
significant osmotic effect to alter the gastrointestinal transit. 
 
Figure 46: 13C breath excretion curve in one healthy volunteer 
 
3) Study 2: Whole gut transit time (WGTT) test using MRI 
Healthy volunteers swallowed 5 MRI marker pills, measuring 20x9 mm, at 09:00 am, 
24 hours before having an MRI scan of the abdomen. The volunteers were given the 
pills and had to swallow them under direct observation.  
a) MRI marker pills for whole gut transit 
The MRI marker pills were manufactured in-house using a biologically inert 
polyoxymethelyne (Figure 47). The pill consisted of 2 half shells with a cuff that 
would allow the two shells to be glued together using cyanoacrylate glue. A small 
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hole had been drilled in the top of one half shell so the pill could be hand filled with 
Ϭ.ϰ ŵl of ϭϱ μM of GadoteƌiĐ aĐid ;Gd-DOTA). A plastic screw was inserted into the 
hole and glued with cyanoacrylate glue to prevent leakage. To ensure there was no 
leakage, 20% of the pills that was produced for each batch were tested by adding 
blue dye, sealing and immersing in water at 37OC for 48 hours. Dye leakage was 
detected by using a spectrophotometer reading at 400 nm. Any batches showing 
leakage were rejected (this was extremely rare). 
 
Figure 47: MRI marker pilled made of polyoxymethelene. 2 half shells were glued 
together and haŶd filled ǁith Ϭ.ϰ ŵl ϭϱ μM Gd-DOTA. The pill has the dimensions 
of 20 x 7 mm. 
 
The Gd-DOTA (Dotarem©, Guerbet, France) that was used to fill the pill is a 
complex of Gd3+ and the chelating agent DOTA. This is non-toxic, safe to use and has 
been routinely used in clinical practice as an MRI imaging contrast agent216, 217. This 
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agent shortens the T1 relaxation times of protons 218 thus increasing the signal on 
the T1 weighted images. There have been preliminary works to find the optimal 
concentration of Gd-DOTA at the Sir Peter Mansfield Magnetic Resonance Centre, 
UŶiǀeƌsitǇ of NottiŶghaŵ. ϭϱ μM Gd-DOTA was used to give the maximum signal 
intensity from the capsule in the T1 weighted images 219. The concentration of the 
Gd-DOTA was achieved by diluting 1 ml of Gd-DOTA, at a concentration of 280 
ml/ml, with 33 ml of distilled water. 
The volunteers were scanned in a 3T Philips Achieva MRI scanner using a multi-
transmit body coil. The scan images and sequences can be found in the study by 
Chaddock et al213. Since a single scan cannot cover the entire abdomen, 2 scan 
images were obtained at 2 stations (with a 30mm overlap) in coronal view using 
two different sequences. Firstly, a T1 weighted 3D Turbo Field Echo (TFE) sequence 
(TE = 1.3 ms; TR = 2.9 ms, FA = 10°, FOV = 250 x 398 x 160 mm3, Acquired resolution 
[AQR] = 2.3 x 2.3 x 4 mm3), was used to count and locate the number of capsules 
remaining in the colon at 24 h (Figure 48). Secondly, a multi-echo FFE sequence220 
(TE1 = 1.07 ms; TE2 = 1.9 ms; TR = 3.0 ms, FA = 10°, FOV = 250 x 371 x 200 mm3, 
AQR 1.8 x 1.8 x 3.6 mm3; SENSE factor = 2), using a 16 channel XL torso coil to 
receive the signal, was used to create a movie using the maximum intensity 
projections (MIP) of the water only images213 (Figure 49).  
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Figure 48: Coronal sections obtained at 2 stations with 30mm overlap using the 3T 
multi-transmit body coil 
 
 
Figure 49: T1 weighted maximum intensity projection MR image showing 5 
marker pills in the colon 
 
 
 
 
 
 
SliĐe ϯϭ SliĐe ϯϯ SliĐe ϯϱ Head 
Feet 
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The movies allowed rotation of the colonic image and were useful to clarify the 
position of the pills at 24 hours if the T1 weighted TFE images were not conclusive. 
Based on the MRI images, a transit score was calculated by dividing the distal small 
bowel and colon into 8 sections (Figure 50) and each pill was scored according to its 
position in the colon at 24 hours. On several data sets, 1 or 2 pills were separated in 
position by several segments from the rest of the pills (visualized together in a 
group). Since only 5 pills were used to calculate a transit score compared to the 
standard radio opaque marker tests (20 markers/day), a weighting factor was 
included into the calculation. This was to reduce the effect of outliers. The 
weighting factor was calculated for each capsule depending on the difference of the 
capsule score from the median capsule score.  For a difference of 0 and 1 the 
weighting factor was 1, for all differences larger than 1 the weighting was the 
inverse of the difference. Finally, the weighted average transit score of the MRI 
marker pills was determined for each volunteer (Figure 51). 
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Figure 50: Segmented colon used to score the MRI marker pills 24 hour after 
ingestion. 0= not found (presume pill to be excreted), 1= sigmoid and rectum, 2 = 
descending colon, 3 = left transverse colon, 4 = right transverse colon, 5 = upper 
ascending colon, 6 = lower ascending colon and 7 = small bowel.  
 
 
Figure 51: Formula to assess average weighted transit score based on the position 
of the MRI marker pills 
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An example to calculate the average weighted transit score:  
There was 1 MRI marker pills in region 0, 2 in region 1 and 2 in region 2. The median 
position score was 1. The differences of each pill score from the median position 
score were -1, 0, 0, 1 and 1. All pills, which have a difference from median of 0 or 1, 
were given a weighting of 1. Those pills further away are weighted as 1/difference. 
Weightings for this example are: 1,1,1,1 and 1. Weighted average then becomes: 
(1*0+1*1+1*1+1*2+1*2)/(total weighting of 5 pills = 5) = 1.2  
A non-weighted least square fit was applied to the MRI marker pill scores and their 
corresponding ROM transit scores (based on the Metcalf study73) to determine a 
transit time in hours. This is based on the equation: y = mx+c. x is the average MRI 
marker position, m and c are unique coefficients determined from this study and y 
is the transit time in hours (Figure 52). 
 
Figure 52: Formula to calculate WGTT for the MRI marker pills 
 
b) Radio-opaque markers (ROM) test  
The ROM test used was based on the Metcalf study73. Volunteers swallowed 20 
ROMs on 3 consecutive days (days 1, 2 and 3) and an abdominal x-ray was taken on 
day 4, immediately after an MRI scan was used to locate the MRI marker pills 
consumed the day before (day 3); see Figure 45. The ROM was made of silicone 
tubing that was impregnated with 13.5% barium. The dimension of each ROM was 
2.42 x 5.09 mm (Altimex, Nottingham, UK). The WGTT was calculated by counting 
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the number of ROMs remaining on day 4 and multiplying by 1.2 to give WGTT in 
hours (Figure 53). 
 
Figure 53: WGTT using the ROM method 
 
1.13.2.4. Statistical analysis and power of studies: 
1) Statistics:  
All data analysis was carried out using Prism 5 software (GraphPad Software Inc, 
“aŶ Diego, U“AͿ. Data distƌiďutioŶ ǁas assessed usiŶg the D͛AgostiŶo aŶd PeaƌsoŶ 
omnibus normality test. Since the data was not normally distributed, the results 
ǁould ďe iŶ ŵediaŶ ;IQ‘Ϳ aŶd the “peaƌŵaŶ͛s ƌaŶk ĐoƌƌelatioŶ ĐoeffiĐieŶt test ǁas 
used to assess correlations. To assess the reproducibility of the different methods 
as already described, intra-class correlation coefficient test (ICC) was used.  
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2) Power calculation:  
Based on the study by Horikawa et al. 78, the mean colonic transit for healthy 
volunteers was 35.7 ± 12.9 h. For 80% power to detect a 25% difference in transit 
between the 2 methods, 19 participants would be needed for the study. 21 
participants were recruited into the study to allow for dropouts and technical 
difficulties. 
 
1.13.2.5. Results 
All 21 healthy volunteers completed the study with no adverse events. 1 volunteer 
did not attend the x-ray appointments (Study 2) and 1 breath test data from study 1 
was omitted due to high background noise within the data produced.  
1) OCTT measurement using MRI and LUBT 
The OCTT measured with LUBT was 225 min (165-278) and with MRI it was 225 
(180-270). The correlation between these 2 methods to assess OCTT was weak with 
spearman, r = 0.28 (p=0.08) (Figure 54). The limit of agreement between the 2 
methods for OCTT was shown using the Bland-Altman plot in Figure 55. This graph 
showed a small mean difference of -7.32 min between measures. The difference 
between measurements ranges from -197.6 min to 183.0 min. It appeared to show 
that the longer the transit time, there is a tendency for the difference between the 
2 methods of measurements to increase. ICC test was used to assess repeatability 
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of these methods on two separate occasions. The ICC for repeat OCTT 
measurement using LUBT and MRI were 0.35 (p=0.058) and 0.45 (p=0.017) 
respectively. The inter-observer agreement for the MRI OCTT measurement gave an 
ICC of 0.44 (p=0.002). Inter-observer agreement for LUBT OCTT was not calculated 
as the OCTT results were generated automatically using an in house analysis 
program. 
 
 
Figure 54: Correlation between MRI and LUBT tests for OCTT 
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Figure 55: Bland-Altman plot to show agreement between the 2 OCTT methods 
 
2) WGTT measurement using MRI marker pill and ROM 
The mean (SD) WGTT measure using ROM was 31.2 (20.8) hours whilst the median 
average weighted transit score using the MRI marker pill was 0.8 (0-1.6). The 
average weighted transit score at 24 hour (post ingestion) was converted into 
WGTT in hours by using a regression equation linking these 2 techniques. Following 
this conversion, the WGTT for the MRI marker pills gave a median of 27.6 (3.7-50.0) 
hours. The correlation between these 2 methods was good giving a spearman r of 
0.85 (p<0.0001), (Figure 56). The agreement between these 2 methods using the 
Bland-Altman plot showed the mean difference of 0.0045 hours but the 95% limits 
of agreement were from -25.69 to 25.68 (Figure 57). The repeatability test for MRI 
marker pill and ROM methods, which were obtained on 2 separate study days, were 
Agreement between OCTT measurements
100 200 300 400
-400
-200
0
200
400
Average LUBT+MRI OCTT (min)D
if
fe
re
n
c
e
 b
e
tw
e
e
n
 L
U
B
T
 O
C
T
T
 a
n
d
 M
R
I 
O
C
T
T
 (
m
in
)
+1.96 SD (183)
Mean (-7.32)
-1.96 SD (-197.6)
160 
assessed usiŶg ICC giǀiŶg a ƌeasoŶaďle sĐoƌe of Ϭ.ϲϭ ;p=Ϭ.ϬϬϭͿ aŶd Ϭ.ϲϵ ;pчϬ.ϬϬϭͿ 
respectively. The inter-observer agreement between WGTT measurement using 
MRI marker pill and ROM methods were assessed using ICC. The ICC for MRI marker 
pill ŵethod ǁas good at Ϭ.ϳϴ ;pчϬ.ϬϬϭͿ aŶd as foƌ ‘OM method; the ICC was very 
good at Ϭ.ϵϵϱ ;pчϬ.ϬϬϭͿ. 
 
 
Figure 56; Correlation between MRI marker pills and ROM for WGTT 
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Figure 57: Agreement between WGTT measurements 
 
3) Other results: 
Extra information was obtained during the MRI scans of the healthy volunteers. 
These were used to measure their regional and total colonic volumes at t=460 min 
(before meal) and at t=405 min (after meal) and small bowel water content (SBWC). 
The scanning methods used were coronal dual echo fast field echo sequence images 
for colonic volumes 221 and single shot fast spin echo images used to assess 
SBWC214.  
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There was no correlation between colonic volume, SBWC and transit time (both 
OCTT and WGTT). There was no significant correlation between transit time (OCTT 
and WGTT) with BMI, anxiety and depression score (Table 21). There was a weak 
correlation between OCTT and age. There was no significant difference in the 
colonic volumes between genders. Baseline total colonic volumes for male and 
female were 568 (139) and 616 (217) ml respectively, p=0.55. There was no 
correlation between baseline colonic volumes with weight, height, BMI and age 
(Table 22). Both female and male healthy volunteers have similar transit times with 
median of 27.6 (3.7- 45.4) for male and 25.6 (3.7-58.8) for female; p=0.7. 
Table 21: Correlation between MRI parameters and healthy volunteers' 
demographic 
 OCTT (min)* WGTT (hr)** 
Age r = 0.36 (p=0.02) r = -0.08 (p=0.61) 
Height (m) r = -0.04 (p=0.81) r = -0.11 (p=0.50) 
Weight (kg) r = 0.09 (p=0.56) r = -0.21 (p=0.18) 
BMI (kg/m2) r = 0.13 (p=0.41) r = -0.23 (p=0.14) 
Anxiety score r = -0.29 (p=0.08) r = 0.42 (p=0.16) 
Depression score r = -0.15 (p=0.38) r = 0.16 (p=0.31) 
Total colonic volume at 
t=360min (ml) 
r = 0.26 (p=0.10) r = 0.16 (p=0.33) 
Ascending colon volume 
at t=360min (ml) 
r = 0.13 (p=0.41) r = 0.13 (p=0.41) 
Transverse colon volume 
at t=360min (ml) 
r = 0.02 (p=0.89) r = 0.13 (p=0.42) 
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Descending colon volume 
at t=360 min (ml) 
r = 0.29 (p=0.07) r = 0.17 (p=0.27) 
Δ t=ϰϬϱ-t=360 change in 
ascending colonic volume 
(ml) 
r = -0.19 (p=0.23) r = -0.10 (p=0.90) 
Δ t=ϰϬϱ-t=360 transverse 
colonic volume (ml) 
r = -0.11 (p=0.50) r = -0.16 (p=0.31) 
Δ t=ϰϬϱ-t=360 change in 
descending colonic 
volume (ml) 
r = -0.04 (p=0.81) r = -0.13 (p=0.43) 
Fasted small bowel water 
content (SBWC) (ml) 
r =0.17 (p=0.28) r = -0.08 (0.61) 
AUC SBWC (ml/min) r = -0.01 (p=0.97) r = 0.08 (p=0.65) 
ƌ = speaƌŵaŶ͛s ƌaŶk ĐoƌƌelatioŶ ĐoeffiĐieŶt;  
* = OCTT measured using LUBT;  
** = WGTT measured using MRI marker pill 
 
Table 22: Correlation between total baseline colonic volumes and healthy 
ǀoluŶteers͛ deŵographiĐ 
Correlation between baseline 
total colonic volume (ml) 
Spearman, r P value 
Age 0.07 0.77 
Weight 0.04 0.88 
Height 0.33 0.15 
BMI -0.18 0.44 
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1.13.2.6. Discussion  
There was no difficulty in identifying the MRI marker pills in the MRI images. If the 
T1 weighted TFE image was inconclusive, the 3D rotating MIP movie was used. It 
showed the exact position of each of the pills in the large bowel. This method is 
simpler compared to the Metcalf ROM method as the latter can be difficult to 
identify the precise site of ROMs located in the pelvic region on a plain abdominal x-
ray. The method quantifying WGTT in this MRI marker pill was similar to that of 
colonic transit using scintigraphy. It is based on the use of geometric mean and 
colonic segments as previously described by Krevsky et al.197. However, the novel 
aspect of this study using MRI marker pill WGTT is the formula used to calculate the 
transit time takes into consideration of the spread of MRI markers position along 
the gut. This was calculated by looking at the difference of each pill position from 
the median pill position and using this to apply to a weighting factor to each pill 
score. In the majority of the healthy volunteers, the MRI marker pills travelled along 
the gut as a group. In a few healthy volunteers, a few of the MRI marker pills 
separated substantially from the group, which heavily affect the mean position 
score. Thus a weighting factor was applied to each pill score to reduce this 
dispersion factor. The use of weighting factor for the MRI marker pills scores made 
only a small change to the average median pill position unit, 0.97 (non-weighted) 
versus 0.8 (weighted) but if this was applied to a slow transit bowel, this would 
make a large change to the transit time. Also, if the weighted score was used, the 
“peaƌŵaŶ͛s ƌaŶk ĐoƌƌelatioŶ ĐoeffiĐieŶt ǁith the ‘OM ŵethod iŵpƌoǀes fƌoŵ Ϭ.ϳ 
(p<0.01) for non-weighted to 0.85 (p<0.01) for weighted.  
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This study was built on a previous MRI feasibility study by Buhmann et al.222 where 
the study used 5 small eppendorf tubes (2.4 x 0.6 cm) filled with Gadolinium-DPTA 
and normal saline solution as markers of transit, giving a transit time of 41±9 h in 
women and 31±10 h in men. As methodology and analysis were different from our 
current study, it would be very difficult to compare results. Based on this study, the 
SPMMRC had designed and optimised the MRI marker pill to be used in clinical 
practice, comparing the method against the widely used Metcalf ROM method and 
using the MRI scans at a single 24 h time point instead of 6 time points over 60 h. 
The optimal assessment period for measuring colonic transit using scintigraphy was 
24 h 223 and had showed lowest short-term intra-subject variation. This 
methodology was adopted into this study. However, other studies have suggested 
that 48 h assessment does better for slow transit198, therefore it would be 
worthwhile to include a 48 h MRI scan to address this point.  
In this study, there was a strong correlation between the WGTT measure by MRI 
and the ROM method. Other studies have suggested that ROM, which are normally 
2mm in diameter, and the MRI marker pills, which are larger (2.0 x 0.7cm), may 
travel through the different regions of the bowel at different rates. Small pellets < 
2mm diameter empty from the stomach during the digestive phase whilst larger 
capsules will empty slower after a meal during the phase III of the migrating motor 
complexes224, 225. This is confirmed with another recent study using scintigraphy and 
the WMC to assess gut transit201. However, once pills/markers are in the small 
bowel and mixed with chyme, the movement is unaffected by the size of markers226, 
227. There has been suggestion that larger capsules would move ahead of smaller 
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markers in the larger bowel228, but a study by Rao et al.229 showed similar WGTT 
between ROM (29.7 [IQR 22.4-45.7] h) and the WMC. This result was similar to that 
observed in this study.  
The MRI method to assess WGTT allows us to easily and accurately assess the 
position of the MRI pills and assign accurately to the upper or lower half of the 
ascending, transverse and descending colon. However, the sigmoid is more 
convoluted making it difficult to assign markers with such precision, therefore the 
sigmoid and rectum, were grouped together.  
The reproducibility for WGTT was better than for OCTT, similar to other studies76, 
giving an ICC value of 0.69 (p<0.01) for the ROM method and 0.61 (p<0.01) for the 
MRI marker pill method. In this study, there was an interest in developing a purely 
MRI method to quantify both WGTT and OCTT. MRI and LUBT were used for OCTT 
assessment. The median OCTT value using LUBT was 225 min (IQR 165-278 min), 
which was slightly faster compared with another study which gave an OCTT value of 
292±58 min187. The slight difference in OCTT could likely be accounted to the type 
of meal used which in the study by Geypens et al, the breakfast consisted of one 
scrambled egg and 2 slices of bread, which was smaller than the one used in this 
study. The ICC values for repeated measurements of LUBT and MRI were both poor 
at 0.35 (p=0.06) and 0.46 (p=0.02), suggesting OCTT depends on other 
uncorrected/uncontrolled factors as others have reported198. The individual 
variability is similar to both techniques and this suggests the variability reflects 
intrinsic biological variability rather than methodological variability76. 
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There is no gold standard of measuring OCTT. Current tests such as the lactulose 
breath hydrogen test are used commonly. It is known to have an osmotic effect on 
the unabsorbable lactulose, which accelerates transit when compared with 
scintigraphy185, thus making it unsuitable for assessment. Interpretation of breath 
hydrogen is quite complex especially in patients since bacterial overgrowth is 
common and would give spuriously short OCTT time. It is also true for the LUBT test 
but as the dose used in this study was small, it would not alter the transit in the way 
lactulose does. The WMC can be used to assess OCTT (as discussed earlier) by 
measuring the time the pH rises on entering the duodenum to the time it falls on 
entering the colon230. The median OCTT using a standard eggbeater meal (196 kcal) 
in the study by Sarosiek et al. showed 276 min. The disadvantages of this method 
are limited by cost and the risk of the pill getting stuck in the small bowel (e.g. 
CƌohŶ͛s disease aŶd ƌadiatioŶ eŶteƌitisͿ. “o faƌ, the ͚ďest͛ staŶdaƌd used for OCTT 
measurement would be scintigraphy but at present, the techniques used are varied 
and normal range is wide231. Measuring OCTT using our MRI technique has been 
described in the past212 and involved looking at the arrival of the high intensity head 
of a 362 kcal rice pudding meal in the caecum. The median value for OCTT was 225 
min (IQR 180-270), which were in very close agreement with values reported212. In 
this study, the OCTT values using LUBT and MRI were similar but showed poor 
agreement between the two methods (Figure 55). The limitation to the MRI 
technique compared with LUBT was the prolonged scanning time interval, which 
was every 45 min, where as the LUBT breath test sampling time interval was every 
10-15 min. The other limitation to the MRI technique for OCTT was the difficulty in 
interpretation of the arrival of the head of the meal on the MRI images, especially in 
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cases where bright residues appeared in the caecum before or soon after eating the 
rice pudding meal, which could cause confusion with the later actual arrival of the 
head of meal. There was poor inter-observer agreement for measuring OCTT using 
MRI, giving an ICC of 0.44 (p=0.002), which suggests that this would not be a useful 
technique for OCTT as it is very operator dependent.  
On the other hand, the MRI marker pills described here are simple. It involved 1 
visit for a set of MRI scans which takes around 5 min to perform. The images are 
easy to interpret due to the detailed anatomical information provided. The MRI 
scanning sequences are similar and available to any clinical MRI scanner platforms. 
For these reasons, it could be widely adopted in clinical use. By using the algorithm 
in this study, the results of this test can be interpreted easily by a clinician. 
Furthermore, there was a very strong inter-observer agreement between 
measurements using this method giving an ICC of 0.78 (p<0.01). In this study, a 3T 
MRI scanner was used but this method can be used in a 1.5T MRI scanner 
(Unpublished, see subsequent chapter). Also, as the T1 weighted 3D TFE sequence 
does not require the use of a dedicated torso coil to receive the radio-frequency 
signal, this increases the portability and simplicity of the method for use in clinical 
practice. If a dedicated torso coil is used, it can acquire images that can be 
converted into a 3-D rotating movie and these provide good spatial resolution, 
which can be very useful for further confirmation of the exact position of the MRI 
marker pills. Since the images are easy to interpret a trained research assistant 
could report scans.  
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The cost of MRI is falling and this possibly could be an advantage for cost 
effectiveness if other tests could be avoided. Using this technique, not only does it 
measures WGTT, MRI scans could provided further information of the gut such as 
colonic transit and small bowel water content of patients with various 
gastrointestinal dysfunctions. This method is non-invasive, does not expose the 
patient to radiation allowing the use of it for repeated tests in young women and 
children following treatment and is also a very patient acceptable test.    
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1.14. Clinical use of MRI testing on IBS 
1.14.1. Background 
 
Community surveys indicate that over 25% of the population report suffering from 
constipation at least some of the time 232.  When patients are asked what specific 
symptoms trouble them most the commonest complaint is straining to pass stool, 
followed closely by hardness of stool and infrequent bowel movements.  About 2/3 
also complain of abdominal pain 233. Abdominal pain associated with constipation is 
a key feature of irritable bowel syndrome (IBS) with constipation (IBS-C) which 
distinguishes it from functional constipation (FC) in which pain is either absent or 
not prominent7. The other symptoms of these two conditions like hard stools and 
straining overlap extensively and if one suspends the requirement for FC patients to 
not have IBS, then 44% of patients with functional constipation also meet Rome III 
IBS-C criteria while 85% of IBS-C meets the criteria for functional constipation234. 
However making the distinction may be worthwhile since as we show below the 
underlying pathophysiology and response to treatments differ in important ways. 
While IBS is frequently associated with rectal hypersensitivity as assessed by rectal 
barostat 235, rectal hyposensitivity with lack of urge to defecate has been reported  
in 23% of unselected patients with constipation236. When compared to healthy 
volunteers, slow transit constipation sufferers show reduced sensitivity and higher 
threshold for urge while IBS-C have lowered threshold to pain perception237. 
Furthermore motility differs in important ways, with some studies showing delayed 
tƌaŶsit iŶ ͞paiŶless ĐoŶstipatioŶ͟ ǁhile paiŶful ĐoŶstipatioŶ ;Ŷoǁ Đalled IB“-C) was 
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associated with reduced pain threshold but variable transit within the normal 
range238. More recent prolonged (24 h) ambulatory manometry recordings in FC 
with severe slow transit have shown reduced motility, with reduction in the normal 
stimulatory effect of waking and eating 239. In contrast studies using radiotelemetry 
it is shown that IBS-C patients have increased contractions, particularly in the distal 
quartile of colonic transit compared to both FC and healthy controls240. These 
different underlying mechanisms have implications for treatment since prokinetic 
agents such as Prucalopride, which benefit FC, are not licensed for IBS-C in whom 
clinical experience shows a higher incidence of pain and diarrhoea. Likewise bulk 
laxatives like polyethylene glycol (PEG) electrolyte which treat FC well do not 
alleviate the pain of IBS-C even though they stimulate more frequent defecation241. 
The need for bowel cleansing for both ambulatory manometry and the rectal 
barostat test significantly alters the underlying pathology and the techniques 
introduce many other variables including psychological distress which may account 
for why their results correlate poorly with other clinical features.  Furthermore not 
all patients will agree to such invasive tests making the observations biased in 
unpredictable ways. There are limitations of pure observational studies since many 
patients change both lifestyle and diet in order to minimise symptoms making it 
more difficult to distinguish underlying abnormalities of function, which might be 
more clearly shown by assessing the response to a standardised intervention. We 
have recently developed a non-invasive magnetic resonance imaging (MRI) 
technique which allows measurement of intestinal water content214 , colonic 
volumes 221, motility and transit 213 in a highly patient acceptable way. We have 
used these techniques to create a test of colonic function by giving a large dose of 
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the osmotic laxative, Moviprep®, a combination of PEG and electrolyte to distend 
the ascending colon and allow observation of the colonic response which, as our 
results show, differ in the two conditions of IBS-C and FC. 
 
1.14.2. Aim of the study 
 
To assess: 
1) The fasting small bowel water 
2) The whole gut transit time (WGTT) 
3) Colonic volumes at baseline and during the 4 h MRI scanning following 1L 
Moviprep® 
4) Motor function of the ascending colon using the motility index score 
 
1.14.3. Methods 
 
This was an open label study examining the response of the small and large 
intestine to acute ingestion of 1 litre of polyethylene glycol (PEG) and electrolyte 
solution (Moviprep®). We used a virtually identical protocol to that already 
reported in healthy controls (HV)242 to  study patients with constipation. These 
studies were approved by the National Research Ethics Service, United Kingdom 
(10/H0906/50 and 11/EM/0440) and by the Medicines and Healthcare products 
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Regulatory Agency (MHRA CTA reference number 03057/0045/001-0002). This 
study was registered with the ClinicalTrials.gov (Identifier NCT01622972) and the EU 
clinical trials register with EudraCT number 2010-021879-85.  There were no 
changes to the protocols from that published at registration. All participants gave 
written informed consent and the studies were carried out according to the Good 
Clinical Practice principles.  
 
1) Subjects: 
 48 (45 females, 3 males, 21-68 years old) patients with constipation were recruited 
from general gastroenterology clinics in the Nottingham University Hospitals Trust, 
Nottingham.  These comprised two groups classified according to the Rome III 
criteria into functional constipation (FC) or irritable bowel syndrome predominantly 
constipation (IBS-C)7.  Since this was a secondary referral practice these patients 
had all failed at least 1 simple laxative in the past before entry into the study. 
Participants were required to stop any laxatives and medications that would affect 
the gut motility for at least 7 days prior to the allocated study day. All participants 
completed a safety questionnaire to exclude contraindications to MRI such as metal 
implants in the body. They also all completed the Hospital Anxiety and Depression 
Score (HADS) questionnaire and Patient Health Questionnaire 12 Somatic Symptom 
scale (PHQ12SS) to assess psychological and somatic distress. Data from 12 HV (6 
females, 6 males, 20-50 years old) free from gastrointestinal diseases and 
medications that could alter the gut motility who were also part of a previous study 
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involving an identical protocol except for omission of the whole gut transit 
measurement242 were used to compare with the patient data.   
 
2) Study design: 
The HV group protocol was as follows.  Subjects attended on the study day 
following a minimum of 4 hours fasting. They had the baseline MRI scan before 
being given 1 litre of Moviprep® containing 100 g PEG (mean molecular weight 3350 
Daltons), 7.5g Na2SO4, 2.7g NaCl, 1g KCl, 4.7g ascorbic acid, 5.9g Na ascorbate which 
they were required to consume within 60 minutes. Following this, they had hourly 
MRI scans and completed bowel symptom questionnaires throughout the 5-hour 
study period. The bowel symptom questionnaire consisted of a 100mm VAS scale 
on each of the following symptoms: abdominal pain, bloating, abdominal 
distension, abdominal fullness and nausea. They also filled in a stool diary based on 
the Bristol Stool Form Scale chart a week before the study day (whilst off laxatives 
to assess the baseline bowel symptoms), during the study day and 6 days after the 
study day. Particular note was made of the time to first defecation following 
ingestion, which often occurred within a few hours. 
The constipated patient group followed the same protocol but also had an MRI 
assessment of whole gut transit time (WGTT), which required them to swallow 5 
MRI marker pills (20mm x 7mm) at 8 am, 24 hours before the study day with 
imaging the next morning. This method of whole gut transit time (WGTT) using the 
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magnetic resonance imaging correlates well with the standard radio-opaque marker 
test 73, 213. The patients were required to fast overnight before the study day. 
Following their baseline scans to assess transit markers and make baseline volume 
measurements, they ingested 1 litre of Moviprep® within 60 minutes before 
undergoing hourly MRI scans for 4 hours. We were able to reduce the study time to 
4 hours as our HV results indicated all the important responses could be observed in 
4 hours.  Patients completed the bowel symptom questionnaire and stool diaries 
similar to the ones used on the HV group.  Both groups were allowed to drink ad 
libitum after 60 minutes into the study.  
 
3) MRI scanning protocol 
All MRI scans were carried out in a 1.5T Philips Achieva scanner (Philips, Best, The 
Netherlands), using a 16-channel XL torso coil. All participants were scanned in a 
supine position for approximately 13 minutes while between scans they were sitting 
in an up-right position in the waiting room. A turbo spin echo single shot sequence 
(TR/TE = 8000/320 ms, FA = 90o, FOV = 400x362x168 mm3, ACQ res = 1.56x2.90x7.0 
mm3) was used to acquire T2 weighted coronal images for measurement of small 
bowel water content (SBWC) as previously validated 212, 214, 243. This sequence gives 
high intensity signals from areas with free fluid and little signal from body tissues. 
Assessment of WGTT required coronal section images, which, as a single scan would 
not cover the entire abdomen, were obtained at 2 stations with a 30 mm, overlap 
using 2 different sequences. A T1 weighted 3D TFE sequence was used to count and 
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locate the number of pills remaining in the colon after 24 hours of pill ingestion. 
Secondly, to confirm the location of the pills, a multi echo FFE sequence was used to 
create a movie using the maximum intensity projection of the water only images as 
previously used in another study 213. This movie allowed a 3D visualisation of the 
colon and the position of the pills in the uncommon event that the T1 weighted 
image scan was not conclusive. A coronal dual echo fast field echo sequence 
(TR/TE1/TE2 = 157/2.3/4.6 ms, FA = 80o, FOV = 450x362x168 mm3, ACQ res = 
2.01x2.87x7 mm3) was used to assess colonic volumes221. This was performed 
during an expiration breath hold of 13s and a transverse dual echo FFE sequence 
under a 20s expiration breath hold. Lastly, motility scans of the ascending colon 
involved a single sagittal cross sectional slice, using a balanced turbo field echo 
sequence (TR/TE = 3/1.52 ms, FA = 70o, FOV = 330x228x15 mm3, ACQ res = 
1.5x1.5x15 mm3), through the ascending colon which was scanned repetitively 
every second for 2 minutes during which time the participants were allowed to 
ďƌeathe fƌeelǇ. These iŵages Đould ďe plaǇed at higheƌ speed as a ͚ĐoloŶic motility 
ŵoǀie͛ aŶd ǁeƌe saǀed as WiŶdoǁs Media Video files. 
 
1.14.4. Data analysis 
 
All results in patients except WGTT were compared with the previously published 
healthy controls242.  WGTT in patients were compared with previous values in 
healthy volunteers 213 from another study because the MRI marker pills were not 
optimised for usage at the time the HVs were studied.  Sensitivity index (SI) score is 
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defined as the bloating score divided by the ascending colon volume, units per litre 
(-l). Motility index (MI) was calculated as the duration of each contraction (in 
seconds) multiplied by the number of sections of the AC (proximal, mid or distal) 
involved, summed over all contractions in the 2-minute scanning interval. See 
Figure 58. 
 
Figure 58: Example showing how MI was calculated 
 
1.14.5. Statistics 
 
All statistical analysis was carried out using the GraphPad Prism version 6.0 for 
Windows (GraphPad Software, La Jolla California USA). D'Agostino and Pearson 
omnibus normality test was used to assess distribution of data. Normal distributed 
data is expressed as mean ± standard deviation (SD) and non-normal distributed 
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data is expressed as median (interquartile range; IQR). Normally distributed data 
was analysed using the unpaired t-test, 1 way ANOVA and 2 way ANOVA as 
appropriate while non-normally distributed data was analysed using Mann-Whitney 
test and Kruskal-Wallis test. 
 
1) Power calculation  
This used previous data of the effect of another non-absorbable osmotic laxative, 
mannitol212. The mean (SD) change in SBWC at 40 minutes postprandially after 
ingesting 300ml glucose was 6 (39.5) and using n=12, we calculated we could detect 
an increase of 55 ml with 90% power which was very much less than predicted from 
theoretical considerations which suggest a change of >1000ml. The plan was to use 
24 per group to ensure the secondary endpoints were met, for which there is no 
data to perform a power calculation. There was no previous study using MRI to 
assess small and large bowel motility/function in IBS-C and FC so the power 
calculation was not done for these parameters. 
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1.14.6. Results 
 
60 participants were recruited into the study (see Figure 59).  11 HV, 23 FC and 20 
IBS-C were included in the intention to treat analysis following a total of 6 
withdrawals. 
 
Figure 59: Recruitment flow chart 
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1) Demographics 
Median age for HV was 25 (20-29), significantly younger than the FC = 47 (35-51), 
p<0.001 and IBS-C = 39 (27-52.8), p<0.02. The male to female ratio was by design 
5:6 for HV, with a female predominance in patients, 2:21 for FC and 0:20 for IBS-C. 
As expected the FC and IBS-C groups had significantly higher psychological distress 
as assessed by the total HAD scores compared to HV (1way ANOVA, p<0.01) with 
means of 4.09 (2.63) for HV, 15.23(10.38) for FC and 12.25 (8.18) for IBS-C. The FC 
and IBS-C groups also had significantly higher somatic symptoms as assessed by the 
PHQ12SS scores compared to HV (1way ANOVA, p<0.01) with means of 2.73 (1.49) 
for HV, 6.61 (3.86) for FC and 7.05 (4.47) for IBS-C.  
2) MRI parameters 
a) Transit 
WGTT was significantly greater in both the FC and IBS-C groups when compared 
with HV (Kruskal-Wallis p<0.01). The median WGTT was 109.7 (79.4-129.6) h for FC, 
63.3 (47.8-100) h for IBS-C and 27.5 (3.7-50.0) h for HV. The WGTT for FC was 
significantly greater than IBS-C, p<0.01. Figure 60. 
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Figure 60: Whole gut transit time (WGTT) 
 
b) Intestinal volumes 
Fasting SBWC was significantly higher in FC compared to IBS-C with 82.46 (63.37-
141.9) ml and 38.45 (14.61-70.20) ml respectively, p <0.01. Figure 61. 
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Figure 61: Fasting small bowel water (SBWC) 
 
Baseline ascending colon volume was significantly higher in the FC groups 
compared to HV and IBS-C (Table 23 and Figure 62).  2 h after ingestion of 
Moviprep®, the AC volumes significantly increased in the FC group compared to HV 
and IBS-C (Table 23 and Figure 62). 
When the total colonic volume was measured, FC had significantly higher total 
colonic volume compared to HV and IBS-C (Table 23). As can be seen in Figure 63 
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the total colonic volume for FC nearly doubled from baseline at 2 hours following 
ingestion of 1 litre Moviprep®, and remained significantly higher during the 
subsequent 3 hours when compared to HV and IBS-C (2-way ANOVA p <0.01).  
There was no significant differences in the total colonic volumes for the IBS-C group 
at baseline and subsequent total colonic volumes when challenged with 1 litre of 
Moviprep® when compared with HV.  
Table 23: Colon volumes Mean (SD) 
 HV FC IBS-C P value; 
1 way 
ANOVA 
Baseline AC volume 
(ml) 
193 (84.1) 314 (100.8) 
a,b 
226.2 (70.9) <0.01 
AC volume at 2 h 
following ingestion 
of Moviprep® 
356.5 
(153.3) 
596.9 (170.2) 
c,d 
389.2 (163.3) <0.01 
Baseline total 
colonic volume (ml) 
589.5 
(260.5) 
847.2 (279.8) 
e,f 
662.2 (239.5) 0.0151 
a significantly different from HV, p=0.0016; b significantly different from IBS-C, 
p<0.01 
c significantly different from HV, p=0.0004; d significantly different from IBS-C, 
p<0.01 
e significantly different from HV, p=0.0152; f significantly different from IBS-C, 
p=0.03 
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Figure 62: AC volume at baseline and 2h after Moviprep© ingestion 
 
185 
 
Figure 63: Total colonic volumes during the study day 
 
c) Motility and sensitivity indices 
The motility index (MI) of the ascending colon was significantly lower in FC 
compared to both HV and IBS-C at 2 hours (Table 24 and Figure 64). The SI at 2 
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hours was significantly higher in both FC and CC group compared to HV (Table 26) 
but not different between the patient groups (Figure 65).  
Table 24: Motility and sensitivity indices at 2h post ingestion of Moviprep© 
2 h post ingestion 
of PEG 
[Median (IQR)] 
HV FC IBS-C Kruskal-Wallis, 
p value 
MI 82 (48-111) 15.5 (0-49.5)* 
58.5 (20.3-
84) 
<0.01 
*P<0.01 
compared to IBS-C 
SI  
4.18 (1.34-
8.47) 
12.55 (7.15-
16.91) 
15.0 (5.84-
21.42) 
0.02 
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Figure 64: Motility index throughout the study day 
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Figure 65: Sensitivity index 2 h after Moviprep ingestion 
 
d) Bowel habit 
The FC patients had significantly fewer bowel movements in the 24 hour period 
following ingestion of Moviprep® with only 3 (2-5) bowel movements compared to 
HV and IBS-C which was 7 (6-10) bowel movements/24 h in both of these 2 groups, 
Kruskal-Wallis p<0.01. The time to the first bowel movement following ingestion of 
Moviprep® was significantly longer in FC group compared with HV and IBS-C, 
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Kruskal-Wallis p<0.01, being 106 (67.5-175.0) min, 295 (116.3-526.3) min and 84 
(48.8-111.3) min in HV, FC and IBS-C respectively (Figure 66).  
 
Figure 66: Time to first bowel movement (min) 
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e) Correlation between time to first bowel movement and MRI parameters 
Time to first bowel movement correlated positively with ascending colon volume at 
2h post Moviprep®, Spearman r= 0.44, p<0.01 and the fasting SBWC, Spearman 
r=0.34, p=0.04. If a cut off time at 230min was used in the time to first bowel 
movement, the sensitivity of this test to distinguish IBS-C from FC was 55% and 
specificity of 95%. SI correlated weakly with total HAD scores, Spearman r=0.23, 
p=0.09  (Figure 67). 
 
Figure 67: Correlation between baseline total hospital anxiety and depression 
(HAD) score and sensitivity index (SI) 
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1.14.7. Discussion 
This is the first report of a non-invasive assessment of colonic function using MRI in 
constipated patients and as such provides much new data. Very early studies using 
X-rays had provided details of colonic motility and response to eating but only in an 
anecdotal way 244 and the realisation of the dangers of irradiation brought such 
studies to a rapid end. Subsequent studies have used transit of radio-opaque 
markers 73 and clearance of  isotope from the colon 193 as surrogate markers of 
motility which do correlate reasonably well with symptoms223. Constipation is 
associated with slow transit245 and diarrhoea with fast whole gut transit77  and 
accelerated clearance of the ascending colon215  but in each case the overlap with 
normal is substantial as is the day to day variability 76 at around 25%.  This is 
undoubtedly because transit depends on many uncontrolled factors such as diet, 
microbiota, psychological factors as well as motility. Direct measurement of colonic 
motility has been possible but requires bowel preparation and is arduous for both 
patieŶt aŶd iŶǀestigatoƌ, siŶĐe giǀeŶ ŵotilitǇ͛s suďstaŶtial diuƌŶal ǀaƌiatioŶ it 
requires very prolonged (up to 24 hours) recording to characterise239. This has 
limited its use despite the exquisite detail it provides246.  The technique in this study 
is by contrast extremely easy to administer and very patient acceptable. There was 
no difficulty in getting volunteer patients who were keen to see how their bowel 
functioned.  
By providing a large distending stimulus, this study demonstrated distinct motor 
responses, which are impaired in FC throughout the 4 hours of the study.  IBS-C 
patients in contrast show a normal initial response but in the later half of the study 
this appears to tail off significantly while it is maintained in HV. Whether these 
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responses are useful clinically to predict response to therapy requires further study 
but anecdotally this has been used in the clinic in Nottingham and the results do 
separate out IBS-C from FC quite well and do guide therapy. The hypomotile colon 
in FC seems to respond well to prokinetics such as Prucalopride while the active IBS-
C patient tends to get pain and diarrhoea without benefit. 
The analysis of motility used in this study, though blind as to the subject, is very 
subjective and time consuming. The SPMMRC is working on automation to make 
this less subjective and to make it feasible to analyse longer time periods though 
the strength of the stimulus does mean that less time is required when waiting for 
spontaneous contractions. 
All the images are analysed by an operator blind as to the patient details to avoid 
bias but our reproducibility studies are reassuring. The inter-observer variability for 
colonic volumes is 5%. For colonic transit, the inter-observer variability is good with 
intra-class correlation coefficient = 0.78; while the day to day repeatability of transit 
is acceptable with intra-class correlation coefficient of 0.61213 . 
In this study, visceral hypersensitivity was measured, non-invasively, by looking at 
the symptomatic response to the Moviprep® stimulus, which distends and causes 
vigorous contractions in both healthy volunteers and IBS-C subjects.  Unfortunately 
there was substantial overlap possibly because the FC group starts from a much 
larger initial volume, which may make the arrival of large volumes of fluid more 
painful than in IBS patients who started with a relatively normal ascending colon. 
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While expense will limit the use of this test to specialist centres, its use in very 
severe cases in whom colectomy or sacral nerve stimulator implantation is 
contemplated, could be easily justified if it prevented an IBS-C patient from 
undergoing unnecessary and ineffective treatments.  
Even for those without access to MRI for such patients, the Moviprep® challenge 
could be used without imaging since defecation within 230 minutes identifies 95% 
of IBS while only being found in 45% of FC.  This is very useful since it should 
prevent the use of strong stimulant laxatives and suggest that an agent with both 
laxative and pain reliving properties such as Linaclotide might be the preferred 
treatment247,248. 
 In summary this is a patient acceptable, technically undemanding colonic function 
test, which defines the differing underlying pathophysiology of FC and IBS-C, two 
common causes of constipation that require rather different treatments. 
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1.15. Imaging the gastrointestinal tract in IBS 
1.15.1. Introduction 
 
At present, there are no biomarkers using the MRI as a tool to objectively measure 
and evaluate symptoms of irritable bowel syndrome. MRI is still perceived as an 
expensive tool for this although it is patient acceptable and a non-invasive method 
to assess undisturbed bowel. 
At the University of Nottingham, we have collaborated with the research MRI 
centre, Sir Peter Mansfield Magnetic Resonance Centre (SPMMRC) and took 
advantage of its availability/ speciality to evaluate MRI parameters in IBS patients. 
The SPMMRC had validated the quantification of small bowel water content using 
MRI214 and this had been used to measure fasting small bowel water content 
(SBWC) on healthy controls and IBS-D patients212. This study by Marciani et al 
showed that fasting SBWC was lower than healthy controls which was confirmed by 
previous studies reporting faster orocaecal transit time (OCTT) and increased 
motility249-251. The migrating motor complex is more frequent in IBS-D and this has 
probably led to increased delivery of water into the ascending colon251. We also 
showed in IBS-D patients, a good correlation between anxiety and small bowel 
transit time which was assessed on the magnetic resonance (MR) images by the 
arrival of the bright fluid from the small bowel into the ascending colon. 
 Other new parameters to image the small and large bowel are slowly being 
developed here at the University of Nottingham. For example, T1 and T2 imaging 
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sequences have been used as part of a research tool to look into the chyme of the 
ascending colon. In a recent study in Nottingham, T1 sequence in the ascending 
colon in the untreated cohort of IBS-D patients was significantly higher than normal 
subjects (unpublished). The reason behind this difference may be the effect on the 
change in the colonic microbiota but it is still in the exploratory phase. In this 
section, further MRI imaging parameters on IBS-D will be explored and discussed.  
 
1.15.2. Small bowel tone by measurement of fasting small    
bowel water content and other parameters through 
MRI  
  (Result from the MIBS study: Chapter 2) 
1.15.2.1. Aim of the study: 
1) To assess the effect of Mesalazine on the small bowel tone by measurement 
of fasting small bowel water content 
2) To assess the ability of MRI parameters (T1/T2 sequence) to predict treatment 
response 
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1.15.2.2. Method: 
Participants with IBS-D who met the modified Rome III criteria were recruited into 
the Mesalazine for irritable bowel syndrome with diarrhoea (MIBS) trial. This was a 
double blind randomised placebo controlled trial. See chapter 2. For participants in 
Nottingham, following consent, they had additional tests including the magnetic 
resonance imaging (MRI) of the abdomen at the beginning and end of the study 
visit. The MRI scan was performed in the 1.5T Sir Peter Mansfield Magnetic 
Resonance Centre at the University of Nottingham. Participants fasted overnight 
prior to MRI scans for both visits. To ensure safety, they filled in a MRI safety 
questionnaire prior to each visit.  
1) Subjects: 
40 patients (16 males, 24 females) aged between 19-65 years consented to have 
MRI scans of the abdomen during the trial.  
2) MRI scanning protocol: 
All MRI scans were carried out in a 1.5T Philips Achieva scanner (Philips, Best, The 
Netherlands), using a 16-channel XL torso coil. All patients were scanned in a supine 
position for approximately 13 minutes in total. An initial survey scan was to locate 
the position of the abdominal organs before a range of MRI scans were taken. This 
scan consists of a dual gradient echo imaging sequence (dual-echo fast field echo, 
FFE) with TE1 = 2.3 ms, TE2 = 4.6 ms and TR = 158 ms. This comprised 24 coronal 
197 
plane and 45 transverse images with in-plane resolution 1.76 mm × 1.76 mm and a 
slice thickness of 7 mm, with no gap between slices243 (Figure 68). 
  
Figure 68: Initial survey scan to look at anatomy of abdominal organs using a dual 
gradient echo imaging sequence 
 
A turbo spin echo single shot sequence (TR/TE = 8000/320 ms, FA = 90o, FOV = 
400x362x168 mm3, ACQ res = 1.56x2.90x7.0 mm3) was used to acquire T2 weighted 
coronal images for measurement of small bowel water content (SBWC) as 
previously validated 212, 214, 243 (Figure 69).  
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Figure 69: Single shot fast spin echo to analyse small bowel water content 
 
The MRI sequences such as T1, reflecting the spin lattice relaxation time, and T2, 
reflecting the spin-spin relaxation times, were used in this protocol. The 
methodology for TI sequence was similar to a recently published study by Marciani 
et al 242. The longitudinal relaxation time T1 of the ascending colon chyme was 
measured from a single, sagittal slice through the ascending colon using an 
Inversion Recovery Balanced Turbo Field Echo sequence with the following 
parameters: 1 sagittal slice, TR/TE= 3.0/1.5 ms, field of view = 400 x 400 mm, matrix 
size 256x256, slice thickness of 10mm and 8 different inversion times (TI) ranging 
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from 100-5000 ms. Each image was acquired during a breath-hold with 15 s of free 
breathing between each different TI to allow for full relaxation of the MRI signal.  
As for T2 MRI sequence, the MRI protocol was similar to a previous study by the 
MRI research group at the University of Nottingham252. The relaxation time for T2 of 
the ascending colon was measured from a single sagittal slice through the ascending 
colon based on a T2-prepared bTFE sequence (TR/TE = 3.0/1.5 ms, TEprep values 
(ms): 20, 29, 43, 63, 93, 137, 201, 295, 434, 637, resolution 1.56 x 1.56 mm and a 
slice thickness of 7 mm)252, 253. Each image was acquired during a breath-hold with 
intermittent free breathing between each different T2.  
 
3) Data Analysis 
All data analysis was performed by a single person (CL) and the analyser was 
blinded to the study treatment. 
a) SBWC 
Fasting SBWC was analysed using in-house semi-automatic extraction and 
quantification software (Figure 70). This method was validated in the past using 
mannitol infusion into the small bowel via the nasoduodenal tube214. 
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Figure 70: Method for quantification of small bowel water content (ml) 
 
b) T1 and T2 
T1 and T2 were calculated using an in house software program developed by the 
SPMMRC, University of Nottingham253. 3 regions of interest (top, middle and 
bottom of the ascending colon) were drawn to obtain either T1 or T2 values for 
each region. A mean of these regions were used to represent an overall T1/T2 
relaxation time for the whole ascending colon. See figures 71 and 72 as an example 
of T1 and T2 quantification of the ascending colon.  
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Figure 71: T1 analysis showing a region of interesting, top of the ascending colon. 
The eǆpoŶeŶtial Đurǀe oŶ the right shoǁiŶg the ͚reĐoǀerǇ period͛. 
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Figure 72: T2 analysis showing the decay curve in 1 region of interest, middle 
section of the ascending colon  
 
1.15.2.3. Statistical analysis 
1) Statistics 
All statistical analyses were carried out using the GraphPad Prism version 6.0 for 
Windows (GraphPad Software, La Jolla California USA). D'Agostino and Pearson 
omnibus normality test was used to assess distribution of data. Normal distributed 
data is expressed as mean ± standard deviation (SD) and non-normal distributed 
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data is expressed as median (IQR). Normally distributed data was analysed using the 
paired t-test, 1 way ANOVA and 2 way ANOVA while non-normally distributed data 
was analysed using Mann-Whitney/Wilcoxon test (for paired values) and Kruskal-
Wallis test. 
2) Power calculation 
Power calculation was based on the primary end point of stool frequency (See 
chapter 2). There was no study using MRI parameters to assess the gastrointestinal 
tract following treatment of Mesalazine so we were not able to perform a power 
calculation for this.  
1.15.2.4. Results 
1) Baseline characteristics 
20 participants were equally allocated to each arm. Baseline characteristics 
between the two treatment groups were similar. See table 25. 
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Table 25: Baseline characteristics between Mesalazine and placebo group 
Median (IQR) Mesalazine (n=20) Placebo (n=20) P value 
Age 40.9 (16) 42.7 (12.5)  
Female (%) 14 (70%) 10 (50%)  
Anxiety score 9 (5-12) 8 (5-10) 0.45 
Depression score 4 (2-9) 4 (2-7) 0.52 
Total HAD score 13 (8-19) 12 (7-17) 0.60 
PHQ12SS 6 (2-11) 6 (4-8) 0.97 
 
2) Fasting SBWC 
Baseline fasting SBWC average (SD) was 73 (56) ml for all 40 IBS-D patients. There 
was no significant change in fasting SBWC following treatment with Mesalazine, 
mean difference (SD) of -0.42 (0.67) ml compared with placebo, mean difference 
(SD) of -5.1 (53.8) ml, p=0.41 (Figure 73). There was no correlation between 
baselines fasting SBWC with other clinical parameters (Table 26). 
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Figure 73: Fasting SBWC following treatments with Mesalazine and placebo 
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Table 26: Correlation between fasting SBWC with clinical parameters 
Fasting SBWC Correlation Spearman, r P value 
Abdominal pain severity 
(0-10) 
0.14 0.38 
Urgency (0-10) 0.16 0.34 
Bloating (0-10) -0.02 0.90 
Average stool frequency 0.15 0.37 
Average stool consistency -0.09 0.59 
Total HAD score 0.17 0.28 
Anxiety score 0.16 (Pearson, r) 0.31 
Depression score 0.12 0.45 
PHQ12SS score 0.17 0.30 
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3) T1 relaxation  
Following treatment with Mesalazine, T1 relaxation time was reduced significantly 
when compared with placebo (2way ANOVA, p=0.02), Figure 74, Table 27.  
 
Figure 74: T1 relaxation time (s) significantly reduced following treatment with 
Mesalazine 
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Table 27: Comparison showing significant difference in T1 relaxation time 
following treatments with Mesalazine and placebo. 
Sidak's multiple comparisons 
test 
Mean Diff. 95% CI of diff. Adjusted 
P Value 
Before treatment - After treatment 
Mesalazine 0.2663 0.05208 to 0.4805 0.0132 
Placebo -0.02914 -0.2222 to 0.1639 0.9236 
 
Mesalazine group only:  
There was no significant correlation between the baseline T1 relaxation time and 
baseline clinical parameters such as abdominal pain severity, urgency, bloating, 
average bowel frequency and stool consistency. 
Mean differences in T1 relaxation time did not correlate with either mean 
difference in bowel frequency or stool consistency following treatment with 
Mesalazine (Table 28). 
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Table 28: Mean differences for T1 relaxation time, bowel frequency and stool 
consistency. 
Correlation between T1 changes (s) 
following treatment with Mesalazine 
Pearson, r P value 
Change in average daily bowel frequency 
(After treatment – baseline) 0.11 0.71 
Average stool consistency (After 
treatment – baseline) 0.29 0.33 
 
4) T2 relaxation time 
T2 relaxation time did not significantly change following treatment with either 
Mesalazine or placebo, Figure 75. There was no significant correlation between T2 
relaxation time and bowel frequency and stool consistency (Table 29).  
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Figure 75: T2 relaxation time following treatments with Mesalazine and placebo 
 
Table 29: Correlation between T2 relaxation time with bowel frequency and stool 
consistency 
T2 relaxation time (s) Correlation, Spearman r P value 
Average bowel frequency 0.004 0.98 
Average stool consistency -0.12 0.48 
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1.15.2.5. Discussion: 
This study looked at the use of MRI as a tool to search for a biomarker for IBS. 
Previous studies looking at small bowel water content have reported IBS-D patients 
have lower fasting SBWC with median values of 42 (IQR 28-62)212 and 36 (17-77) ml 
[unpublished data from a previous study looking at SBWC in IBS-D]. In this study, 
the fasting SBWC was higher with median values of 58 (IQR 28-115) ml. The 
possibility could be that the patients may not be compliant to fasting instructions 
but this would have shown on MRI scanning. The other possibility that might 
explain this may be the heterogeneity of IBS-D and the cohort of IBS-D patients 
used in the previous two studies compared to the current studied group may be 
different altogether. Further analysis of fasting SBWC did not differ between male 
and female which gave a mean (SD) fasting SBWC of 72 (51) and 74 (59) ml 
respectively, p=0.92. There was no correlation with fasting SBWC and anxiety unlike 
previous report212 and no correlation between fasting SBWC with clinical 
parameters such as bowel frequency and stool consistency. A previous study had 
suggested IBS-D patients have significantly lower fasting SBWC that correlated with 
anxiety. In this cohort of patients, 15 of 40 patients had fasting SBWC content less 
than 35 ml (25th centile healthy control), which may indicate increased gut transit. 
In this small group of patients, there was no significant difference in their baseline 
characteristics such as anxiety, depression, bowel frequency and stool consistency 
when compared with patients whose fasting SBWC was greater than 35 ml. 
Furthermore, there were no correlation between fasting SBWC with anxiety, 
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depression, bowel frequency or stool consistency in the group of patients who had 
very little fasting SBWC. 
Analysis of T1 and T2 relaxation time of the ascending colon are still in the research 
phase. There have been no previous studies visualising the colon and its colonic 
chyme in undisturbed bowel. In this study, we use T1 and T2 relaxation times to 
assess the mode of action of Mesalazine in the ascending colonic chyme.  Analysis 
of T1 and T2 relaxation times were analysed using semi-automated software. As 
mentioned in the method section, T1/T2 were taken as an average of 3 sections in 
the ascending colon (top, middle and bottom).  Not all T1 and T2 images of the 
ascending colonic chyme were analysed. This was maiŶlǇ due to high ͚ďaĐkgƌouŶd͛ 
noise leading to poor fitting of the relaxation curves. Factors that could cause the 
high ͚ďaĐkgƌouŶd͛ Ŷoises were the motion artefacts and the acute angle the sagittal 
image was taken at during MRI scans. Furthermore, some ascending colons were 
full of gas or had collapsed which limited further analysis of T1/T2 relaxations times. 
For these reasons, this may be a limitation to use this test as a potential biomarker.  
T1 relaxation following treatment with Mesalazine showed a significant change 
when compared to placebo. Unfortunately this does not correlate with clinical 
symptoms. Mean (SD) T1 relaxation time in this study showed 0.79 (0.26) s 
compared to another cohort of IBS-D patients (Ondansetron for IBS-D) 0.78 (0.29) s, 
p=0.9. When T1 relaxation time in this cohort of IBS-D patients was compared with 
healthy controls, T1 relaxation time in IBS-D is significantly longer giving a mean 
(SD) 0.79 (0.26) in IBS-D and 0.45 (0.17) in healthy controls, p <0.01. Therefore, T1 
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may be a marker to assess IBS-D but at present its utility is unclear and this will 
need further research.  
T2 is a measure of how protons interact with each other following magnetisation. 
Pure water has a long T2 relaxation time approximately 2s and tissue/fat would 
have a shorter T2 relaxation time. In this study, T2 analysis did not showed any 
significant changes following treatment with either Mesalazine or placebo. There 
was no clinical correlation between T2 and clinical symptoms. Again, when 
comparing the baseline T2 results with another cohort of IBS-D patients from 
previous study (Ondansetron for IBS-D), the T2 results were consistent. The median 
T2 relaxation times for this study vs. another cohort of IBS-D patients were 0.06 
(0.05-0.09) and 0.06 (0.05-0.07) s respectively, p=0.07. 
Overall, the use of MRI to image functional bowel is promising. Although this study 
did not show much promising results for small bowel water, this is still in the early 
stages of research. There have been some developments of using MRI to assess 
colonic volumes221 and gas95. This would give a better understanding of patients 
with IBS-D as the majority of patients complain of bloating along with abdominal 
pain and erratic bowel habit. Analysis of bowel gas and colonic volumes using MRI 
and correlating with their symptoms may be useful. Recently, MRI has been used to 
study patients with scleroderma and coeliac disease. This showed increased fasting 
SBWC in untreated coeliac disease patients254 and the severity of the coeliac disease 
based on the Marsh grading tool, correlated with fasting total colonic volumes. 
Therefore, the use of MRI as a tool to visualise small and large bowel in functional 
gastrointestinal disorder is encouraging.  
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Conclusion 
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The introduction of this thesis gave a general view of irritable bowel syndrome and 
its multiple pathophysiology. IBS is common and remains heterogeneous.  It is a 
waxing and waning condition. IBS is an important condition since it affects the 
quality of life of patients and is a substantial burden to the health service 
worldwide. The Rome Foundation had taken the challenge of forming a set of 
diagnostic criteria for IBS. The criteria for irritable bowel syndrome were based on 
symptoms and lacked the evidence-based approach and remained applicable 
mainly in the research setting. The sensitivity of the current Rome III criteria for IBS 
remained modest at approximately 70% with specificity of 80%9. Therefore many 
physicians in secondary care would have put patients through many investigations, 
as IBS remained a diagnosis of exclusion. Due to its multiple pathophysiology, 
treatment for this condition remained symptom based. Therefore, this has left 
patients bereft of an effective treatment for their condition and thus led to 
dissatisfaction in patients during consultations. 
IBS is an interaction between a disturbed central pain processing pathway and local 
gut pathology. In chapter 2, I have focused mainly on pathology of the gut leading 
to symptoms of IBS. The introduction to this chapter mainly discussed the 
pathophysiology of post-infectious IBS as it clearly defines the onset and effect of 
IB“. ‘eĐeŶtlǇ, theƌe haǀe ďeeŶ ĐoŶfliĐtiŶg ƌepoƌts of ͚iŵŵuŶe aĐtiǀatioŶ͛ iŶ the gut 
mucosa of IBS patients. The use of a local anti-inflammatory drug treatment, such 
as 5-ASA, targeting the gut mucosa of IBS was promising but these studies were 
few, small in numbers of participants and the studies were not blinded. Therefore, 
this chapter described one of the largest trials in the use of Mesalazine (5-ASA) in a 
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subgroup of IBS patients who have diarrhoea. The purpose of this trial was to define 
the clinical benefit of Mesalazine in IBS-D patients and possible mediators/ 
biomarkers in IBS-D.  Disappointingly, this study did not show any clinical benefit on 
the use of Mesalazine in unselected patients with IBS-D but potentially may be of 
benefit for patients with PI-IBS. On the mechanistic side of the study, mast cell 
percentage area stained were elevated in IBS-D patients but had no correlation with 
mast cell tryptase supernatant or other clinical symptoms. The reason may be that 
the measurement of mast cells overall, iŶĐluded aĐtiǀated aŶd ͚lateŶt͛ ŵast Đell that 
may not be pertinent in correlating with clinical symptoms. Lymphocyte CD3 counts 
seemed to be significantly higher following treatment of Mesalazine. The reason for 
this is unclear but it is a possibility that the side effect of Mesalazine may be the 
cause of this elevation. Basic mechanism for Mesalazine/ 5-ASA is still unknown but 
based on this study, 5-ASA did not influence the 5-HT pathway as all three markers 
of serotonin e.g. 5-HT supernatant, 5-HT cell count and the ratio of 5HIAA and 5-HT 
showed no significant changes following treatment with mesalazine. Otherwise, I 
was not able to demonstrate any potential mediators or biomarkers to predict or 
evaluate the response of Mesalazine in IBS-D. Although this was a negative study, it 
had shed some light in the use of Mesalazine in IBS-D and the likelihood of ͚iŵŵuŶe 
aĐtiǀatioŶ͛ iŶ the gut ŵuĐosa of IB“ patieŶts may be an epiphenomenon.  
Gut transit measurements are variable and very often involve exposure to ionising 
radiation. The third chapter explored the use of magnetic resonance imaging in the 
gut transit. The use of the MRI marker pills for whole gut transit time is very 
promising. It had good correlation with the gold standard radio-opaque marker with 
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abdominal x-ray. The optimisation of WGT using the MRI marker pills had been 
applied to assess patients with chronic constipation. This was the first report using 
MRI to assess colonic function in patients with functional constipation and IBS-C in a 
non-invasive manner. These two conditions overlap significantly thus targeting 
treatment for these conditions remained quite difficult. This study described in 
Section 3.3 provided insightful information on the resting colonic volumes and its 
sensory motor function that differ between functional constipation and IBS-C 
following bowel distension with a stimulus such as 1 litre of Moviprep®. Other MRI 
parameters such as T1 and T2 image sequence to look into colonic chyme may be 
beneficial in the study of functional gastrointestinal disorder but so far, it had 
limited evidence especially in the IBS-D cohort. It would be interesting to assess T1 
and T2 relaxation time in the cohort of IBS-C patients and compare these findings 
with IBS-D patients.  The vast amount of information gained e.g. colonic volumes, 
small bowel water and colonic gas, following MRI scans of the abdomen especially 
after a standardized stimulus like macrogol or lactulose may hopefully be applicable 
in future clinical settings. 
In conclusion, there is still a need to unravel the pathophysiology of IBS, as it will 
lead to novel treatments for IBS-D. Potential new treatment for IBS-D that might 
emerge in the near future are Eluxadoline255 (currently in Phase 2 trial, a mixed μ-
opioid receptor agoŶist aŶd δ-opioid receptor antagonist), Ebastin256 (Histamine 1 
receptor antagonist), Ibudotant257 (currently in Phase 3 trial, neurokinin type 2 
receptor antagonist) and Asimadoline258 ;ĐuƌƌeŶtlǇ iŶ Phase ϯ tƌial, κ-opioid 
agonist). The role of MRI in the search for biomarkers in IBS remains promising. 
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While fasting measurements have limited value, assessment of both motility and 
sensation when used in conjunction with a standardized stimulus such as dietary 
provocation, prokinetics or distension such as that provided by macrogol, could be a 
valuable way to screen new drugs.  
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1.16. Appendix 1: Excluded Medication 
Excluded medication and dose controlled medication. Please use in conjunction 
with the exclusion criteria definition. 
Excluded Medication 
NSAIDS 
Aceclofenac 
Acemetacin 
Azapropazone 
Celecoxib 
Dexibuprofen 
Dexketoprofen 
Diclofenac Sodium 
Etodolac 
Etoricoxib 
Fenbufen 
Fenoprofen 
Flurbiprofen 
Ibuprofen 
Indometacin 
Ketoprofen 
Mefenamic Acid 
Meloxicam 
Nabumetone 
Naproxen 
Piroxicam 
Sulindac 
Tenoxicam 
Tiaprofenic Acid 
Aspirin 
 
Long-term antibiotics 
Please refer to the latest version of 
BNF 
 
Antispasmodics 
Alverine Citrate 
Mebeverine Hydrochloride 
Peppermint Oil 
Antimuscarinics 
Atropine Sulphate 
Dicycloverine Hydrochloride 
Hyoscine Butylbromide Propantheline 
Bromide 
Opiates / Anti-diarrhoeal 
Codeine  
Loperamide  
Morphine 
 
Anti-inflammatory 
Prednisolone 
Budesonide 
Hydrocortisone 
Azathioprine 
Mercaptopurine 
 
5-ASA containing 
Balsalazide Sodium 
Mesalazine 
Olsalazine Sodium 
Sulfasalazine 
 
Dose Controlled Medication 
SSRIs 
Citalopram 
Escitalopram 
Fluoxetine 
Fluvoxamine Maleate 
Paroxetine 
Sertraline 
 
TCAs 
Amitriptyline Hydrochloride 
Clomipramine Hydrochloride 
Dosulepin Hydrochloride 
Doxepin 
Imipramine Hydrochloride 
Lofepramine 
Nortriptyline 
Trimipramine  
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1.17. Appendix 2: Clinical questionnaires 
1. Hospital Anxiety and Depression Scale Questionnaire 
Please complete each of the following questions, checking the one response that 
comes closest to how you have been feeling in the past week. 
ϭ.I feel teŶse oƌ ͚ǁouŶd up͛: 
1 □ Most of the time 
2 □ A lot of the time 
3 □ Sometimes 
4 □ Never 
 2.I still enjoy the things I used to enjoy: 
1 □ Definitely as much 
2 □ Not quite as much 
3 □ Only a little 
4 □ Hardly at all 
3.I get a sort of frightened feeling as if something awful is about 
    to happen: 
1 □ Definitely and quite badly 
2 □ Yes, but not too badly 
3 □ A little, ďut it doesŶ͛t ǁoƌƌǇ ŵe 
4 □ Never 
 4.I can laugh and see the funny side of things: 
1 □ As much as I always could 
2 □ Not quite as much now 
3 □ Definitely not as much now 
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4 □ Never 
5.Worrying thoughts go through my mind: 
1 □ All of the time 
2 □ A lot of the time 
3 □ Sometimes, but not too often 
4 □ Rarely 
6.I feel cheerful: 
1□ Never 
2□ Not often 
3□ Sometimes 
4□ Most of the time 
7.I can sit at ease and feel relaxed: 
1□ Definitely 
2□ Usually 
3□ Not often 
4□ Never 
8.I feel as if I am slowed down: 
1□ Nearly all the time 
2□ Very often 
3□ Sometimes 
4□ Never 
ϵ.I get a soƌt of fƌighteŶed feeliŶg like ͚ďutteƌflies͛ iŶ the stoŵaĐh: 
1□ Never 
2□ Occasionally 
3□ Quite often 
4□ Very often 
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10.I have lost interest in my appearance: 
1□ Definitely 
 2□ I doŶ͛t take as ŵuĐh Đaƌe as I should 
 3□ I may not take quite as much care 
 4□ I take just as much care as ever 
11.I feel restless, as if I have to be on the move: 
1□ Very much 
2□ Quite a lot 
3□ Not Very much 
4□ Never 
12.I look forward with enjoyment to things: 
1□ As much as I ever did 
2□ Somewhat less than I used to 
3□ Definitely less than I used to 
4□ Hardly at all 
13.I get sudden feelings of panic: 
1□ Very often 
2□ Quite often 
3□ Not very often 
4□ Never 
14.I can enjoy a good book or TV program: 
1□ Often 
2□ Sometimes 
3□ Not often 
4□ Rarely 
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 Thank you very much for taking the time to fill in this questionnaire. 
 Please check that you have answered all the questions. 
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2. CDC HRQoL-4 questionnaire 
: 
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3. PHQ15 questionnaire 
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4. EQ5D questionnaire 
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1.18. Appendix 3: Stool diary used during the study period   
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1.19. Appendix 4: Histamine measurement using commercial 
kit (Neogen) 
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1.20. Appendix 5: Stool calprotectin measurement 
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1.21. Appendix 6: Methodology for stool tryptase  
1. Stool supernatant 
a) Before processing starts, stool sample was defrosted for an hour prior  
b) 1g of stool sample were transferred into a Falcon Tube before adding 5 ml of 
Tris Buffer and vortexed until stool has dissolved. Samples had to be 
sonicate if samples were not dissolved initially by vortexing. 
c) These samples was placed into a centrifuge at 1000 x g at room temperature 
for 15 minutes 
d) Supernatants obtained was stored in the -80 0C freezer until further 
processing 
2. Stool filtration 
a) Stool supernatant was spun at 15000 x g for 5 minutes at room 
temperature. 
b) The spun stool supernatants was transferred to a 0.45 ul filter (Spin-X 
centrifuge tube filters pore size 0.45ul by SIGMA CLS8163) 
c) Filtrate was spun at 10 000 x g for 2 minutes 
d) The stool supernatant was transferred to a 0.22 ul filter (Spin-X centrifuge 
tube filters pore size 0.22 ul by SIGMA CLS8161) and was placed into the 
centrifuge at 10 000 x g for 2 minutes. 
e) This processed was repeated until all stool supernatants have passed 
through the 2 filters 
3. Procedure for Serine Protease Assay  
a) 0.1mL TBS was added into each (Reaction) microplate well. 
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b) 0.1mL Trypsin (at 10-fold excess of previously optimised upper 
concentration) was added into wells E1, F1 and G1).  It was diluted into 2-
fold serially to column-12 and residual 0.1mL discarded. 
c) 0.1mL was added into each test stool extract to A to C, 1, 5 and 9 and then 
diluted each serially by 2 fold 1-4, 5-8 and 9-12 respectively, discarded 
residual 0.1mL. 
d) 0.1mL 2% (w/v) azo-casein was added into each well and it was mixed briefly 
using an orbital shaker or tapping by hand.  
e) Wells were sealed using an adhesive film-seals and transfer to a 37oC 
incubator for 30 minutes. 
f) Film seal was removed and 0.1 mL 10% (v/v) TCA added into each well. 
Solution was mixed briefly using an orbital shaker or tapping by hand. 
g) The well were re-sealed and incubated for 2 minutes at room temperature. 
h) The microplates were centrifuged. 
i) 150ul supernatant was transferred into the corresponding wells of the 
analytical microplate.  
j) The absorbance was read at 440nm. 
k) Protease activity was expressed as units per mg of protein against activity 
elicted by 1Unit of standard trypsin.    
4. Procedure for Bradford Assay 
a) 150ul water was added into to each microplate well, allowing 1 plate per 18 
(or 6 triplicate) test samples 
b) 150ul 1mg/ml BSA was added into to wells 1A and 1B. Dilute 2-fold serially 
to column 12 and discard residual 150ul to waste 
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c) 150ul distilled water was added into C1, C5 and C9 
d) 150ul was added into each test stool extract and then the solution was 
diluted each serially 2-fold and residual 150ul discarded. E.g. test 1 in D1-D4, 
test 2 to D5-D8, test 3 to D9-D12 
e) 150ul Bradford reagent was added into each well and mixed briefly using an 
orbital shaker or by tapping by hand.  
f) The plate was incubated at room temp for 15 min. 
g) Whilst incubation was happening, 100ul of plate contents was transferred 
into a new plate (flat bottom ELISA style).  
h) Absorbance was read at 595/600nm 
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1.22. Appendix 7: Supplementary results 
Supplementary table 1: Recruitment into study 
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Actual 
per 
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1 0 1 1 8 2 3 5 2 1 3 5 1 4 9 4 11 7 6 17 4 0 9 12 6 14 0 0 0 
Cumul
ative 
1 1 2 3 11 13 16 21 23 24 27 32 33 37 46 50 61 68 74 91 95 95 104 116 122 136 136 
13
6 
136 
Compl
eted 
0 0 0 0 0 0 2 7 9 12 16 16 17 19 25 27 31 36 40 48 51 61 73 80 81 87 97 
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2 
116 
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0 0 1 0 2 3 3 4 6 7 7 7 7 7 7 9 9 9 10 11 12 12 12 14 15 17 18 20 20 
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Supplementary table 2: Recruitment for each site 
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Supplementary table 3: Summary of number of days with stool diary entered at 
baseline and 11-12 weeks 
 Number of days with stool diary recorded:  
Mean (SD) 
Median [IQR] 
Baseline  13.9 (0.3) 
14 (14,14) 
11-12 weeks  13.8 (1.2) 
14 (14,14) 
 
 
